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Abstract 
 
Toll-like receptors (TLRs) are germline-encoded pattern-recognition receptors that initiate 
innate immune responses by recognising molecular structures shared by a wide range of 
pathogens, known as pathogen-associated molecular patterns (PAMPs). TIR domain-
containing adaptor inducing IFN-β (TRIF) is an important adaptor protein in TLR3 and 
TLR4 signalling pathways that mediate proinflammatory cytokine and IFN responses 
following their activation by doubled-stranded RNA and LPS, respectively.  
 
In the present study, we sought to investigate the novel proteins and pathways that serve to 
modulate the functionality of TRIF. To this end, immunoprecipitation and LC-MS analyses 
of the overexpressed and endogenous TRIF immunocomplexes were performed. A 
disintegrin and metalloproteinase domain-containing protein 15 (ADAM15), Segment 
polarity protein dishevelled homolog DVL3 (DVL3) and Optineurin (OPTN) were 
identified as TRIF-interacting partners. Their interactions with TRIF were also confirmed 
by direct immunoprecipitation experiments of overexpressed and endogenous TRIF. 
 
More specifically, ADAM15 was found to interact with TRIF at 60 and 20 min. upon 
poly(I:C) and LPS stimulation, respectively. Overexpression of ADAM15 in HEKT293, 
HEK293-TLR3 and HEK293-TLR4 inhibited TRIF, TLR3 and TLR4-dependent activation 
of NF-κB, IFNβ and Rantes promoter activation, respectively. Moreover, downregulation 
of ADAM15 by esiRNA enhanced poly(I:C) and LPS-induced cytokine/chemokine 
secretion in the U373-CD14 cell line.    
 
This study also demonstrated that all of the three DVLs isoforms (DVL1, DVL2 and DVL3) 
interacted constitutively with TRIF when overexpressed in HEK293-TLR4. However, 
immunoprecipitation of endogenous TRIF in U373-CD14 cell line showed that DVL3 
associated with TRIF at 20-40 min upon LPS, but not poly(I:C) stimulation. 
Overexpression of all DVLs isoforms in HEKT293 and HEK293-TLR3 decreased TRIF 
and TLR3-induced NF-κB, IFNβ and Rantes, respectively. Nevertheless, DVLs inhibition 
using a chemical inhibitor attenuated poly(I:C) and LPS-dependent upregulation of TNFα, 
xii 
 
IFNβ and Rantes mRNA, as well as LPS-induced phosphorylation of IRF3 in wild-type 
murine BMDMs. 
 
Furthermore, the study also showed that OPTN interacted constitutively with TRIF when 
overexpressed in HEK293-TLR3. Immunoprecipitation of endogenous TRIF revealed that 
OPTN interacted with TRIF in a ligand-dependent manner only. Poly(I:C) and LPS 
stimulation in U373-CD14 increased OPTN protein expression levels after 24 h. 
Overexpression of OPTN negatively regulates TRIF and TLR3-dependent reporter gene 
activation. In addition, suppression of OPTN expression using esiRNA increased poly(I:C)-
induced IFNβ mRNA expression as well as TNFα, and Rantes secretion in U373-CD14. 
However, suppression of OPTN decreased/increased LPS-induced TNFα/Rantes, 
respectively. 
 
In conclusion, this study analysed, for the first time, TRIF immunocomplex and identified 
ADAM15, DVL3 and OPTN as novel TRIF interacting proteins and showed their role in 
TRIF-mediated TLR signalling. This study has advanced our understanding of the 
complexities of TRIF signalling in the context of TLR and we proposed that TRIF could be 
a key modulator of alternate signalling pathways. 
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Chapter 1 
 
 
General Introduction 
 
 
 
 
 
 
 
 
 
 
1 
 
1.1    The Innate immune system 
 
The immune system is the host defence against invading microbial pathogens. It eliminates 
microorganisms by discriminating between self and non-self. In mammals the immune 
system can be divided into two branches: innate immunity, and adaptive immunity (Takeda 
et al., 2005; Kanzler et al., 2007). The innate immune system is responsible for the early 
detection and destruction of invading pathogens and relies on a set of germ line-encoded 
pattern recognition receptors (PRRs) for detection (Lee and Kim, 2007). In contrast, the 
adaptive immune response detects non-self through recognition of peptide antigens using 
antigen receptors expressed on the surface of B and T cells and provides the host with 
immunological memory (Tauszig-Delamasure et al., 2002). To initiate immune responses, 
PRRs recognize pathogen associated molecular pattern (PAMPs) and induce activation of 
various intracellular signalling pathways leading to inflammation. Once invading pathogens 
cross the epithelial barrier they are recognized by resident tissue macrophages. Activated 
macrophages release a host of cytokines and chemokines, which promote the recruitment of 
neutrophils to site of infection and initially invading microorganisms. Mediators of the 
innate immune system also induce upregulation of co-stimulatory molecules on dendritic 
cells (DCs), resulting in recruitment of cells of the adaptive immune system (Janeway and 
Medzhitov, 2002; Lee and Kim, 2007; Mogensen, 2009). 
 
1.2    Pathogen Recognition Receptors  
The innate immune system utilizes PRRs in three different compartments including cell 
membranes, body fluids and cytoplasm (Lee and Kim, 2007). PRRs are expressed as the 
first line of defense against infection by macrophages, monocytes, dendritic cells, 
neutrophils and epithelial cells, as well as, cells of the adaptive immune system (Mogenson, 
2009; Takeuchi and Akira, 2010). Several classes of PRRs have been identified: Toll-like 
receptors (TLRs), retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs), NOD-like 
receptors (NLRs), C-type lectins receptors (CLRs) and DNA sensors (Keating et al., 2011, 
Marsili et al., 2012) (Figure 1.1). Upon recognition of the microbial components, PRRs 
activates a cascade of signalling pathways leading to the induction of a range of specific 
inflammatory and antiviral genes and cytokines that orchestrate innate immunity and 
chemokines and co-stimulatory molecules that promote T cell activation and specific 
2 
 
 
 
Figure 1.1: Cellular PRRs. TLRs are membrane-bound receptors localized at the cellular 
or endosomal membranes, recognizing PAMPs via the LRR domain and transducing 
signals to the intracellular environment through the TIR domain. RLRs with a C-terminal 
helicase domain bind RNA and become activated to transduce CARD-dependent signalling. 
DNA-dependent activator of IFN-regulatory factors (DAI) and absent in melanoma 2 
(AIM2), RNA polymerase III, Leucine-rich repeat (LRR) flightless-interacting protein 1 is  
(LRRFIP1), interferon, gamma-inducible protein 16 (IFI16), and Ku70 are DNA sensors. 
Most PRR signalling pathways converge on activation of NF-κB, which results in the 
transcription of proinflammatory cytokines. Activation of the RLRs, endosomal TLRs, 
TLR4, IFI16 and Ku70 also leads to activation of interferon regulatory factor 3 (IRF3) and 
IRF7, resulting in the production of type I interferons.  LRRFIP1 activation leads to nuclear 
translocation of β-catenin where it interacts with IRF3 and IRF7. (MDDCs: monocytes-
derived dendritic cells). (Adapted from Marsili et al., 2012). 
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immunity (Marsili et al., 2012) (Figure 1.1). TLRs are the best characterised signalling 
receptors among the PRRs (Iwasaki and Medzhitov, 2004) and will be discussed in more 
detail below. The cytosolic receptors RIG-I and melanoma-differentiation-associated gene 
5 (MDA5) are RNA-sensing helicases. They detect dsRNA of many replicating viruses 
(Kato et al., 2008). Recent reports show that RIG-I can also trigger IL-1β and/or IL-18 
production typically induced by inflammasome (poeck et al., 2010). NLRs are a further set 
of intracellular PRRs distinct from RLRs that have emerged as central regulators of 
immunity and inflammation with demonstrated relevance to human diseases. NLRs 
recognize PAMPs, as well as, host-derived danger signals or DAMPs (danger associated 
molecular patterns) and much attention has been focused on the ability of several NLRs to 
activate the inflammasome complex and drive proteolytic processing of inflammatory 
cytokines (Schroder et al., 2010). The C-type lectin family of proteins encompasses 
upwards of 1000 members with diverse functions including cell adhesion, regulation of 
natural killer function, complement activation, tissue remodeling, platelet activation, 
endocytosis, phagocytosis and innate immunity. Many C-type lectins recognize 
carbohydrate structures on viruses, bacteria, parasites and fungi and have been shown to 
play a role in host defense, exerting functions independent of other PRRs (Osorio et al., 
2011). Cytosolic dsDNA produced during DNA-virus infection is also a potent activator of 
innate immune responses. Several cytosolic DNA sensors have recently been described, all 
of which contribute to recognition of infecting viral DNA. These DNA sensors include DAI 
(DNA-dependent activator of IRF) IFN-inducible IFI16 protein (IFI16), Stimulator of 
interferon genes, STING RNA polymerase-III (Pol-III), absent in melanoma 2 (AIM2) 
extra chromsomal histone H2B, leucine rich repeat (in FLII) interacting protein (LRRFIP1) 
Ku70 ( Keating et al., 2011; Marsili et al., 2012). 
 
1.3    Toll-like Receptors  
It was initially thought that the innate immune system largely functioned in a non- specific 
manner. However, in 1989, Janeway found that the innate immune system specifically 
detect pathogens via germ line-encoded receptors termed pattern recognition receptors 
(PRR). PRRs recognize highly conserved microbial structure and thereby initiate an 
immune response (Janeway, 1989). The first proof of specificity in innate immunity came 
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with the discovery of the Drosophila protein Toll (dToll), which was critical for effective 
immune response to fungus Aspergillus fumigatus in the adult fly (Lemaitre et al., 1996). 
Soon after that a human homologue of Toll (hToll, later called Toll-like receptor 4) was 
discovered (Medzhitov et al., 1997). At least 13 TLRs have been identified in mammals so 
far (Brikos  and O'Neill, 2008). Both humans and mice express TLR1-9 (Figure 1.2). In 
addition humans, but not mice, express TLR10. However, mice, but not humans, express 
TLR11, 12, and 13 (Lee and Kim, 2007; Carpentier et al., 2008). The TLRs are type I 
transmembrane receptors, consisting of an N-terminal leucine-rich repeats (LRR) in the 
extracellular domain, a Toll-interleukin (IL)-1R (TIR) homologous region in the cyto-
plasmic domain and a transmembrane domain (O’Neill et al., 2000, Takeda et al., 2005). 
The TLRs differ from one another in terms of the cell types in which they are expressed, 
their ligand specificity, the signalling adaptors that they utilise and the cellular responses 
they induce (Iwasaki and Medzhitov, 2004). The most characterised TLRs are TLRs 1-9, 
which can be broadly divided into two groups on the basis of their PAMP specificity. The 
first group are expressed on the cell surface and recognise PAMPs in cell wall components 
and flagellin from both Gram-positive and Gram-negative bacteria, yeast, and fungi. This 
group includes TLR2 that forms a heterodimer with TLR1 or TLR6 and recognises 
bacterial lipoproteins and lipopeptides, TLR4 which recognises lipopoly-saccharides (LPS) 
and TLR5 which recognises flagellin (Mogensen 2009; Boo et al., 2010).  The second 
group of TLRs, which reside in intracellular compartments, detects PAMPs in nucleic acids 
derived from bacterial and viral pathogens. This includes TLR3 which recognises double-
stranded RNA, a product of viral replication in host cells, TLR7 and TLR8, which 
recognises single-stranded RNA derived from RNA viruses and small interfering RNA 
(siRNA), and TLR9 which recognises unmethylated CpG-containing DNA of bacterial and 
viral origin origin (Chaturvedi et al., 2008; Mogensen 2009; Boo et al., 2010).  
 
1.3.1    TLR1, TLR2 and TLR6  
TLR2 is located on the cell surface and recognises extracellular ligands. It forms 
heterodimers with either TLR1 or TLR6 and recognises many different microbial and 
synthetic components. These include lipoproteins/lipopeptides from various pathogens, 
peptidoglycan and lipoteichoic acid from Gram-positive bacteria. TLR1/2 heterodimers  
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Figure 1.2: An overview of human Toll-like receptors and their ligands. TLR2 is 
essential in the recognition of microbial lipopeptides. TLR2 heterodimerises with TLR1 to 
facilitate recognition of triacyl lipopeptides and with TLR6 to facilitate recognition of 
diacyl lipopeptides. TLR3 is implicated in the recognition of viral dsRNA. TLR4 is the 
receptor for LPS. TLR5 recognises flagellin, whereas TLR7 is implicated in viral-derived 
ssRNA recognition. TLR9 is essential in CpG DNA recognition. TLR signalling may 
originate from either the cytoplasmic TIR domain of plasma membrane localised TLRs 
(TLR1/2, TLR2/6, TLR4, TLR5) or from the endosomally localised intracellular TLRs 
(TLR3, TLR7, TLR8, TLR9). (Adapted from Muccioli, et al., 2012). 
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recognize triacyl lipopeptides such as Pam3CSK4 (a synthetic bacterial lipopeptide), and 
TLR2/6 heterodimers recognize diacyl lipopeptides such as the Mycoplasma-derived 
macrophage-activating lipopeptide 2 (MALP2) (Janeway and Medzhitov, 2002). Moreover 
several viruses, such as Herpes simplex virus (HSV), Cytomegalovirus (CMV), Hepatitis C 
virus (HCV) and Measles virus induce type I IFNs and proinflammatory cytokines via 
TLR2 signalling (Boo and Yang, 2010). In support of these findings is the fact that 
macrophages from TLR6-deficient mice do not show any production of inflammatory 
cytokines in response to mycoplasma-derived diacyl lipopeptides. However, these cells 
showed normal production of inflammatory cytokines in response to triacyl lipopeptides 
derived from Gram-negative bacteria (Takeuchi et al., 2001). In contrast, macrophages 
from TLR1-deficient mice showed a normal response to mycoplasma-derived diacyl 
lipopeptides, but an impaired response to triacyl lipopeptides (Takeuchi et al., 2002). Thus, 
TLR1 and TLR6 functionally associate with TLR2 and discriminate between diacyl or 
triacyl lipopeptides. TLR2 has been shown to functionally collaborate with distinct types of 
receptors such as dectin-1, a lectin family receptor for the fungal cell wall component β-
glucan recognition (Gantner et al., 2003). Thus, TLR2 recognises a wide range of microbial 
product through functional cooperation with several proteins that are either structurally 
related or unrelated and this facilitates the emanation of various signalling cascades 
(Takeda and Akira, 2005). 
 
1.3.2    TLR 3 
Double-stranded RNA (dsRNA), is a replication intermediate of several viruses, is detected 
by the innate immune system through TLR3. TLR3 expression is predominantly observed 
in the intracellular compartments of dendritic cells (DCs) and macrophages, while some 
fibroblasts also express TLR3 on their cell surface (Yoneyama and Fujita, 2010). Notably, 
dsRNA is produced during the replication of most RNA viruses, including the enveloped 
Respiratory Syncytial virus (RSV), Influenza A virus and the West Nile virus (WNV) 
(Groskreutz et al., 2006; Le Goffic et al., 2006; Kong et al., 2008; Boo and Yang 2010). 
TLR3 also plays an important role in the detection of DNA viruses including mouse CMV 
and HSV (Tabeta et al., 2004; Zhang et al 2007).  
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The role of TLR3 in antiviral immune responses was experimentally proved using an 
artificial dsRNA ligand and TLR3 knockout mice (Alexopoulou et al., 2001). The synthetic 
dsRNA ligand, polyinosinic:polycytidylic acid (poly(I:C) has immunostimulatory activity 
similar to dsRNA and TLR3-deficient mice have been found to have their response to 
dsRNA impaired (Alexopoulou et al., 2001). However, the function of TLR3 in antiviral 
immunity is controversial. It has been shown that the expression of Type 1 interferon (IFN) 
and inflammatory cytokines were reduced but not abolished in cells such myeloid DCs 
derived from TLR3 deficient mice in response to dsRNA and poly(I:C) (Takeda et al., 
2003; Alexopoulou et al., 2001). Moreover, reports have suggested that TLR3 is involved 
in the support of viral growth or pathogenesis rather than protection (Wang et al., 2004; Le 
Goffic et al., 2006). TLR3-independent mechanisms of dsRNA recognition have been 
reported. Studies have shown that the Retinoic acid-inducible gene I-like helicases such as 
RIG-I and MDA-5 can also sense viral RNA in the cytoplasm of infected cells (Andrejeva 
et al., 2004; Yoneyama et al., 2004). Although TLR3 was reported to play a key role in 
sensing poly(I:C) by epithelial cells (Guillot et al., 2005; Rudd et al., 2006; Matsukura et 
al., 2007), it played only a moderate or minor role in sensing poly(I:C) in macrophages or 
conventional DCs (Alexopoulou et al., 2001; Yamamoto et al., 2003). In contrast, RIG-I 
and MDA5 were found to play a more important role than TLR3 in sensing poly(I:C) in 
fibroblasts and DCs (Kato et al., 2005, Kato et al., 2006). 
 
1.3.3    TLR4 
TLR4 was the first cloned mammalian TLR and has been the most extensively studied. It 
has been identified in many cell types, such as endothelial cells, monocytes, thyroid cells, 
endometrial cells, mesangial cells, adipocytes and human β-cells (Garay-Malpartida et al., 
2011). TLR4, together with the co-receptors MD2 and CD14, form a signalling complex 
that responds to lipopolysaccharide (LPS), the endotoxin component of Gram-negative 
bacteria outer membrane (Janeway and Medzhitov, 2002; Lee and Kim, 2007). It has been 
suggested that the co-receptor CD14 may facilitate diversification of the TLR4 ligand 
repertoire and also aids towards the full activation of the downstream signalling pathways 
(Godowski, 2005) 
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 In addition to LPS, TLR4 recognizes other ligands such as taxol, heat shock proteins 60 
and 70, oligosaccharides of hyaluronic acid, heparan sulfate and fibrinogen (Takeda and 
Akira, 2005). However, all these endogenous ligands require very high concentrations to 
activate TLR4 which is in contrast to the low concentrations of LPS that are required to 
mediate TLR4 activation (Takeda and Akira, 2005). TLR4-deficient mice generated by 
gene targeting are hypo-responsive to LPS, confirming that TLR4 is the essential receptor 
for LPS recognition (Hoshino
 
et al., 1999). It has been reported that TLR4 was also 
involved in the recognition of certain group of viruses including mouse mammary tumor 
virus, molony murine leukemia virus and RSV (Takeda and Akira, 2003). TLR4 has been 
established as an essential component in the recognition of LPS. However, several reports 
indicated that LPS can also be recognized independently of TLR4. The NOD family, 
NOD1 and NOD2 confer intracellular recognition to LPS and mutant NOD2 protein was 
defective in LPS-induce-NF-κB activation (Inohara et al., 2001; Ogura et al., 2001). 
 
1.3.4    TLR5 
TLR5 recognizes an evolutionarily conserved site on bacterial flagellin that is required for 
flagellar filament assembly and motility (Andersen-Nissenet et al., 2005). It is responsible 
for flagellin-induced responses in epithelial cells, endothelial cells, macrophages, DCs and 
T cells (Steiner, 2007). In addition, flagellin activates TLR5 on CD4 and CD25 T-
regulatory cells, leading to increased suppressive activity, suggesting that flagellin has a 
complex role in bridging innate immunity and adaptive immunity (Crellin et al., 2005). 
Flagellin was shown to have TLR5-independent proinflammatory activity that depends on 
two related intracellular pattern recognition receptors, Neuronal apoptosis inhibitory protein 
5 (Naip5) and  Ice protease-activating factor (Ipaf), which are members of the NACHT-
leucine-rich repeat-containing receptor (NLR) family (Steiner, 2007). Flagellin acts as a 
PAMP in plants as well, whereby flagellin is sensed through the Flagellin-sensing 2 gene 
(FLS2). This gene encodes a LRR transmembrane receptor-like kinase with similarities to 
TLRs in mammals (Akira and Hemmi, 2003). Evidence indicates that the LRR domain of 
FLS physically interacts with flagellin. However, there is no significant homology between 
the LRR domains of TLR5 and FLS2 (Akira and Hemmi 2003; Takeda and Akira 2003). 
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1.3.4    TLR7 and TLR8  
TLR7 and TLR8, which are localised to endolysosomal compartments, are structurally 
highly conserved proteins that recognise the same ligand in some cases (Akira and Hemmi 
2003; Larange´ et al., 2009). More specifically, they recognize viral infections in the form 
of foreign nucleic acids. TLR7 can recognize synthetic RNA homologs such as resiquimod 
(R848) and ssRNA derived from ssRNA viruses such as vesicular stomatitis virus (VSV) 
(Gorden et al., 2006). However, studies have demonstrated that non-rodent (human, bovine, 
and porcine) TLR8 signalling can be activated by synthetic ligands such as imiquimod 
(R837), resiquimod and some guanine nucleotide analogs. In contrast, rodent (mouse and 
rat) TLR8s, whose primary sequences and structures are identical to non-rodent TLR8s, 
were not activated by non-rodent ligands (Akira and Hemmi 2003; Govindaraj et al., 2011). 
TLR7 is expressed in plasmacytoid DCs (pDCs) and in response to TLR7 stimulation, 
pDCs produce large amounts of IFNα. TLR7 activation also leads to DC maturation and 
expression of CD40, CD80, and CD86 (Gorden et al., 2006). TLR8 is expressed in myeloid 
DCs (mDCs), and monocytes. It’s activation in mDCs leads to IL-12 and TNFα production 
as well as upregulation of CD8, CD40 and CD80 (Larange et al., 2009). 
 
1.3.5    TLR9  
TLR9 is essential for recognition of synthetic CpG oligonucleotides and unmethylated CpG 
motifs in bacterial and viral DNA. It is highly expressed in pDCs and, most likely, 
recognises its ligand intracellularily, perhaps in the endosome or lysosomes (Ahmad-Nejad 
et al., 2002). The critical involvement of TLR9 in the recognition of bacterial DNA was 
demonstrated using TLR9-deficient mice. Hemmi and colleagues showed that TLR9 
deficient mice do not show any response to CpG DNA, in terms of splenocyte proliferation, 
inflammatory cytokine production from macrophages and maturation of DCs (Hemmi et 
al., 2000; Akira and Hemmi, 2003). Recently, it has been reported that Hepatitis B virus 
(HBV) impaired TLR9 expression and function in pDCs and B lymphocytes, which may in 
turn contribute to the establishment and/or persistence of chronic infection (Vincent et al., 
2011). Activation of the TLR9 pathway by CpG motifs is also impaired severely in human 
keratinocytes expressing human papilloma virus (HPV) or E6 and E7 the major on-
coproteins from this dsDNA virus (Hasan et al., 2007). It has been discovered that the full-
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length TLR9 has to be cleaved from the N-terminal to generate a functional (processed) 
TLR9 C-terminal. Interestingly, though both the full-length and cleaved forms of TLR9 are 
capable of binding ligand, only the processed form recruits MyD88 upon activation, 
arguing that this truncated receptor, rather than the full-length form, is functional (Ewald et 
al., 2008, Balashov  et al., 2010). 
 
1.3.6     TLR10  
Like other TLRs, TLR10 has multiple leucine-rich repeats and TIR domain. It shares the 
highest homology with TLR1 and TLR6.  TLR10 can form either a homodimer or a 
heterodimer with TLR1 or TLR2. TLR10 expression has been detected in pDCs, 
monocytes and B cells (Lazarus et al., 2004). The ligand for TLR10 has not yet been 
identified. However, a study investigating TLR10 polymorphisms in asthmatic patients 
suggested that TLR10 may be involved in the recognition of airborne pathogens or airborne 
allergens (Lazarus et al., 2004; Nyman et al., 2008). It has been reported that hypoxia or 
reactive oxygen species (ROS) increased TLR10 expression in human monocytes (Kim et 
al., 2010).  
 
1.3.7    TLR11, TLR12 and TLR13 
TLR11, TLR12 and TLR13 are present in mice but not in human. Protozoan profilin-like 
protein from Toxoplasma has been reported to activate DCs through TLR11 and is the first 
defined ligand for this TLR. Moreover, TLR11 is required for in vivo parasite-induced IL-
12 production and optimal resistance to infection, thereby establishing a role for TLR11 
receptor in host recognition of protozoan pathogens (Lauw et al., 2005; Yarovinsky et al., 
2005). Little is known about ligand recognition by TLR12 and TLR13. However, Mishra et 
al. (2008) studied the expression and distribution of TLR11-13 in the murine brain. It was 
found that parasite infection caused an increase of both mRNAs and protein levels of all 
three TLRs. All three TLR proteins were present in both CNS and immune cell types. 
Among them TLR13 was expressed the most, followed by TLR11 then TLR12 (Mishra et 
al., 2008). Recently TLR13 has been shown to be involved in the recognition of the 
vesicular stomatitis virus and bacteria RNA (Shi et al., 2010, Oldenburg et al., 2012, 
Hidmarket al., 2012). In addition, small interfering RNA against TLR13 reduced cytokine 
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induction by bacteria RNA in DCs. Moreover, Chinese hamster ovary cells transfected with 
TLR13, but not with TLR7 or 8, could activate NF-κB in response to bacteria RNA or 
Streptococcus pyogenes in an RNA-specific manner (Hidmarket al., 2012). 
 
1.4    TLRs signalling pathway 
Stimulation of TLRs by microbial components triggers the expression of several genes that 
are involved in immune responses. Microbial recognition of TLRs facilitates dimerization 
of TLRs. Whilst TLR2 has been shown to form a heterodimer with TLR1 or TLR6, in other 
cases, TLRs are believed to form homodimers (Akira and Takeda, 2004). Ligand 
engagement with their respective TLRs leads to a conformational change within the TLR 
which facilitates the interaction of their cytoplasmic TIR domains with downstream TIR 
domain-containing adaptor molecules. Upon recognition of their cognate ligand, TLRs 
induce the expression of a variety of host defense genes. These include inflammatory 
cytokines, chemokine and upregulation of the immune cells (Janeway and Medzhitov, 
2002). TLR signalling is mediated by adaptor proteins and protein kinases, ultimately 
leading to the activation of IFN regulatory factors (IRF), IRF3, 5 and 7, or nuclear factor- 
κB (NF-κB) family and release of pro-inflammatory cytokine including tumor necrosis 
factor α (TNF-α), IL-1β, IL-6 , IL-12 and IL-18 (Sirén  et al., 2005; Häcker et al., 2006). As 
a major transcription factor for anti-viral activity, NF-κB is thought to play an important 
role in the induction of pro-inflammatory molecules, such as IL-1β and TNF-α, upon 
cellular responses against viral infections (Schoenemeyer et al., 2005). Moreover, 
activation of the IRF pathway leads to the secretion of type I IFNs such as IFN-α and IFN-
β. Whilst IRF5 is a strong transcription activator for IFN-α production, IRF7 can induce 
both IFN-α and IFN-β (Romieu-Mourez et al., 2006; Yang and Seki, 2012). The TLRs 
signalling pathways are illustrated in Figure 1.3. 
 
 1.5    TLR adaptors 
All TLRs have a TIR domain that initiates the signalling cascade through TIR adaptors. 
The TLR adaptors serve as platforms that organise downstream signalling cascades leading 
to a specific cellular response. To date, five adaptor proteins have been discovered, 
Myeloid differentiation protein-88 (MyD88), MyD88 adaptor-like (Mal, also referred to as  
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Figure 1.3: Overview of TLR signalling. All TLRs recruit either MyD88 and/or TRIF and 
these in turn, recruit IRAKs to the receptor upon ligand binding. IRAK then activates 
TRAF6, leading to the activation of the IκB kinase (IKK) complex consisting of IKKα, 
IKKβ and NEMO/IKKγ. The IKK complex phosphorylates IκB, result in nuclear 
translocation of NF-κB which induces expression of inflammatory cytokines. TIRAP, a 
second TIR domain-containing adaptor, is involved in the MyD88-dependent signalling 
pathway via TLR2 and TLR4. In TLR3 and TLR4-mediated signalling pathways, activation 
of IRF3 and induction of IFN-β are observed in a MyD88-independent manner. A third TIR 
domain-containing adaptor, TRIF, is essential for the MyD88-independent pathway. TRIF 
mediates IRF-3 activation through IKKε and TANK-binding kinase 1 (TBK1). A fourth 
TIR domain-containing adaptor, TRAM, is specific to the TLR4-mediated MyD88-
independent/TRIF-dependent pathway (Adapted from Yang and Seki, 2012).  
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TIR-domain containing adaptor protein (TIRAP)), TIR-domain-containing adaptor 
inducing interferon (TRIF also known as TIR-containing adaptor molecule (TICAM-1)), 
TRIF-related adaptor molecule (TRAM also called TIR-containing adaptor molecule-2 
(TICAM-2)) and Sterile alpha and Armadillo repeat protein (SARM) (Takeda et al., 2004;  
O'Neill and Bowie, 2007) (Figure 1.4). MyD88, which was the first adaptor molecule to be 
identified, is involved in signalling triggered by all TLRs, with the exception of TLR3, and 
plays a major role in TLR-induced signal transduction. Despite the prominent role of 
MyD88 in TLR signalling, studies using MyD88-deficient mice revealed the existence of 
both MyD88-dependent and -independent pathways. (Takeda and Akira, 2005; Mogenson, 
2009). 
 
1.5.1    MyD88  
Whilst MyD88 was discovered in 1990 (Lord et al., 1990), its role in TLR signalling was 
not known until 1998 (Medzhitov et al., 1998). Prior to being implicated in TLR signalling, 
MyD88 was found to be an adaptor molecule that functions to recruit the Interleukin-1 
receptor (IL-1R) associated protein kinase (IRAK-1) to the Interleukin-1 receptor complex 
following IL-1 stimulation resulting in the activation of NF-κB (Wesche et al., 1997).  
MyD88 is 296 amino acids and contains three domains, a N-terminal death domain which 
enables interactions with the IRAKs, an interdomain and a C-terminal TIR domain which 
facilitates homotypic interaction with other TIR-containing proteins (Medzhitov et al., 1998; 
O'Neill and Bowie, 2007). MyD88 functions as a universal adaptor and is shared by all 
TLRs, except TLR3 which exclusively recruits TRIF. MyD88 deficient mice and 
macrophages failed to secrete the proinflammatory cytokines IL-6 and TNF-α in response 
to LPS stimulation. Furthermore, MyD88 deficient mice were found to be more resistant to 
LPS-induced death than wild type mice (Kawai et al., 1999). However, mitogen activated 
protein kinases (MAPK) and NF-κB activation was still present, albeit delayed in the 
MyD88 deficient mice in response to LPS. This was the first indication of the presence of a 
MyD88-independent pathway in LPS signalling (Kawai et al., 1999). Further studies using 
MyD88-deficient macrophages found that they were completely unresponsive to TLR2, 
TLR7 and TLR9 ligands (Takeuchi et al. 2000; Alexopoulou et al., 2000). In terms of 
signalling upon stimulation, MyD88 recruits members of the IRAK family through  
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Figure 1.4: Domain structure of the TIR-domain-containing adaptor proteins. MyD88 
contains a C-terminal death domain (DD), intermediate domain (ID) and an N-terminal TIR 
domain. MAL contains at the N-terminus a PIP2 binding domain followed by the TIR 
domain and TRAF6 binding motif (T6BM). It also contains two phosphorylation sites for 
Bruton’s tyrosine kinase at positions 86 and 187. Located at position 180 is 
theserine/leucine site linked to the genetic susceptibility to several diseases including 
tuberculosis (TB) and malaria. At position 198 is the aspartic acid indicating the presence 
of the caspase-1 cleavage site. TRIF is 712 amino acid long. It consists of a TRAF6 binding 
motif (T6BM), the TIR domain and a receptor-interacting protein (RIP) homotypic 
interaction motif (RHIM). TRAM consists of 235 amino acid. It contains a myristoylation 
site at the N terminus, followed by serine at position 16 which is phosphorylated by protein 
kinase C-ε and the TIR domain between amino acid 75 and 235. SARM consist of two 
sterile α-motif (SAM) domains followed by the TIR domain. (Adapted from O’Neill and 
Bowie, 2007). 
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homotypic interaction of the death domain of both molecules. IRAK-1 was the first IRAK 
shown to be important in the ability of LPS to induce NF-κB activation. Other studies 
demonstrated that IRAK-4 is crucial in NF-κB activation in response to TLR ligands and is 
responsible for both the recruitment and phosphorylation of IRAK-1 (Wesche et al., 1997; 
Li et al., 2002; Swantek et al., 2000). Data suggested that IRAK-2 may play a prominent 
role in NF-κB activation, particularly during the late phase of TLR signalling (Chen, 2005; 
Mogenson, 2009). The phosphorylation of IRAK-1 leads to the recruitment TNF-receptor 
associated factor 6 (TRAF6) which is an ubiquitin E3 ligase that works in conjunction with 
a ubiquitin conjugating enzyme complex to polyubiquitinate target proteins, including itself 
(Chen, 2005). IRAK-1 and TRAF 6 association lead to the activation of two distinct 
signalling pathways. One pathway leads to activation of transcription factor activator 
protein 1 (AP-1) through activation MAPK (Change and Karin, 2001). Another pathway 
activates the transforming growth factor activated kinase1 TAK1 and TAK1 binding 
protein 2 (TAB2) complex, which enhances activity of the IκB kinase (IKK) complex 
(Takeda and Akira, 2004; Jenkins and Mansell, 2010). Once activated, the IKK complex 
induces phosphorylation and subsequent degradation of IκB, which leads to nuclear 
translocation of the transcription factor NF-κB and subsequent activation of NF-κB 
dependent genes, including the pro-inflammatory cytokines IL-1, IL-6 and TNFα (Feng and 
Chao et al., 2011) (Figure 1.4). 
In 2010 Lin et al., showed the crystal structure of the MyD88: IRAK4: IRAK2 
death domain (DD) complex, which reveals a left-handed helical oligomer that consists of 6 
MyD88, 4 IRAK4 and 4 IRAK2 DDs. Assembly of this helical signalling tower is 
hierarchical, in which MyD88 recruits IRAK4 and the MyD88: IRAK4 complex recruits 
the IRAK4 substrates IRAK2 or the related IRAK1. Formation of these Myddosome 
complexes brings the kinase domains of IRAKs into proximity for phosphorylation and 
activation (Lin et al., 2010). In addition to the MyD88 pathway, which results in NF-κB 
translocation, there is a cell specific pathway which activated by TLR7, TLR8 and TLR9. 
In pDCs, the activation of these TLRs results in IFNα production. This pathway is MyD88 
dependent and involves the nuclear translocation of IRF-7 (Honda et al., 2004). In pDCs it 
has been shown that the DEAD/H-box helicases DHX9 and DHX36 directly bound to the  
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Figure 1.4: MyD88-dependent pathway. (1) Stimulation of TLR, by TLR ligand MyD88-
dependent activation of NFκB and MAPK. IRAK4 interacts with MyD88 through death 
domain interactions. (2) IRAK-4 is thought to phosphorylate both IRAK-1 and IRAK-2 
which induces their autophosphorylation activity. (3) Phosphorylated IRAK-1 is released 
from the receptor complex and subsequently associate with TRAF6. (4) IRAK-1 
phosphorylates Pellino which can ubiquitinate IRAK-1. IRAK-1 and Pellino form a 
complex with TRAF6. (5) NEMO binds to ubquitinated IRAK-1. (6) IRAK-2 induces the 
poly-ubiquitination of TRAF6. The polyubiquitination of TRAF6 results in the recruitment 
of the TAK-1/TAB2 complex and activation of TAK-1. (7) TAK-1 activates the IKK 
complex. (8) The IKK complex phosphorylates IκBα which allows p65/p50 to translocate 
in the nucleus. (9) For MAP kinase activation, TAK-1 activates MKK3/6 and MKK4/7 for 
p38 and JNK activation, respectively. (10) The IKK complex phosphorylates the inhibitory 
protein p105. Upon phosphorylation and degradation of p105, tpl2 is activated and 
subsequently activates MKK1/MKK2. MKK1/MKK2 activates ERK1 and ERK2. (Adapted 
from Flannery and Bowie, 2010). 
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TIR domain of MyD88, showing a TLR9-independent, MyD88 depending DNA sensing in 
pCDs (Kim et al., 2010). Moreover, the DHX36 governs a pathway specific for IRF7 
activation and IFN-α induction whilst the DHX9 triggers nuclear translocation of the NFκB 
subunit p50 and subsequent upregulation of genes such as TNFα and IL-6 (Kim et al., 
2010, Keating et al., 2011). Furthermore, recently new MyD88-dependent signalling 
mechanism has been identified. This signalling pathway proceeds via IFNγ receptor/C-C 
chemokine receptor type 2 and governs the mobilization and activation of monocytes in 
response to challenge with a systemic intracellular bacterium (Pietras et al., 2011). 
  The MyD88 pathway is negatively regulated by three proteins, MyD88 short 
(MyD88s), transforming growth factor-β (TGF-β) and IRAK-M (Janssens et al., 2002; 
Kobayashi et al., 2002; Naiki et al 2005). MyD88s is a splice variant of MyD88 and 
missing the interdomain located between the DD and TIR (amino acids 110-157) and its 
expression is induced in response to continuous stimulation with bacterial products or pro-
inflammatory cytokines (Janssens et al., 2002). Naiki et al. (2005) showed that TGF-β 
blocked NF-κB activation and cytokine production in response to TLR2, TLR4 and TLR5 
ligands by decreasing MyD88 protein but not mRNA levels. Another negative regulator of 
MyD88 signalling is IRAK-M. IRAK-M prevents the dissociation of IRAK-1 and IRAK-4, 
which results in IRAK-1 being unable to interact with TRAF6 and is therefore unable to 
induce a signalling cascade (Kobayashi et al., 2002). 
 
1.5.2    Mal 
Mal was the second TLR adaptor protein to be described (Fitzgerald et al., 2001; Horng et al., 
2001). Mal is 235 amino acids in size and contains an N-terminal phosphatidyl-inositol-4,5-
bisphosphate (PIP2) binding domain and a C-terminal TIR domain (Nunez Miguel et al., 2007; 
O'Neill and Bowie, 2007). Initially, Mal was characterised as a protein that specifically 
associates with TLR4 and found to interact with MyD88 in co-immunoprecipitation assays as 
well as in a yeast two-hybrid screen. Overexpression of Mal was found to activate NF-κB and 
JNK (Fitzgerald et al., 2001; Horng et al., 2001) and Mal-deficient mice were found to respond 
normally to the ligands for TLR5, TLR7 and TLR9 (Horng et al., 2002). However, as well as 
having defects in cytokine production and activation of NF-κB and MAP kinases in response to 
the TLR4 ligand, they were shown to have impaired response to TLR2 ligands (Yamamoto et 
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al., 2002). Similar to MyD88-deficient mice, Mal-deficient mice were found to be completely 
resistant to LPS-induced shock and were shown to have delayed activation of NF-κB and MAP 
kinases in response to LPS (Horng et al., 2002). The ability of Mal to act as a bridging adaptor 
for MyD88 is dependent on its localisation to the plasma membrane. The localisation of Mal to 
the plasma membrane is facilitated by its PIP2 binding domain (Nunez Miguel et al., 2007). At 
the plasma membrane, Mal acts as a bridging adaptor for MyD88, bringing it to the activated 
TLR4, to initiate signal transduction. A role of Mal distinct from that of MyD88 was identified 
when a putative TRAF6 binding motif was identified in Mal but not in MyD88. Mal was found 
to co-immunoprecipitate with TRAF6 and a mutation within the TRAF6 binding motif of Mal 
abolishes NF-κB activation by TLR2 and TLR4 (Mansell et al., 2004). Mal like many 
components of the TLR signalling pathway is subject to negative regulation. It has been shown 
that suppression of cytokine signalling 1 (SOCS1) mediates polyubiquitination of Mal on two 
N-terminal lysine residues, thereby mediating Mal degradation via the 26S proteasome 
(Mansell et al., 2006). 
 
1.5.3.1    TRIF  
TRIF was identified following the analysis of databases for TIR domain containing proteins 
and following a two hybrid screen (Yamamoto et al., 2002; Oshiumi et al., 2003). TRIF, 
712 amino acids in length, is much larger than the other TLR adaptors. It contains three 
TRAF6-binding sites in its N terminal domain, a TIR domain and a receptor-interacting 
protein (RIP) homotypic interaction motif (RHIM) in its C-terminal domain (Oshiumi et al., 
2003). Although TRIF contains a TIR domain, its amino acid sequence is very divergent 
from other TIR domain-containing adapter protein sequences (Han et al., 2004). Oshiumi 
and his colleagues showed that TRIF interacted with TLR3 in both co-immunoprecipitation 
assays and yeast two-hybrid screen. No interaction was found with either TLR2 or TLR4.  
In contrast to MyD88 and Mal, TRIF dramatically induce IFN-β promoter activity. 
Overexpression of TRIF also induced activation of NF-κB promoter but at low level 
compared with MyD88 or Mal. A dominant negative version of TRIF, but not MyD88 or 
Mal, inhibited TLR3 activation of NF-κB and IFN-β indicating a unique role for TRIF in 
TLR3 signalling (Yamamoto et al., 2002; Oshiumi et al, 2003). Moreover, TRIF deficient 
mice were impaired in TLR3 and TLR4-induced IFN-β production and activation of IRF3. 
19 
 
Furthermore, inflammatory cytokine production in response to TLR4 ligands was severely 
impaired, whilst responses to TLR2, TLR7 and TLR9 ligands in TRIF-deficient 
macrophages were not impaired (Yamamoto et al., 2003). Mice deficient in both MyD88 
and TRIF showed complete loss of NF-κB activation in response to TLR4 stimulation. 
These findings demonstrate that TRIF is essential for TLR3 and TLR4-mediated signalling 
pathways (Yamamoto et al., 2003). In contrast to MyD88 and Mal-deficient mice, TRIF-
deficient mice displayed normal LPS-induced MyD88-dependent activation of IRAK-1, 
NF-κB and MAPK indicating that TRIF is not involved in LPS-induced activation of the 
MyD88-dependent pathway. However, the production of pro-inflammatory cytokines in 
response to LPS, but not other TLR ligands was impaired in these mice. This led to the 
suggestion that in the case of TLR4, both the MyD88-dependent and MyD88- independent 
pathways need to be intact to enable the production of pro-inflammatory cytokines 
(Yamamoto et al., 2003). When the response to LPS was examined in embryonic 
fibroblasts from MyD88 and TRIF double knockout mice, activation of NF-κB and JNK 
was completely abolished, confirming that TRIF was responsible for the delayed activation 
of NF-κB previously found in MyD88-deficient mice (Yamamoto et al., 2003).  
During TLR3 and TLR4 signalling, TRIF (associated with TRAM in the case of 
TLR4) (Fitzgerald et al., 2003) is responsible for initiating a signalling pathway through 
TRAF3, TBK1 and IKKε (Hacker et al., 2006; Guo et al., 2007) which mediate direct 
phosphorylation of IRF3 and IRF7. As a consequence of phosphorylation, IRF3 and IRF7 
form hetero- or homodimers, translocate to the nucleus, in association with transcriptional 
coactivators such as CBP and p300 and bind to target sequences in DNA, such as IFN-
stimulated response elements (Fitzgerald et al., 2003). IRFs, together with NF-κB and AP1, 
can form a multiprotein complex termed the ‘enhanceosome’, which induces transcription 
of the IFN-β gene (Sharma et al., 2003). TRIF-dependent activation of NF-κB occurs 
through binding of TRAF6 to TRIF and subsequent ubiquitination-dependent recruitment 
and activation of TAK1 (Sato et al., 2003). In order to obtain robust NF-κB activation, a 
second molecule, receptor interacting protein 1 (RIP1), involved in TNF-receptor mediated 
NF-κB activation, is also recruited to TRIF (Meylan et al., 2004). RIP1 is polyubiquitinated 
to form a complex with TRAF6, and these two molecules appear to cooperate in facilitating 
TAK1 activation, resulting in IKK-mediated activation of NF-κB as well as activation of 
20 
 
the MAPK pathway (Cusson-Hermance et al., 2005). Recently, using yeast two-hybrid 
screening, it was found that three TRAF proteins TRAF1, 2 and 6, interacted with the N-
terminal region of TRIF. Further, it was suggested that the binding of TRAF2 and TRAF6 
to TRIF cooperatively activates the IFN-inducing pathway through ubiquitination of TRIF, 
a modification which occurs unrelated to TRAF3 recruitment in the TRIF signalling 
complex (Sasai et al., 2010). A simplified TRIF signalling pathway is predicted in figure 
1.5. In addition to NF-κB and IRF3 activation, TRIF is the only TLRs adaptor that induces 
apoptosis upon overexpression in human embryonic kidney (HEK) 293 cells. Domain 
mapping experiments indicate that the N-terminal and middle TIR domains did not induce 
apoptosis, whereas the C-terminal 181 amino acids (positions 532-712) were sufficient to 
induce apoptosis (Han et al., 2004). Moreover, TRIF-induced apoptosis was not inhibited 
by IκBα, a dominant negative of IRF3, or IRF7 or by various combinations of these 
molecules. TRIF-induced apoptosis was also not inhibited by kinase inactive mutants of 
TBK1, IKKβ, and IKKε. It was found that TRIF induced apoptosis through a RIP/Fas-
associated death domain (FADD)/caspase-8-dependent pathway (Han et al., 2004).  
Han et al. (2010) reported the identification of a splice variant of TRIF lacking the TIR 
domain and is therefore designated as TRIS. TRIS form heterocomplex with TRIF through 
their C-terminal RHIM motifs. Overexpression of TRIS activates NF-κB and IRF3, while 
knockdown of TRIS inhibited TLR3-mediated NF-κB and IRF3 activation (Han et al., 
2010). 
The TRIF pathway is negatively regulated by a number of molecules, however in 
most cases they do not target TRIF specifically, but affect downstream components of the 
TRIF pathway such as TBK1 or IRF (O’Neill and Bowie, 2007). It has been reported that 
SRC homology 2 (SH2) domain containing protein tyrosine phosphatase2 (SHP2) 
negatively regulates TRIF signalling by binding to the kinase domain of TBK1 thereby 
preventing its activation (An et al., 2006). SHP2 was found to negative regulate TLR3 and 
TLR4 activated IFN-β production as well as pro-inflammatory cytokine production in 
response to TLR3 but not TLR2, TLR7 or TLR9 ligands. Knockdown of SHP2 was found 
to increase TLR3 and TLR4 induced IFN-β production (An et al., 2006). SARM, the fifth 
TLR adaptor has also been shown to negatively regulate the TRIF but not the MyD88 
pathway (Carty et al., 2006) and will be discussed below. A splice variant of TRAM called 
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TRAM adaptor with GOLD domain (TAG) was also shown to inhibit IRF3 activation upon 
LPS stimulation probably by displacing TRIF from TRAM (Palsson-McDermott et al., 
2009). Knockdown of TAG was shown to enhance induction of the chemokine CCL5 
(RANTES), but not IL-8 upon LPS stimulation in human peripheral blood mononuclear 
cells (Palsson-McDermott et al., 2009).  
Su et al. (2006) showed that overexpression of TRAF1 inhibited TRIF and TLR3-
mediated activation of NF-κB, IFN-stimulated response element and the IFN-β promoter. 
Overexpression of TRIF caused caspase-dependent cleavage of TRAF1 and the cleaved N-
terminal, but not C-terminal, fragment of TRAF1 was responsible for inhibiting TRIF 
signalling. Further, mutation of the caspase cleavage site of TRAF1, or addition of the 
caspase inhibitor cram, inhibited TRAF1 cleavage and abolished the ability of TRAF1 to 
inhibit TRIF signalling (Su et al., 2006).  
In some cases, virally encoded proteases directly target components of the innate 
immune system to abolish anti-viral signalling. Targeted proteolysis of adaptor molecules 
serves as a powerful means to eliminate anti-viral signalling by suppressing common 
downstream targets of key innate immune signalling pathways (Mukherjee et al., 2011). 
Hepatitis C virus contains a serine protease NS3- 4A that causes the proteolysis of TRIF (Li 
et al., 2005). The cleavage of TRIF by NS3-4A inhibits TLR3 mediated activation of NF-
κB and IRF3, thus inhibiting the innate immune response to the virus (Li et al., 2005). 
Moreover the vaccina virus protein A46R contains a TIR domain which facilitates its 
interaction with all the TLR adaptors, except SARM. The interaction of A46R with TRIF 
leads to the inhibition of IRF3 activation and concomitant gene induction (Stack et al., 
2005). Also, Coxsackievirus B3 (CVB3) mediates TRIF cleavage through the virally-
encoded protein, termed 3C
pro
. Mukherjee et al. (2010) demonstrated that 3C
pro
 cleaves 
both the N and C-terminal domains of TRIF, localises with TRIF in the cytoplasm and 
inhibits TRIF mediated type I IFN and apoptotic signalling. Recently, Qu and colleagues 
showed that a 3CD protease-polymerase from Hepatitis A Virus (HAV), disrupted TLR3 
signalling by targeting TRIF for degradation, thus inhibiting poly(I:C)-mediated 
dimerization of IRF3, IRF3 translocation to the nucleus and IFN-β promoter activation (Qu 
et al., 2011). 
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1.5.3.2    TLR3-indepndent TRIF-dependent pathways 
Recently, it was demonstrated the presence of a TLR3-independent, TRIF-dependent 
poly(I:C) sensor in dendritic cells. It was shown that three new members of the DExD/H-
box helicase family, DDX1, DDX21, and DDX36 use TRIF to activate the NF-κB pathway 
and type I IFN responses (Zhang et al., 2011). Moreover, it was shown that TRIF also 
mediates TLR5 signalling in intestinal epithelial cells (Choi et al., 2010). Choi et al. (2010) 
demonstrated that stimulation of cells with flagellin induces a physical interaction between 
TLR5 and TRIF in a time dependent manner. In fact, suppressed TRIF expression reduces 
TLR5-induced NF-κB and MAPK activation in response to flagellin, and TRIF deficiency 
inhibited flagellin-induced cytokine expression (Choi et al., 2010). However, the same 
group reported that TRIF plays an inhibitory role in TLR5-elicited responses by inducing 
proteolytic degradation of TLR5 (Choi et al., 2010). TRIF overexpression in human 
HEKT293 and human colonic epithelial (NCM460) cells abolishes the cellular protein level 
of TLR5, whereas it does not alter TLR5 mRNA level. Also, TRIF overexpression 
dramatically suppresses flagellin-TLR5-driven NF-κB activation in normal human colon 
mucosal epithelium NCM460 cells. Also, TRIF-induced TLR5 protein degradation is 
completely inhibited in the presence of a caspase inhibitor, indicating that TRIF induced 
caspase activity mediates TLR5 protein degradation (Choi et al., 2010). In addition, it was 
shown that the C-terminus of TRIF and the extracellular domain of TLR5 are required for 
TRIF-induced TLR5 degradation. Furthermore, TRIF-induced proteolytic degradation is 
extended to TLR3, TLR6, TLR7, TLR8, TLR9, and TLR10, whereas the cellular level of 
TLR1, TLR2, and TLR4 was not affected by TRIF overexpression. These results suggest 
that, in addition to mediating TLR3- or TLR4-induced signalling as an adaptor molecule, 
TRIF can participate in proteolytic modification of certain members of TLRs to modulate 
the functionality of TLRs at the post-translational level (Choi et al., 2010). 
 
1.5.4    TRAM 
TRAM was identified following a database screening in 2003 (Oshiumi et al., 2003). It 
consists of 235 amino acids and is the smallest TLR adaptor protein. It contains a putative 
myristoylation site at the N-terminus and undergoes phosphorylation by protein kinase Cε 
(PKCε) at the serine residue at position 16 and a TIR domain in its C-terminus (Rowe et al.,  
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Figure 1.5: TRIF signalling pathway: DsRNA binds to TLR3 in the endosome activating 
TRIF. TLR4 can also activate TRIF via TRAM adaptor protein. TRIF interacts with TBK1 
via NAP1 and TRAF3 and the signal transduced to the IKKi leading to the phosphorylation 
of IRF3. PI3K is also required to complete IRF activation. IRFs dimerise then translocate to 
the nucleus where they bind to the DNA and transactivate type 1 IFN genes expression in 
conjunction with the co-activator CBP/p300. TLR3 also activates NFκB by a TRAF-6 
mediated interaction with TRIF involving the TAK1/TAB1/TAB2/TAB3 complex which 
activate TAK1 causing it to phosphorylate and activate IKK. This phosphorylate IκB and 
targets it for degradation causing NFκB nuclear translocation. Signalling via RIP1 is 
required for full activation of NFκB and transcriptional of target genes. (Adapted from 
Dunlevy et al., 2010)  
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2006; O’Neill and Bowie, 2007). TRAM physically interacts with TLR4, TRIF and Mal, 
but not with TLR3, and acts as bridging adaptor between TLR4 and TRIF in the MyD88-
independent pathway (Fitzgerald et al., 2003; Oshiumi et al., 2003; Yamamoto et al., 2003). 
Using RNAi knockdown, both TRIF and TRAM were shown to be required for LPS 
induced IFN-β production (Oshiumi et al., 2003). Overexpression of TRAM barely 
activates AP-1 and only weakly activates NF-κB and the IFN-β promoter. Unlike the other 
TIR-containing adaptors, TRAM has been implicated in the TLR4 signalling pathway. 
Originally, TRAM was thought to be localised to the plasma membrane which facilitated its 
ability to signal (Rowe et al., 2006). However, it has been shown that TRAM contains a 
sorting signal that controls its trafficking between the plasma membrane and endosomes 
and that TRAM does not induce TRIF-dependent signalling from the plasma membrane. It 
has been demonstrated that TLR4 and TRAM must be delivered to the endosomes to 
facilitate the activation of IRF3 signalling (Kagan et al., 2008). Another modification of 
TRAM, which has been shown to be essential for its signalling ability, is the 
phosphorylation of the serine at position 16 by PKCε. Mutation of this phosphorylation site 
(Serine16Alanine) results in loss of phosphorylation and the ability of TRAM to signal in 
response to LPS (McGettrick et al., 2006). TRAM-deficient cells were found to have 
impaired TLR4 mediated cytokine production and B cell activation, while other TLR were 
not affected (Yamamoto et al., 2003). 
 
1.5.5    SARM 
SARM was the last TIR-containing adaptor protein to be characterised. It was originally 
identified as an orthologue of Drosophila protein CG7915 (Mink et al, 2001). SARM is a 
690 amino acid long and contains two sterile α motifs (SAMs) domains, a C-terminal TIR 
domain and N-terminal heat Armadillo repeat motif (ARM) (O’Neill et al., 2003). It was 
found that overexpression of SARM did not activate NF-κB or IRF3 (Liberati et al., 2004). 
In contrast to the other TLR adaptors, SARM was found to act as a negative regulator of 
TRIF-dependent TLR signalling. It blocked gene induction downstream of TRIF, but not 
MyD88, and suppression of endogenous SARM expression led to enhanced TRIF-
dependent cytokine production (Liberati et al., 2004; Carty et al., 2006). Carty et al. (2006) 
showed that association between TRIF and SARM was strongly enhanced following LPS 
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or poly(I:C) treatment. It was hypothesised that SARM mediated its inhibitory effects by 
preventing the interaction of TRIF with upstream or downstream signalling molecules. 
However, Peng et al. (2010) demonstrated that human SARM is capable of blocking the 
LPS-induced MyD88- and TRIF-mediated AP-1 activation. Suppression of endogenous 
SARM with siRNA increased AP-1 basal level. In addition, Belinda et al. (2008) showed 
that the horseshoe crab orthologue SARM (CrSARM) downregulated TRIF dependent TLR 
signalling in response to infection. The CrSARM expression was upregulated within 3 h 
and strongly repressed at 6 h of infection. This suggested that SARM negatively regulating 
TRIF signalling is evolutionary conserved from horseshoe crab to human (Belinda et al., 
2008). Surprisingly in contrast to its role in human cells, murine SARM in the CNS appears 
to positively regulate TNF-α induction, which affects microglia activation and 
accumulation and protects critical neuron subsets from virus-induced pathology. Mice 
lacking SARM were reported to be more susceptible to lethal West Nile virus (WNV) 
disease. This phenotype was also associated with region-specific differences in WNV 
replication, with higher levels of viral RNA observed in the brainstem of SARM knockout 
mice (Szretter et al., 2009). Recently, Ddrosophila SARM has been shown to be involved 
in axonal degradation. SARM knockout neurons in slice cultures exhibit reduced cell death 
in response to oxygen/glucose deprivation (Osterloh et al., 2012).  
 
1.6    Negative regulation of TLR signalling 
Defects in TLR signalling make the host susceptible to various pathogens. However, 
stimulation of TLRs by microbial components can triggers excess production of 
inflammatory cytokines such as TNF-α, IL-6 and IL-12, which may lead to systemic 
disorders with a high mortality rate in the host (Takeda and Akira, 2005). To control TLR 
signalling, a number of negative regulators are upregulated and serve to modulate the TLR 
immune response through negative feedback mechanisms (Figure 1.6). Others negative 
modulators of TLR signalling are constitutively expressed and control primary TLR 
signalling events. Together these molecules serve to prevent potentially harmful immune 
responses (Janssens et al., 2002). In addition, anti-inflammatory factors produced indirectly 
during immune responses can also negatively regulate TLR signalling. Such potent anti-
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inflammatory factors include TGFβ, IL-10 and steroid hormones (Janssens et al., 2002; Lee 
and Kim, 2007).  
 Negishi et al. (2005) showed that IRF4 inhibited the expression of MyD88-
dependent and IRF5-dependent genes following TLR stimulation. Moreover, it was found 
that TLR activation induced IRF4 mRNA, which competes with IRF5, for interaction with 
MyD88. In addition, TLR-dependent induction of proinflammatory cytokines is markedly 
enhanced in peritoneal macrophages derived from IRF4-deficient mice, whereas the pro-
inflammatory cytokine induction is inhibited by ectopic expression of IRF4 in a 
macrophage cell line (Negishi et al., 2005).  Dok1 and Dok2, downstream adaptors of 
protein tyrosine kinases, are constitutively expressed and activated within minutes 
following TLR4 stimulation (Shinohara et al., 2005). These proteins specifically inhibit the 
extracellular-signal-regulated kinases (ERK) pathway, but not the pathways involving p38, 
JNK, and NF-κB. The inhibition seems to be specific for TLR4 (Shinohara et al., 2005). 
Other TLRs regulators include β-arrestin 1 and β-arrestin 2. It has been demonstrated that 
β-arrestin 1 and β-arrestin 2 interact with TRAF6 after TLR activation in macrophages. 
This interaction inhibits TRAF6 autoubiquitination and concomitant NF-κB and AP-1 
activation. Endotoxin treated β-arrestin 2 deficient mice had higher expression of pro-
inflammatory cytokines and were more susceptible to endotoxic shock (Wang et al., 2006). 
Recently, Xia et al. (2011) showed that Nucleotide-binding oligomerization domain protein 
26 (NLRX1), a NOD-like receptor family member, negatively regulates TLR-mediated NF-
κB activation. NLRX1 interacts with TRAF6 or IκB kinase (IKK) upon LPS stimulation 
resulting in inhibition of IKKα and IKKβ phosphorylation and NF-κB activation. In 
addition, knockdown of NLRX1 in various cell types enhances IKK phosphorylation and 
production of NF-κB-responsive cytokines after LPS stimulation. Knockdown of NLRX1 
in mice markedly enhanced their susceptibility to LPS-induced septic shock and levels of 
plasma IL-6 (Xia et al., 2011). In addition to the negative regulators of the MyD88 and 
TRIF pathways that have been mentioned described herein, TLRs can be negatively 
regulated by nuclear receptors, including the glucocorticoid receptor (GR), liver X 
receptors (LXRs) and peroxisome proliferator-activated receptor γ (PPARγ) (lee and Kim, 
2007). 
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Figure 1.6: The negative regulators of TLR signalling pathways. The negative 
regulators were marked in brown near to their targets proteins. Triad3A, acts as an E3 
ubiquitin-protein ligase and enhances ubiquitination and proteolytic degradation of certain 
TLRs. Suppressor of cytokine signalling (SOCS)-1 interacts with Mal and induces its 
polyubiquitination and subsequent proteasomal degradation and their by act as negative 
regulator of TLR2 and TLR4 signalling. The Tripartite-motif protein (Trim) 30α act as a 
negative regulator of TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for 
degradation. Radioprotective 105 (RP 105) and its helper molecule, MD-1, have a physical 
association with TLR4/MD2, and this association inhibits LPS-TLR4/MD2 complex 
formation. Other negative regulators such as IRF4, MyD88s, IRAKM, SARM and SHP2 
were discussed in more details in the text (Adapted from Wang et al., 2009). 
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1.7    Role of TLRs in human disease 
Different mutation of the TLRs and many experimental models have revealed the 
significance of TLRs in susceptibility to infection and their involvement in the patho-
genesis of a number of non-infective inflammatory disorders such as cancer, allergy, 
autoimmunity, inflammatory bowel disease and atherosclerosis (Montero and Martin, 
2009). For example, a clear role for TLR4 in sepsis, rheumatoid arthritis (RA) and allergy 
is documented (O’Neill et al., 2009; Shotorbaniet al., 2011). TLR2 has been implicated in 
similar pathologic conditions and also in systemic lupus erythematosus (SLE) and tumor 
metastasis. Also, TLR7 has also been implicated in SLE (O’Neill et al., 2009; Shotorbaniet 
al., 2011). 
Atherosclerosis is considered as a disease whereby excessive inflammation of endothelium 
and smooth muscle cells of the artery wall is evident. The TLRs have been reported to 
participate in the initiation and development of atherosclerosis (Schoneveld et al., 2008). 
Specifically, increased TLR2 and TLR4 mRNA expression in atherosclerotic plaques and 
on circulating blood cells during atherosclerotic lesion development was reported (Curtiss 
and Tobias, 2009; Schoneveld et al., 2008). Moreover, other reports have suggested that 
polymorphisms in the human TLR4 gene are associated with the development and 
progression of atherosclerosis (Kiechl et al., 2002).TLR dysregulation has been reported in 
patients with inflammatory bowel disease (IBD). Pathophysiological features of IBD 
include uncontrolled excessive inflammation in the gastrointestinal mucosa and the 
upregulation of proinflammatory and T cell cytokines. While TLR3 expression was 
reported to be downregulated, TLR4 expression was upregulated during the IBD (Cario and 
Podolsky, 2006). Results have also suggested that TLR2 and its co-receptors TLR1 and 
TLR6 are involved in the initial immune response to bacteria in the pathogenesis of IBD 
(Pierik et al., 2006). 
 Functional TLRs are expressed in a wide variety of tumours and evidence suggests 
that TLR signalling pathways in tumours may be associated with subversion of host 
defense in favour of the neoplastic process (Huang et al., 2008). It is suggested that 
activation of tumoral TLRs induces the synthesis of proinflammatory factors and 
immunosuppressive molecules. These enhance the resistance of tumour cells to cytotoxic 
lymphocyte attack and facilitate their evasion or, may promote proliferation and survival of 
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tumour cells by inducing the release of cytokines such as IL-6, IL-13,TNF-α and other 
growth factors (Huang et al,. 2005). Moreover, it has been reported that TLRs induce 
resistance to apoptosis, increase angiogenesis and vascular permeability, and enhance 
tumour cell invasion by regulating metalloproteases and integrins. (Huang et al., 2008; 
Wang et al., 2003). Other studies have directly demonstrated that NF-κB plays a pivotal 
role in TLRs-induced tumourgenesis when TLRs are activated by their ligand, as 
constitutively active NF-κB is often found in a number of human malignancies ((Palayoor 
et al., 1999; Pikarsky et al., 2004). However, there are studies suggesting that TLR3 
triggers apoptosis of human prostate cells and breast cancer cells. Because apoptosis may 
be a potent mechanism of eliminating tumor cells, these results suggest that TLR3 or TLR3 
ligands may be very useful tool for cancer therapy (Salaun et al., 2006;  Paone et al., 2008). 
SLE is a complex chronic inflammatory disease that arises spontaneously and can affect the 
skin, joints, kidneys, lungs, nervous system, and other organs (Marshak-Rothstein, 2006). 
Nucleic acid-sensing TLRs (TLR3, 7, 8 and 9), particularly TLR7, have been implicated in 
SLE and are thought to exacerbate the disease pathology. Single nucleotide polymorphism 
analyses as well as experimental mouse models have shown that TLRs are involved in SLE. 
Regarding the role of TLRs in SLE, it has been proposed that TLRs may be stimulated by 
exogenous antigens, like viral ssRNA, which then stimulate resident immune cells, or the 
TLRs may recognise endogenous self-antigens, thus initiating and propagating 
inflammation and autoimmunity (Montero and Martin, 2009; Horton et al., 2010). The 
involvement of the TLRs in such disease makes them important targets for the development 
of new vaccines and innovative therapies to prevent and treat human diseases. 
 RA is a chronic autoimmune disease that is characterised by inflammation of the 
synovial joints, which leads to joint destruction (McCormack et al., 2009; Shotorbaniet al., 
2011). Roelofs et al. (2005) showed that TLR2, TLR3, TLR4 and TLR7 expression was 
markedly increased in synovial tissue from RA patients, compared with synovial tissue 
from healthy controls. Moreover, DCs from RA patients have been shown to produce 
increased levels of the pro-inflammatory cytokines TNF-α and IL-6 upon engagement of 
TLR2 or TLR4, but not TLR3 and TLR7 (Roelofs et al., 2005). Other studies have shown 
that inhibition of TLR4 suppresses the severity of experimental arthritis and results in lower 
IL-1 expression in arthritic joints (Abdollahi-Roodsaz et al., 2007). In addition, clinical and 
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histopathological evaluation of IL-1/TLR2 deficient mice revealed that they presented with 
a more severe arthritis when compared to wild-type counterparts. In contrast, IL-1/TLR4 
deficient mice were protected against severe arthritis and had markedly lower numbers of 
Th17 cells and a reduced capacity (Abdollahi-Roodsaz et al., 2008). 
 
1.8    Project Aims 
The present available knowledge regarding how TRIF activate and transmit TLR signalling 
pathways is much less compared to MyD88-dependent signalling pathways. As mention 
earlier, TLRs activation has been linked to the pathogenesis of infectious disease, tumor 
growth and rheumatoid arthritis. Specifically the TRIF pathways have been shown to have 
a close tie with these diseases (Ouyang et al., 2007, Shotorbaniet al., 2011). Nevertheless, 
better understanding of the TRIF signalling pathways would be therapeutically useful for 
the development of vaccines and treatments that could control disease associated 
inflammations and anti-viral responses. Therefore, the main objectives of this project were: 
1. To characterise the time dependent association of known/unidentified proteins with 
TRIF.  
2. To identify possible differential association of proteins with TRIF following TLR3 
versus TLR4 ligand engagement.  
3. To functionally characterise selected novel TRIF interacting molecules towards a 
greater understanding of TRIF signalling following TLR3/4 ligand engagement.
 Chapter 2 
 
 
General Materials and Methods 
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2.1    General Materials 
See Appendix 2. 
 2.2    Methods 
2.2.1    Cell culture techniques 
All mammalian cells were grown at 37 
o
C in a humid environment with 5 % CO2 in the 
appropriate complete growth culture medium, DMEM or RPMI supplemented with 10 % 
(v/v) FBS 1 % (v/v) penicillin/streptomycin, 1 % (v/v) fungzone, and 1 % (v/v) Sodium 
Pyruvate. Specifically HEK293-TLR3 cells were cultured in complete DMEM containing 
10 mg/ml blasticidin. HEK293-TLR4 cells were cultured in complete DMEM containing 
10 mg/ml blasticidin and 100 mg/ml hygrogold. Human Astrocytoma U373-CD14 cell line 
was cultured in complete RPMI containing 250 μg/ml G418. Adherent cell monolayers 
were detached from tissue culture flasks using trypsin/EDTA, and split every 3-4 days at a 
ratio 1:5 or 1:10 depending on cell growth. 
 
2.2.2    Cell stock freezing and resuscitation 
Adherent cells were trypsinised, re-suspended in full growth medium, and centrifuged at 
380 g for 5 min. Pelleted cells were re-suspended in freezing medium (90 % (v/v) FBS, 10 
%  (v/v) DMSO) and aliquoted into cryovials. Cell stocks were frozen at -80 
o
C for 4 hours 
before long-term storage in liquid nitrogen. For resuscitation of the cells, cryovials were 
thawed at 37 
o
C, and cells were re-suspended in full growth medium before centrifugation 
at 380 g for 5 min. Medium was removed and cell pellet was then re-suspended and grown 
in complete growth medium (DMEM, 10 % (v/v) FBS, 1 % (v/v) penicillin/streptomycin, 1 
% (v/v) fungzone and 1 % (v/v) Sodium pyruvate) at 37 
o
C in a humidified atmosphere of 5 
% CO2. Cells were selected after becoming confluent in appropriate selection medium as 
mentioned earlier.  
 
2.2.3    Transfection of cells with plasmid and esiRNA 
Transfection of cells with plasmid DNA was carried out using Lipofectamine 2000 
transfection reagent (Invitrogen) according to the manufacturer’s instructions. Transfection 
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of esiRNA was performed using DreamFect
™
 Gold (OZ Bioscience) according to the 
manufacturer’s instructions. 
 
2.2.4    Transformation of competent cells 
Plasmid DNA (5 μl; ~100 ng) was added directly to 100 μl of thawed, E. coli DH5α 
competent cells (Invitrogen) and incubated on ice for 30 min. Thereafter, cells were 
transferred to a 40 
o
C heat block for 30 s before being immediately returned to ice for a 
further 2 min. Cells were re-suspended in 0.5 ml LB broth and incubated at 37 
o
C with 
gentle shaking for 1 hour. The microfuge tube was briefly centrifuged and the upper 
medium was removed. Approximately 100 μl of the transformed bacteria were plated out 
onto LB-agar plates supplemented with 100 μg/ml ampicillin. Plates were inverted and 
incubated at 37 
o
C overnight. 
 
2.2.5   Preparation of plasmid DNA 
Single colonies were inoculated into 5 ml of LB broth containing 100 μg/ml ampicillin at 
37 
o
C with gentle shaking for 4-5 h. Thereafter, the inoculum was transferred to a conical 
flask containing 95 ml of LB broth and 100 μg/ml ampicillin and incubated overnight at 37 
o
C with gentle shaking. Bacterial cells were pelleted by centrifugation (380 g, 30 min at 4 
o
C). DNA was extracted from the cells using the High Speed Midi Kit as described by the 
manufacturer (QIAGEN). The DNA concentration determined using the NanoDrop ND-
1000 spectro-photometer (Thermo Scientific).  
 
2.2.6    Glycerol stocks 
The transformed cells (600 μl) were mixed with 800 μl of 50 % glycerol in a cryovial and 
stored at -80 
o
C. The stocks were used to inoculate 100 ml liquid cultures as necessary. 
 
2.2.7   Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed based on Laemmli method and carried out using the mini-gel 
system (Biorad). Plates were first arranged in the relevant casting rig and the system was 
checked for leaks. 10 % acrylamide resolving gels were prepared based on the recipe given 
(Table 2.2.1) and topped with dH2O to ensure a flat surface, prevent drying and air bubbles 
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forming. The resolving gel was poured such that adequate provision was made to allow for 
the stacking gel to be poured. The resolving gel was let set for between 5-30 minutes. The 
5 % stacking gel was prepared as described (Table 2.2.2). The dH2O was decanted from the 
gel. The stacking gel was then poured followed by placing the appropriate spacer comb in 
the gel to form the loading well and the stacking gel was allowed to polymerise for between 
5-30 minutes. The comb was then removed from the gel and the gel was transferred from 
the casting rig to the electrophoresis chamber (Biorad). The chamber was then filled with 
1x running buffer (Table 2.2.4). The samples to be analysed were then mixed with 5x 
loading buffer (Table 2.2.5), followed by boiling at 100 
o
C for 5 min prior to the loading in 
the wells. Routinely, precision plus dual colour standards protein marker (Bio-Rad) was 
loaded and served as molecular weight reference. Electrophoresis was performed at 100 V 
for 2-3 h. Gels were then carefully removed from electrophoresis chamber and casting rig 
and the 5 % stacking gel was cut away and discarded. The gels were then stained or 
subjected to western blot.  
 
2.2.8    Western blot 
Proteins were transferred to polyvinylidene difluoride membrane (PVDF; Millipore), using 
a wet transfer apparatus. Briefly, PVDF membranes were first activated by soaking them in 
methanol for 1 min followed by washing in 1x transfer buffer (Table 2.2.7). The gels and 
the membranes were sandwiched between wet sponge and papers, (sponge, papers, gel, 
membrane, papers, sponge). All sandwiches were clamped tightly after ensuring that there 
is no air bubbles between the gel and the membrane. The sandwiches were then placed in 
the transfer chamber (Fisher Scientific), and the chamber was filled with 1x transfer buffer 
(Table 2.2.7). Transfer was carried out at 200 mA for 1.5 h or overnight at 30 mA. The 
PVDF membrane were then blocked in 5 % (w/v) fat free dry milk in TBST for at least 1 h 
at RT, and then washed with TBST (Table 2.2.9). Primary antibodies were diluted in 5 % 
(w/v) fat free dry milk in TBST or 5 % (w/v) BSA in TBST. Membranes were then 
incubated overnight at 4 
o
C with primary antibody at an appropriate dilution on a roller. 
After multiple washes with TBST, the membrane was incubating with a horseradish 
peroxidase (HRP)-conjugated secondary antibody raised against the appropriate species, 
diluted (1:2000) in 5% (w/v) fat free dry milk in TBST for 1 h. Unbound antibody was 
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washed  away with TBST and specific polypeptide bands were visualized using supersignal 
westdura (Fisher) and then images were captured using the GeneSnap acquisition and 
GeneTools analysis software, (GeneGenius Gel Documentation and Analysis System; 
Syngene). 
 
2.2.9    Immunoprecipitation of HA-TRIF 
HEK293-TLR3 and HEK293-TLR4 were plated into 6 well plates. After 24 h, cells were 
co-transfected with the indicated plasmid using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s instructions. The total amount of DNA (3 µg/well) was kept constant 
by the addition of empty vector. After 20 h, the transfected cells were stimulated with the 
TLR ligands (20 μg/ml poly(I:C) HEK293-TLR3 or 1 μg/ml LPS HEK293-TLR4) for the 
indicated time. The cells were lysed in 600 µl of lysis buffer  (50 mM HEPES, pH 7.5, 150 
mM NaCl, 2 mM EDTA, pH 8.0, 1 % NP-40, 0.5 % sodium deoxycholate supplemented 
with 1 mM PMSF, 1 mM DDT, 1 mM NaVO3, (5mM EGTA for co-IP TRIF and 
ADAM15) and protease inhibitor cocktail) and left on ice for 20 min. The lysates were 
subjected to centrifugation for 5 min (15620 g at 4 
oC) to remove cell debris. Next, 1 μg of 
mouse monoclonal anti-HA antibody (Covance) was incubated with 50 μl A/G Plus-
agarose beads (Santa Cruz) overnight at 4 °C with gentle shaking. Cleared cell lysates were 
mixed with the beads and incubated for 2 h at 4 
o
C with gentle shaking. 
Immunoprecipitated complexes were washed at least 4 times with lysis buffer followed by 
centrifugation for 2 min at 220 g.  Proteins were resolved from the beads by the addition of 
40 μl of loading buffer, followed by boiling for 5 min. Thereafter, samples were separated 
by SDS-PAGE gel electrophoresis followed by staining or immunoblot analysis.   
 
2.2.10    Immunoprecipitation of endogenous TRIF 
Human astrocytoma U373-CD14 cells were plated onto T175 flasks. When the cells 
become confluent (90-95 %), cells were stimulated with 20 µg/ml poly(I: C) or 1 µg/ml 
LPS for different time points as indicated. After that the medium was removed from the 
cells and cells were scraped in 10 ml of ice-cold PBS and centrifuged for 10 minutes (220 g 
at 4
o 
C). Cells were lysed in 600 μl of lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 
2 mM EDTA, pH8.0, 1 % NP-40, 0.5 % sodium deoxycholate supplemented with 1 mM 
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PMSF, 1 mM DDT, 1 mM NaVO3, (5 mM EGTA for co-IP TRIF and ADAM15) and 
protease inhibitor cocktail) and left on ice for 20 min. The lysates were subjected to 
centrifugation for 5 min at 15620 g at 4 
o
C to remove cell debris. Next, precoupling of the 
antibody to beads was performed by incubating 2 μg of anti-TRIF polyclonal antibody 
(Exalpha) with 50 μl slurry of Protein A/G Plus–agarose (Santa Cruz) overnight at 4 oC 
with gentle shaking. Next, 500 μl of the cleared cell lysates was added to the precoupled 
beads and incubated at 4 
o
C for 2 h with gentle shaking. The beads were washed 4 times 
with lysis buffer. Immunoprecipitated complexes were separated by SDS-PAGE and 
subjected to immunoblotting.  
 
2.2.11    Silver staining 
After electrophoresis, gels were placed into fixing solution (30 % (v/v) ethanol, 10 % (v/v) 
acetic acid) for a minimum of 30 min. The gels were then rinsed in 20 % (v/v) ethanol 
twice for 10 min, which was followed by washing twice in milliQ dH2O (10 min per wash). 
The water was removed and sensitising solution (0.8 mM sodium thiosulfate) was poured 
onto the gels for one min after which the gels were once again washed twice in milliQ 
dH2O (2 min per wash). The gels were then stained with staining solution (12 mM silver 
nitrate) for 20 min to 1 h. After the staining solution was removed, the gels were washed in 
milliQ dH2O for 10 s. Next, the developing solution (0.04 % (v/v) formaldehyde in 3 % 
(w/v) sodium potassium carbonate) was added to the gel. Once the protein bands were 
visualised, the gels were placed in stop solution (2 % (v/v) acetic acid in 0.3 M TRIS) for 
storing. 
 
2.2.12    Gel de-staining and sample preparation for Mass Spectrometry (MS) 
Bands from a 1D gel protein gel were excised from the control and experimental lanes and 
placed into siliconised 1.5 ml Eppendorf tubes (Sigma-Aldrich). Silver-stained proteins 
were destained with chemical reducers to remove the silver. The reactive substances of the 
chemical reducers were potassium ferricyanide and sodium thiosulfate. These chemical 
agents were prepared prior to digestion as two stock solutions of 30 mM potassium 
ferricyanide and 100 mM sodium thiosulfate, both dissolved in water. A working solution 
was prepared by mixing a 1:1 ratio of the above stock solutions. This working solution was 
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unstable, and therefore had to be prepared fresh for each reaction. Working solution (50 μl) 
was added to cover the gel plugs and occasionally vortexed. The stain intensity was 
monitored until the brownish colour disappeared, then the gel plugs were rinsed a few times 
with water to stop the reaction. Cysteine residues were reduced and alkylated using DTT 
and Iodoacetamide (IAA) as follows. Briefly, 50 μl 10 mM DTT (in 100 mM NH4HCO3) 
was added to each tube followed by shaking at 56 
o
C for 1 h. The tubes were centrifuged 
briefly and the solution was removed and 50 μl of 50 mM IAA (in 100 mM NH4HCO3) was 
added and incubated for 30 min in the dark at RT with gentle agitation. After brief spinning 
the solution was removed and gel plugs were washed with sequential additions of 
ammonium bicarbonate (NH4HCO3) and acetonitrile (ACN). First, 300 μl of 100 mM 
NH4HCO3 was added to each tube and incubated for 15 minutes at 37 
o
C with gentle 
agitation, followed by addition 1:1 of 20 mM NH4HCO3/ACN for 15 min at 37 
o
C with 
gentle agitation. Finally, the gel pieces were dehydrated in 100 % ACN for 10 min at 37 
o
C 
with gentle agitation. Samples were digested with 4 ng/μl trypsin (Promega) at 37 oC 
overnight. Peptide were extracted using 2:1 ACN: 5 %  (v/v) trifluotoacetic acid (TFA) for 
15 min at 37 
o
C with gentle agitation, dried by vacuum centrifugation overnight at RT and 
stored -20 
o
C for subsequent MS analysis. On the day of MS analysis, samples were re-
suspended in 20 μl of 0.1 % TFA and centrifuged at 13680 g at 4 oC for 15 min, then 
filtered and centrifuged at 13680 g for 5 min at 4 
o
C. From each sample, 10 μl was pipetted 
into MS vials (Agilent) for subsequent protein identification. 
 
2.2.13    Ion Trap Mass Spectrometry 
The mass spectrometric analysis of peptides was performed at the Proteomics Suite of the 
Department of Biology, National University of Ireland Maynooth, using a Model 6340 Ion 
Trap LC/MS apparatus (Agilent Technologies). Peptides were separated using a nanoflow 
Agilent 1200 series system, equipped with a Zorbax 300SB C18 5 μm, 4 mm 40 nl pre-
column and an Zorbax 300SB C18 5 μm, 43 mm x 75 μm analytical reversed phase column 
using HPLC-Chip technology. The mobile phases utilised were A: 0.1 % formic acid, B: 
50 % acetonitrile and 0.1 % formic acid. Samples (5 μl) were loaded into the enrichment 
column at a capillary flow rate set to 4 ml/min with a mix of A and B at a ratio 19:1 (v/v). 
Tryptic peptides were eluted with a linear gradient of 10-90 % solvent B over 15 min with a 
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constant nano pump flow rate of 0.60 ml/min. The capillary voltage was set to 1900 V and 
the flow and the temperature of the drying gas were 4 l/min and 300 ˚C, respectively. A 1 
min post time of solvent (A) was used to remove sample carry over. For protein 
identification, database searches were performed using the Mascot MS/MS Ion search 
(Matrix Science, London, UK). All searches used Homo sapiens (human) as taxonomic 
category and the following parameters: (i) two missed cleavages by trypsin, (ii) mass 
tolerance of precursor ion 1.2 Da and product ions 1 Da, (iii) carboxymethylated cysteine 
fixed modification, and (iv) oxidation of methionine as variable modification. Pathway 
studio software (Ariadne genomics) was used to visualize the interconnectivity between the 
identified protein hits and to make network interaction maps.  
 
2.2.14    RNA isolation using TRIZOL reagent 
Cells were seeded into 6 well plates and treated/transfected as required for the experiments. 
Thereafter, the medium were removed and cells were lysed in 1 ml of TRIZOL (Invitrogen) 
then 0.2 ml of chloroform (5:1 v/v chloroform) was added followed by mixing and incubation 
for 10 min at RT. The mixture was subjected to centrifugation at 15620 g for 15 min at 4 oC. 
After centrifugation, the mixture was separated into lower phenol-chloroform phase (red) and 
upper aqueous phase (colourless). RNA remained exclusively in the aqueous phase. Next, 500 
μl of the upper aqueous phase was transfered into fresh tube, and RNA was precipitated by 
addition of 500 μl isopropyl alcohol. The mixture was incubated for 10 min at RT, followed by 
centrifugation at 15620 g for 15 min at 4 oC. The supernatant was removed and the RNA pellet 
was washed once with 500 μl 75 % ethanol and centrifuged at 13680 g for 5 min at 4 oC. The 
ethanol was removed and the pellet was air drieded for 5 min at RT. The RNA was dissolved in 
30 μl RNAase free water (Sigma), and the RNA concentration was measured using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Samples were stored at -20 
o
C 
until required for first strand cDNA synthesis. 
 
2.2.15    First-strand cDNA synthesis 
 
Total cellular RNA (1 μg) was mixed with 1 μl of random hexamers primers (500 μg/ml)  
(Fisher scientific) and water to make a final volume of 17 μl. The mixture was incubated at 
70 
o
C for 5 min. The mixture was then briefly centrifuged and chilled on ice for 2 min. 
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Next, 5 l of 5x reaction buffer, 1.3 l deoxynucleotides (10 mM dNTP), 0.7 μl Rnase 
inhibitor and 1 l MMLV reverse transcriptase were then added to give a final reaction mix 
of 25 μl. The cDNA synthesis was performed by incubation the reaction mixture in a 
thermocycler at 37 
o
C for 40 min followed by incubation at 42 
o
C for 40 min. Reactions 
were heat inactivated at 80 
o
C for 10 min then held at 4 
o
C. The samples were stored at -20 
o
C until required for PCR.
 
 
2.2.16    PCR 
The first strand cDNA samples were diluted 1:5, then 3.5 μl was used per PCR reaction. 
Next, 5 l of 5x reaction buffer, 2 l of 2.5 mM dNTP, 2 l of 25 mM MgCl2, 2.1 l H2O, 
1.5 l of 20 M forward and reverse primers, 7.5 l of 50 % glycerol and 0.4 l of Taq 
DNA polymerase  were then added to give a final reaction mixture of 25 µl. The samples 
were placed in a Thermocycler (Eppendorf) and the samples were subjected to the 
following cycling conditions: (1) 95 
o
C, 3 min, (2) 94 
o
C, 1 min, (3) 60 
o
C, 30 s (4) 72 
o
C, 1 
min (5) repeat 2 to 4 for 35 cycles, (6) 72 
o
C, 7 min (8) 80 
o
C, 10 min (9) hold at 4 
o
C. 
Samples were subjected to agarose gel electrophoresis. 
 
2.2.17    Real time PCR 
The cDNA samples were used as template and diluted 1:25, then 2.5 μl was used per each 
reaction. Next, 2.5 l of 4 M of both forward and reverse primers, 2.5 l H2O and 10 l of 
Sybr green mater mix (2x) were added to give a final reaction mixture of 20 μl. The 
reactions were performed in duplicate using an Opticon 2 Thermocycler (MJ Research), 
and the samples were subjected to the following cycling conditions: 15 min at 95 
o
C to 
denature the cDNA, followed by 37 cycles of (1 min at 94 
o
C, 15 s at 60 
o
C to permit 
primer annealing, followed by 30 s at 72 
o
C for elongation). The melting curve from 65 
o
C 
to 95 
o
C was recorded every 1 
o
C. 
 
2.2.18    Agarose gel electrophoreses 
Agarose gels were prepared by adding appropriate amount of agarose (depending on the 
required concentration) to TAE (0.04 M Tris-acetate, 1 mM EDTA, pH 8.0) and 
microwaving until the agarose melted. The molten agarose was allowed to cool down, then 
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mixed with 1:10000 dilution of Sybr safe DNA gel Stain (Invitrogen). The agarose was 
poured into a casting tray and a plastic comb was inserted to create the wells and then 
allowed to solidify. The plastic comb was removed and the agarose gel was placed into the 
electrophoresis unit (Hoefer Scientific Instruments). The gel was then covered with TAE 
running buffer. Next, 15 µl of the RT-PCR product was loaded into the well. A voltage of 
100 V was applied to the gel apparatus until sufficient separation was obtained. The DNA 
gel bands were visualized and photographed using the G:box documentation system 
(Syngene). 
 
2.2.19    Reporter assays 
 HEK293-TLR3 and HEK293-TLR4 cells were seeded into 96 well plates (5 x 10
4 
cells/well). After 24 h, cells were co-transfected with vectors encoding either a reporter 
gene for the IFN promoter (p125), IFNβ PRDII, IFNβ PRDIII, NF-κB, or Rantes promoter 
(80 ng/well) and either empty vector or increasing amounts of an expression vector 
encoding full length V5-ADAM15, Myc-DVL1 Myc-DVL2, Myc-DVL3, and Optineurin 
as indicated using lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. A total of 40 ng/well Renilla-luciferase reporter gene was transfected 
simultaneously as an internal control. After 24 h, HEK293-TLR3 were stimulated with 20 
µg/ml poly(I:C)  and HEK293-TLR4 were stimulated with 1 µg/ml LPS for additional 24 h. 
Thereafter, cell lysates were prepared and reporter gene activity was measured using the 
Dual-Luciferase Assay system (Promega). Data were expressed as the mean fold induction 
relative to the control. HEK-293T cells were seeded into 96 well plates (5 x 10
4 
cells/well). 
After 24 h, cells were co-transfected with vectors encoding either a reporter gene for the 
IFN-β promoter (p125), IFNβ PRDII, IFNβ PRDIII, NF-κB, or Rantes (80 ng/well) and 
either empty vector or vector encoding full length HA-TRIF or, vector encoding full length 
Myc-MyD88 (20 ng/well) and increasing amounts of an expression vector encoding V5-
ADAM15, Myc-DVL1, Myc-DVL2, Myc-DVL3, and  Optineurin as indicated using 
lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. A total of 40 
ng/well Renilla-luciferase reporter gene was transfected simultaneously as internal control. 
After 24 h, cells were harvested and cell lysates were prepared followed by assessment of 
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reporter gene activity using the Dual-Luciferase Assay system. (Promega) Data were 
expressed as the mean fold induction relative to the control. 
 
2.2.20    Enzyme-Linked Immunosorbent Assay (ELISA) 
Microtitre plates (Fisher Scientific) were coated with appropriate capture antibody (1 μg/ml 
for TNFα and Rantes, 2 μg/ml for IL-6) overnight at RT. The following day, the plates 
were washed three times with wash buffer (PBS containing 0.05 % (v/v) Tween-20) 
followed by blocking with blocking buffer (PBS containing 1 % BSA) for at least 2 h. The 
plates were then washed three times with wash buffer. Next, serial dilutions of the 
standards (ranging from 0 to 4000 pg/ml; 100 l/well) and the samples were added (100 
μl/well) followed by incubation at 4 oC overnight. Next day, the plates were washed three 
times with the wash buffer followed by the addition of the appropriate detection antibody 
(0.2 μg/ml for IL-6, 0.25 μg/ml for Rantes and 0.5 μg/ml for TNFα) for 2 h at RT. The 
plates were washed three times with the wash buffer followed by the addition of the 
streptavidin-HRP conjugate antibody (1:2000 for Rantes and TNFα; 1:200 for human IL-6) 
for 30 min. Thereafter, the plates were washed three times with the wash buffer followed 
by the addition of the substrate. Plates were incubated at RT for 5 min with gentle shaking. 
The absorbance was measured at 450 nm using a BioTek plate reader. 
 
2.2.21    Meso Scale Human 7-Plex / MMP 3-Plex / IFN-β / RANTES Assay 
Levels of IFN-γ, IL-10, IL-12 p70, IL-1β, IL-6, IL-8, and TNFα in cell free supernatants 
were measured using a Meso Scale 96-Well plate Human 7-Plex ultra-sensitive assay kit or 
a Meso Scale MMP 1, MMP 3, and MMP 9 96-Well MMP 3-plex ultra-sensitive assay kit 
(Meso Scale Discovery (MSD)). Levels of IFN-β and RANTES were measured using a 
Single Plex assay kit (Meso Scale Discovery). The human single/multiplex assay detected 
the respective cytokine/chemokines/MMPs in a sandwich immunoassay format. MSD 
supplied a 96 well ultra-sensitive plate precoated with the respective cytokine 
/chemokine/MMP capture antibodies on spatially distinct spots on the plate.  First, the pre-
coated single/multiplex plate was incubated for 30 min at RT with 25 µl/well of Diluent 2 
with vigorous shaking. Next, the cell free supernatants or appropriate dilution of the 
calibrator (highest calibrator point was obtained by diluting the stock calibrator 10-fold in 
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Diluent 2 and from this an 8 point standard curve with a 4-fold serial dilution was prepared-
assay range 500,000 to 0 pg/ml (MMP3-multiplex), 2500 to 0 pg/ml (7 multi plex and 
Rantes), 25000 to 1.5 pg/ml for IFNβ) were added to the appropriate wells of the MSD 
plate in duplicate. The plate was sealed with an adhesive seal and incubated for 2 h with 
vigorous shaking at RT. Next, the plate was washed three times with wash buffer (PBS, 
0.05 % Tween 20 (PBST)) and was pat dry. Next, the working concentration of Sulfo-tag 
detection antibody was prepared as followed. Briefly, the 50x stock sulfo-tag was diluted to 
a final working concentration of 1x by adding 60 µl of the stock to 2.94 ml of Diluent 3 
supplied with the kit.  Next, 25 µl of the 1x working concentration of Sulfo-tag detection 
antibody was added to each well of the MSD plates followed by sealing of the plates and 
incubation for 2 h at RT with vigorous shaking. Next, the plates were washed three times 
with PBST followed by the addition of 150 µl/well of 2x Read Buffer T to each well of the 
MSD plates. Analysis of the plates was performed using a SECTOR Imager and data 
analysis was performed using the MSD Discovery Workbench analysis software. 
 
2.2.22    Immunofluorescence 
Cells were cultured on Collagen precotaed glass coverslip into 6-well plates. After 24 h, 
cells were transfected with the indicated plasmids. After 24 h, cells were stimulated as 
indicated or left untreated (control). Therafter, cells were washed with PBS and fixed in 4 
% para- formaldehyde for 10 min. Cells were permeabilised using 0.5 % Triton X-100 in 
PBS for 5 min followed by blocking for at least 1 h in blocking  buffer (1 % BSA in PBS 
with 0.05 % (v/v) Tween-20). Next, primary antibodies were diluted (1:50) in the blocking 
buffer and vortexed well followed by centrifugation for 3 min at 15620 g. Next, 200 μl of 
the primary antibody was added to each coverslip followed by incubation for 2 h at RT. 
Thereafter, cells were washed three times (10 min/wash) with wash buffer (PBS containing 
0.05 % (v/v) Tween 20). The Alexa fluor secondary antibodies were diluted 1:200 in the 
blocking buffer, vortexed and centrifuged for 3 min at 15620 g. Then, 200 μl of the diluted 
secondary antibody mix was added to the coverslip followed by incubation for 1 h at RT in 
the dark. Unbound antibodies were removed by washing the coverslips with wash buffer. 
Next, the nuclei was stained with DAPI dye (10 μg/ml) in PBS for 5 min at RT in the dark. 
Coverslips were then washed with PBS, mounted on glass slides using Vectashield 
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mounting solution (Vector laboratories) and stored in the fridge until analysed. Images 
were captured using an Olympus 1000 confocal microscope and analysed using fluoview 
software. 
 
2.2.23   Statistics 
Statistical analyses were performed using Graphpad Prism 4 software. Differences were 
analysed using one-way and two-way ANOVAs and t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3 
 
 
Proteomic analysis of the TRIF interactome 
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3.1    Introduction 
Proteins interact with each other in a highly specific manner, and protein interactions 
play a key role in many cellular processes. Identifying and characterising protein-
protein interactions and their networks is essential for understanding the mechanisms of 
biological processes on a molecular level and is also a useful tool for identifying novel 
disease markers (Schoemaker et al., 2007). There are many approaches that allow the 
identification of interacting partners including, the yeast two hybrid system, immuno-
precipitation pull down assay (IP), chromatin immunoprecipitation (ChIP), in vivo  
fluorescence resonance energy transfer (FRET) and antibody arrays or protein chips 
(Yan and Chen, 2005; Byrum et al., 2011; Bailey et al; 2012).  
Proteomics has emerged as a field for studying global gene expression profiles 
at the protein level. In general, proteomics involves the identification of protein 
components and the measurement of protein abundance in biological systems such as 
cultured cells or tissue samples. The most popular use of the proteomic technology is 
the identification of protein complexes (Zhou and Veenstra, 2007). Currently, mass 
spectrometry (MS) has been overwhelmingly applied as the technology base for 
proteomics analysis. Proteins have been identified and quantified by characterisation of 
their derived peptides using either electrospray ionisation (ESI) or matrix assisted laser 
desorption/ionisation (MALDI)-based MS (Yan and Chen, 2005; Chakravarti et al., 
2002). 
Isolating the protein complex is the most critical step in determining the success 
of the downstream proteomic analysis. While advances in technology have had a huge 
impact, sample preparation issues related to isolation of protein complexes remain a 
critical factor in determining the success of these studies (Zhou and Veenstra, 2007). IP 
of protein complexes followed by liquid chromatography and mass spectrometry (LC-
MS) is a widely used method in proteomics research to identify proteins and to study 
protein-protein interactions. IP techniques allow purification of proteins of interest and 
reduce sample complexity before introduction to the mass spectrometer (lin et al., 2003; 
Zhou and Veenstra, 2007). The effectiveness of IP experiments is an important factor 
for identification of proteins and protein-protein interactions (Yang et al., 2009; Li et 
al., 2011).  
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As mentioned in Section 1.5.3, TRIF plays an important role in TLR3 and TLR4 
signalling pathways. Recent studies revealed that TRIF also involved in TLR2 and 
TLR5. However, the knowledge about how TRIF mediated TLR signalling and whether 
TRIF play another role in other signalling pathways is not fully understood. Analysis of 
TRIF intercome could lead to identification of novel TRIF interacting partners which 
will improve our knowledge about TRIF signalling. Therefore, it is of interest in this 
Chapter to use different strategies (Figure 3.1) to (1) characterise time dependent 
association of known-unknown proteins with TRIF and to (2) identify possible 
differential association of proteins following TLR3 and TLR4 ligand engagement.  
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Figure 3.1: Strategy adopted to identify TRIF binding partners. HEK293-TLR3 and 
HEK293-TLR4 cells were transfected with TRIF-HA for 20 h. Next, cells were 
stimulated with 20 μg/ml poly(I:C) (HEK293-TLR3) or  1 μg/ml LPS (HEK293-TLR4). 
Thereafter, cells were collected and immunoprecipitation of HA-TRIF was performed 
using 1 μg/ml of anti-HA antibody. Proteins were separated by SDS-PAGE and then the 
gels were silver stained. Visualized proteins band were cut in small pieces, destained 
and tryptic digested followed by protein identification using LC-MS analysis. 
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3.2    Results 
3.2.1    Immunoprecipitation of HA-TRIF  
To identify the proteins that interact with TRIF in a ligand and time dependent manner, 
HEK293-TLR3 and HEK293-TLR4 cells were transfected with HA-TRIF. After 20 h, 
cells were stimulated with the indicated ligand for the appropriate time followed by 
immunoprecipitation of HA-tagged TRIF. Correlating with previous report (Han et al., 
2004), TRIF overexpression caused cell death therefore experimental optimisation was 
required to achieve optimal TRIF expression with minimal cell death. It was found that 
transfection of cells in a 10 cm dish with 1-3 μg of TRIF resulted in minimal cell death, 
but TRIF expression was barely detectable. In contrast, transfection of cells with 5-10 
μg of TRIF resulted in massive cell death. It was consistently found that the optimal 
expression of TRIF with minimal cell death was achieved by overexpressing 3 μg of 
HA-TRIF into one well of a 6-well plate followed by cell harvesting 20 h after 
transfection. Thus, HEK293-TLR3 and HEK293-TLR4 were transfected with 3 μg of 
HA-TRIF or empty vector (EV) as negative control into one well of a 6-well plate. After 
20 h, cells were left untreated or stimulated with 20 μg/ml poly(I:C) (HEK293-TLR3) 
or 1 μg/ml LPS (HEK293-TLR4) for 20, 40 and 60 min, in duplicate to ensure adequate 
protein recovery. Thereafter, the cells were collected and TRIF IP was performed as 
described (Materials and methods, Section 2.2.9). It was evident that HA-TRIF 
expression was achieved in both cell types (Figure 3.2, panels A and C) at all-time 
points. It must be noted that whilst the predicted molecular weight of TRIF is 76-78 
kDa, routinely, in the current study, HA-TRIF was detected at approximately 100 kDa. 
This finding concurs with Dansako et al. (2009) who showed that overexpressed TRIF 
was detected at 102 kDa. Alterations in electrophoretic mobility may be attributed to 
post translational modification of TRIF, such as phosphorylation. An aliquot of the 
protein sample was subjected to SDS-PAGE followed by silver staining to visualise the 
protein bands (Figure 3.2, panels B and D). Each gel lane was cut into 24 gel pieces, 
followed by in-gel tryptic digestion and LC-MS analysis as described (Materials and 
methods, section 2.2.12). It is clear that many of the proteins detected were nonspecific 
since they also appeared in the control (EV). Further optimisation of the experimental 
procedure may be required to reduce nonspecific binding. However, this was beyond the 
scope of the current project. Herein, we opted to exclude any proteins that were 
identified by LC-MS in the EV lane. 
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Figure 3.2: Immunoprecipitation of HA-TRIF in HEK293-TLR3 and HEK293-
TLR4. (A, B) HEK293-TLR3 (C, D) HEK293-TLR4 were seeded into 6-well plates. 
When the cells were 80 % confluent, cells were transfected with 3 μg/well of EV or 3 
μg/well of HA-TRIF. After 20 h, cells were left untreated or stimulated with 20 μg/ml 
poly(I:C) (HEK293-TLR3) or 1 μg/ml (HEK293-TLR4) for the times indicated. 
Thereafter, cells were collected and lysed in  lysis buffer (50 mM HEPES, pH 7.5, 150 
mM NaCl, 2 mM EDTA, pH 8.0, 1 % NP-40, 0.5 % sodium deoxycholate, 
supplemented with 1 mM PMSF, 1 mM DDT, 1 mM NaVO3, and protease inhibitor 
cocktail). Cleared cells lysates were incubated with 1 μg of anti-HA monoclonal 
antibody precoupled with 50 μl A/G Plus-Agarose beads for 2 h at 4 oC with gentle 
shaking. Immunoprecipitated complexes were washed 4 times with lysis buffer, and 
proteins were released from the beads with the addition of 40 μl Laemmli loading 
buffer. Immunoprecipitated proteins and whole cell lysates (WCL) were separated by 
SDS-PAGE and subjected to immunoblot analysis using an anti-HA antibody panel (A 
and C). To visualize protein bands for tryptic digestion and LC-MS analysis, gels were 
silver stained (B and D). Images were captured using a G:Box system (Syngene). 
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3.2.2  Identification of HA-TRIF interactors 
Gel plugs were destained followed by tryptic digestion as described (Materials and 
methods, section 2.2.12) and analysed using Agilent 6340 Ion trap LC-MS machine. 
The MS spectra of the peptide ions were identified using the Mascot software 
programme (www.matrixscience.com) to search against the publicly available NCBI 
nonredundant protein database (www.ncbi.nlm.nih.gov). The results generated at each 
time point for each cell line was compared to the control (EV). Proteins which were 
similar to that identified in the control were excluded from further analysis and 
considered as unspecific binding. Proteins that interact with TRIF in a ligand 
independent manner and those that interact with TRIF in a poly(I:C) and LPS dependent 
manner are listed in the Appendix 1, Tables 3.1- 3.4 (HEK293-TLR3 cells) and Tables 
3.5- 3.8 (HEK293-TLR4 cells), respectively. In general, it was found that many 
interactors were unique to either TRIF-dependent TLR3 or TLR4 signalling. Many 
other proteins were identified as being present in the TRIF immunocomplex, regardless 
of the ligand used to stimulate the cell or the time of stimulation, e.g., Prohibitin, 
Prohibitin2, Transgelin and Menin. The proteins that interact with TRIF following time 
dependent poly(I:C) and LPS stimulation will be described in more detail. 
 
3.2.3  TRIF protein interaction networks  
A significant number of proteins were identified as TRIF interactors. To facilitate 
experimental data interpretation, a software package known as Pathway Studio 9.0 was 
utilised (www.ariadnegenomics.com). The software package contextualises proteins in 
terms of signalling pathways, gene regulation networks and protein interaction maps, 
and also permits the filtration of proteins that may involve in regulating TLR signalling 
and innate immunity. The software comes with a built-in resource termed ResNet which 
includes over 800,000 unique relationships derived from over 19 million PubMed 
abstracts as well as 61 full-text journals. The ResNet database also contains a collection 
of reference pathways comprise a large number of receptor signalling pathways and 
cellular process pathways. The proteins that were identified as TRIF interactors were 
selected and details (Swissprot number) of the selected proteins were uploaded to the 
Pathway Studio programme. Next, the relationships between the various proteins were 
defined using various parameters including direct interactions, common targets and cell 
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process menus. In all cases, TRIF (termed TICAM-1 within the Pathway Studio 
Software) was included in each list as it was not identified by MS. 
3.2.3.1    poly(I:C)-independent TRIF interactors 
Following the identification of proteins that interact with TRIF in a ligand independent 
manner, the protein identities were uploaded to the Pathway Studio software program. 
A direct interaction network of the proteins that co-immunoprecipitated with TRIF 
independent of poly(I:C) stimulation in HEK293-TLR3 was generated (Figure 3.3). A 
direct regulation between phosphatidylinositol-3-kinase regulatory subunit beta 
(PIK3CB) and Nibrin (NBN) was found. However, the other identified proteins were 
not found to interact directly with each other. With regard to the identified proteins, the 
common targets network indicated that both TRIF and the newly identified proteins 
were involved in the regulation of mitogen activated protein kinases (MAPKs), inhibitor 
of nuclear factor kappa-B kinase subunit beta (IKBKB), NF-kappa-B inhibitor alpha 
(NFKBIA), caspase-3, (CASP3), caspase-1, (CASP1), transforming growth factor beta 
(TGFB1), the estrogen receptor 1 (ESR1) and apoptosis regulator BCL-2 (Figure 3.4). 
These data showed that both TRIF and PIK3CB are involved in regulation of anti-
apoptotic BCL-2 protein. This finding correlates with a previous study showing that 
BCL-2 interacts with Beclin1, a key component of the PI3 kinase complex that initiates 
autophagosome and leads to autophagy inhibition (Pattingre et al., 2005). Interestingly, 
it has been reported that TLR signalling enhances the interaction of TRIF and MyD88 
with Beclin 1, and reduces the binding of Beclin 1 to BCL-2. These findings indicate 
that TLR signalling via its adaptor proteins reduces the binding of Beclin 1 to BCL-2 by 
recruiting Beclin 1 to the TLR-signalling complex leading to autophagy (Shi and Kehrl, 
2008). Moreover, it was suggested that PI3K p110-beta stimulates tumour growth by 
regulating BCL-2 expression, as knockdown of PI3K p110-beta by siRNA decreased 
BCL-2 protein expression (An et al., 2007). Furthermore, it was found that TRIF and 
the newly identified proteins serve to modulate various cellular processes such as the 
inflammatory response, immunity, innate immune response, phagocytosis, autophagy, 
viral reproduction and cytokine production (Figure 3.5). Notably, many of the newly 
identified proteins are strongly linked with the modulation of apoptosis and this is 
supported by previous studies showing that TRIF is critically involved in mediating 
apoptosis through caspase-8 (Han et al., 2004). Interestingly, caspase-8 has been shown  
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Figure 3.3: Direct interactions network of poly(I:C)-independent TRIF interacting 
proteins. HEK293-TLR3 cells were transfected with HA-TRIF. After 20 h, the cells 
were collected and IP of HA-TRIF was performed. Next, the TRIF IP-complex was 
analysed using the LC-MS. The newly identified protein interactors were uploaded to 
the Pathway Studio software analysis program and direct interaction network was made. 
Red entities indicate proteins that were identified following IP of HA-TRIF. TRIF 
(Ticam-1) is indicated in red with yellow surround. The grey solid line indicates the 
direct regulation of NBN by PIK3CB. 
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Figure 3.4: Common targets network of poly(I:C)-independent TRIF interacting 
proteins. HEK293-TLR3 cells were transfected with HA-TRIF. After 20 h, the cells 
were collected and IP of HA-TRIF was performed. Next, the TRIF IP-complex was 
analysed using the LC-MS. The newly identified protein interactors were uploaded to 
Pathway Studio software analysis program and common targets network was 
constructed. Red entities are the proteins identified following IP and LC-MS of HA-
TRIF. Yellow entities indicate the proteins that are co-regulated by the newly identified 
proteins and TRIF. The red entity with yellow surround indicates TRIF (Ticam-1). Grey 
solid lines indicate direct regulation. Grey dotted lines indicate and regulation. 
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Figure 3.5: Cell processes of poly(I:C)-independent TRIF interacting proteins. 
HEK293-TLR3 cells were transfected with HA-TRIF. After 20 h, the cells were 
collected and IP of HA-TRIF was performed. Next, the TRIF IP-complex was analysed 
using the LC-MS.  The newly identified protein interactors were uploaded to Pathway 
Studio software analysis program and the cellular processes network was constructed. 
Red entities are the proteins identified following IP and LC-MS of HA-TRIF. Yellow 
entities indicate the cellular processes that are co-regulated by the identified proteins 
and TRIF. The red entity with yellow surround indicates TRIF (Ticam-1). Dotted grey 
lines indicate regulation. 
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to activate caspase-3, a protein identified as being commonly modulated by TRIF and 
the newly identified protein, NLRP-1 (Figure 3.4). 
3.2.3.2    TRIF interactors following 20 min poly(I:C) stimulation 
Following transfection of HEK293-TLR3 cells with HA-TRIF, cells were stimulated 
with poly(I:C) for 20 min followed by IP of HA-TRIF and LC-MS  analysis of the 
TRIF-immunocomplex. A number of proteins were identified as being present in the 
HA-TRIF immunoprecipitated complex. Interestingly, it was found that a number of 
these proteins have previously been shown to interact directly with one another (Figure 
3.6, purple lines). For example, the newly identified protein Calreticulin (CALR) was 
shown to bind directly Calnexin (CANX). CALR and CANX serve as molecular 
chaperones for glycoproteins in the endoplasmic reticulum of eukaryotic cells 
(McDonnell et al, 1996). Importantly, Molinari et al. (2004) showed that CALR 
depletion specifically accelerates the maturation of cellular and viral glycoproteins with 
a modest decrease in folding efficiency. CALX depletion prevents proper maturation of 
some proteins such as influenza hemagglutinin but does not interfere appreciably with 
the maturation of several others. Another example is the direct binding of the tumor 
suppressor protein Prohibitin (PHB) to the Minichromosome maintenance complex 
(MCM2). Rizwani et al. (2009) demonstrated that PHB physically interacted with 
MCM2, MCM5 and MCM7 and that PHB can function as a potent inhibitor of DNA 
replication by interacting with members of MCM complex.  
 Interestingly the common targets network showed that both TRIF and the newly 
identified protein Caspase recruitment domain (CARD11) are involved in the regulation 
of TRAF6 (Figure 3.7). CARD11 is a multidomain adapter that is required for NF-κB 
activation during T cell receptor signalling (TCR) (Gaide et al., 2002; Egawa et al., 
2003). It has been demonstrated that during the TCR signalling, upon CARD11 
activation, CARD11 recruits namely, TRAF6, Caspase 8, TAK1, and IKKγ  to induce 
NF-κB activity that is required for T-cell activation and proliferation in the adaptive 
immune response (McCully and Pomerantz, 2008). Accordingly, interaction between 
TRIF and TRAF6 was reported. Disruption of TRAF6-binding motifs of TRIF disabled 
it from associating with TRAF6, and resulted in a reduction in the TRIF-induced 
activation of the NF-κB-dependent but not IFN-β promoter (Sato et al., 2003). These 
indicate involvement of TRIF and the newly identified CARD11 in NF-κB activation 
through binding to TRAF6. 
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Figure 3.6: Direct interactions network of poly(I:C)-dependent TRIF interacting 
proteins. HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 20 μg/ml poly(I:C) for 20 min. Then, IP of HA-TRIF was performed 
and the IP-complex was analysed by LC-MS. The newly identified protein interactors 
were uploaded to Pathway Studio software analysis program and direct interaction 
network was constructed. Red entities indicate proteins that were identified in HA-TRIF 
IP-complex. TRIF (Ticam-1) is indicated in red with yellow surround. Purple line 
indicates direct binding. 
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Figure 3.7: Common targets network of poly(I:C)-dependent TRIF interacting 
proteins. HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 20 μg/ml poly(I:C) for 20 min. Then, IP of HA-TRIF was performed 
and the IP-complex was analysed by LC-MS. The newly identified protein interactors 
were uploaded to Pathway Studio software analysis program and common targets 
network was constructed. Red entities indicate proteins that were identified in HA-TRIF 
IP-complex. Yellow entities indicate the proteins that are co-regulated by the newly 
identified proteins and TRIF. TRIF (Ticam-1) is indicated in red with yellow surround. 
Grey solid line indicates direct regulation. 
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Remarkably, most of newly identified proteins, concomitantly with TRIF, serve to 
regulate many cellular processes including immune response, apoptosis, viral 
replication and phagocytosis (Figure 3.8). For example, the newly identified CALR has 
been shown to function as pro-phagocytic and is highly expressed on the surface of 
several human cancers (Chao et al., 2010). Blockade or knockdown of CALR 
suppressed the phagocytosis of tumor cells by dendritic cells (Obeid et al., 2007). 
Moreover, the CALR homologue CANX plays important role in phagocytosis (Muller-
Taubenberger et al., 2002) and viral reproduction. Pieren et al. (2005) showed that 
inactivation of the CANX affects viral replication and infectivity but not viability of 
mammalian cells. Notably, TRIF is also involves in phagocytosis regulation. It has been 
reported that MyD88-mediated phagocytosis of the Gram-negatvie bacteria Borrelia 
burgdorferi can be initiated by TRIF and is dependent on activation of PI3K (Shin et al., 
2009). Another interesting newly identified protein is the nuclear factor 90, also known 
as interleukin enhancer binding factor 3 (IL3). The IL3 is a ds-RNA binding protein that 
has been shown to inhibit human immunodeficiency virus type 1 (HIV-1) replication in 
stably transfected cell line (Urcuqui-Inchima et al., 2006). Moreover, it was 
demonstrated that IL3 co-IPs with H5N1 viral nucleoprotein (NP) and that suppression 
of IL3 in Hela and A549 cell lines significantly increased viral polymerase complex 
activity and virus replication (Wang et al., 2009). Accordingly, TRIF is known to 
induce IRF3 activation and mediates induction of IFN-β by TLR3 and TLR4 and 
thereby suppresses vaccine virus replication in macrophages (Stack et al., 2005). 
Despite the fact that these proteins have not previously shown to interact with TRIF, 
they share with TRIF, the ability to regulate various cellular processes which may 
indicate that they could regulate TRIF activity during these processes.   
 
3.2.3.3    TRIF interactors following 40 min poly(I:C) stimulation 
Following transfection of HEK293-TLR3 cells with HA-TRIF, cells were stimulated 
with poly(I:C) for 40 min followed by IP of HA-TRIF and LC-MS analysis of the 
TRIF-IP-complex. A number of proteins were specifically identified as being present in 
the HA-TRIF-IP-complex. Direct interaction network showed that phosphoglycerate 
kinase 1 (PGK1) bound to glyceraldehyde 3 phosphate dehydrogenase (GAPDH) 
(Figure 3.9). PGK1 is an ATP-generating glycolytic enzyme that forms part of the 
glycolytic pathway and is directly involved in CXCL12 CXCR4 signalling. Moreover it  
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Figure 3.8: Cell processes of poly(I:C)-dependent TRIF interacting proteins. 
HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
20 μg/ml poly(I:C) for 20 min. Then, IP of HA-TRIF was performed and the IP-
complex was analysed by LC-MS. The newly identified protein interactors were 
uploaded to Pathway Studio software analysis program and cell processes network was 
constructed. Red entities indicate proteins that were identified in HA-TRIF-IP-complex. 
Yellow entities indicate cellular processes that are co-regulated by the identified 
proteins and TRIF. TRIF (Ticam-1) is indicated in red with yellow surround. Grey 
dotted lines indicate regulation. 
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Figure 3.9: Direct interactions network of poly(I:C)-dependent TRIF interacting 
proteins. HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 20 μg/ml poly(I:C) for 40 min. Then, IP of HA-TRIF was performed 
and IP-complex was analysed by LC-MS. The newly identified protein interactors were 
uploaded to Pathway Studio software analysis program and direct interaction network 
was constructed. Red entities indicate proteins that were identified in HA-TRIF IP-
complex. TRIF (Ticam-1) is indicated in red with yellow surround. Purple line indicates 
direct binding. Grey dotted lines indicate regulation. 
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 was found that fibroblasts that overexpress PGK1 displayed a higher proliferative index 
and contributed to the invasion of prostate cancer cells, possibly through expression of 
MMP2, MMP3 and activation of the AKT and ERK pathways (Wang et al., 2010). 
Also, the interaction network showed that both TRIF and Caspase 12 (CASP12) 
regulated Mitogen-activated protein kinase 8 (MAPK8) which in turn regulated Caspase 
12 (Figure 3.9). These data are in agreement with a previous study that showed TLR3 
activation, which exclusively uses TRIF, results in activation of NF-κB, IRF-3 and 
MAP kinase (p38 and JNK) signalling (Johnson et al., 2008). CASP12 is also known to 
be essential for endoplasmic reticulum (ER) stress-induced apoptosis (Nakagawa et al., 
2000) and studies reported activation of CASP12 and JNK during ER stress-induced 
apoptosis (Yoneda et al., 2001) 
 Interestingly, the common targets network showed that the newly identified 
proteins are involved in regulation of many different proteins including, IRF3, TBK1, 
IRF7, MAPK1, and 9 Caspase1, 2, 3 and 8 and NOTCH (Figure 3.10). For example, the 
newly identified DEAD-box helicase (DDX3X) was reported to bind TBK1 and that 
TBK1 and DDX3X acted synergistically in their ability to stimulate the IFN promoter. 
RNAi-mediated reduction of DDX3X expression led to an impairment of IFN 
production in macrophages (Soulat et al., 2008). Schröder et al. (2008) also showed that 
DDX3X is involved in TBK1/IKKε-mediated IRF activation and IFN-β promoter 
induction. The identification of the DDX3X in the TRIF immunocomplex support the 
recent finding that DDX1, DDX21, and DHX36 utilise the TRIF pathway independent 
of TLR3 to activate type I IFN responses in dendritic cells (Zhang et al., 2011). 
Importantly, two newly identified proteins namely polypyrimidine tract binding protein 
1 (PTBP1) and triple functional domain (TRIO) were shown to be involved in Notch 
regulation (Figure 3.10). Notch signalling is an ancient process that regulates cell fate, 
stem cell maintenance and initiation of differentiation in embryonic and postnatal 
tissues (Grego-Bessa et al., 2004). PTBP1 is a multi-functional RNA-binding protein 
and different functions have been identified for vertebrate PTBP1, including 
translational control, mRNA stability, mRNA localization and may also act as a 
transcriptional activator (Dansereau et al., 2002; Cheung et al., 2006). It has been shown 
that in developing Drosophila, the absence of the PTBP1 homolog, hephaestus, resulted 
in increased Notch activity (Dansereau et al., 2002). The present of these two proteins 
that they involved in Notch regulation in the TRIF IP complex may suggest a functional  
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Figure 3.10: Common targets network of poly(I:C)-dependent TRIF interacting 
proteins. HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 20 μg/ml poly(I:C) for 40 min. Then, IP of HA-TRIF was performed 
and the IP-complex was analysed by LC-MS. The newly identified protein interactors 
were uploaded to Pathway Studio software analysis program and common targets 
network was constructed. Red entities indicate proteins that were identified in HA-TRIF 
IP-complex. Yellow entities indicate the proteins that are co-regulated by the newly 
identified proteins and TRIF. TRIF (Ticam-1) is indicated in red with yellow surround. 
Grey sold and dotted lines indicate direct regulation and regulation respectively. 
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role for TRIF in Notch signalling. Interestingly, links between TLR and Notch 
signalling have been previously reported whereby TLR agonists such as bacterial 
lipopeptide, poly(I:C), lipopolysaccharide and unmethylated CpG DNA serve to up-
regulate Notch1 in primary and macrophage-like cell lines (Amsen et al. 2004; Palaga et 
al., 2008). Moreover, stimulation of macrophages with TLRs ligands triggered 
activation of Notch signalling, which in turn regulated gene expression patterns 
involved in pro-inflammatory responses, through activation of NF-κB (Palaga et al., 
2008). Furthermore, most of these identified proteins and TRIF are involved in 
apoptosis inflammatory response, innate immune response, phagocytosis, autophagy, 
viral transcription and viral reproduction regulation (Figure 3.11). This correlates with a 
previous study showing that CASP12 blocks the inflammatory response initiated by NF-
κB and Caspase-1 (Scott and Saleh, 2007). The PTBP1 protein, as discussed earlier, has 
been previously shown to modulate Notch signalling, apoptosis, viral replication and 
viral transcription (Figure 3.11). Li et al. (1999) demonstrated that PTBP1 binds to the 
leader RNA of mouse hepatitis virus and serves as a regulator of viral transcription. As 
TRIF known to be involves in viral recognition and typ1 IFN activation (Riad et al., 
2011), it may be of interest to investigate the role of PTBP1in TRIF-mediated 
signalling. 
 
3.2.3.4    TRIF interactors following 60 min poly(I:C) stimulation  
Following transfection of HEK293-TLR3 cells with HA-TRIF, cells were stimulated 
with poly(I:C) for 60 min followed by IP of HA-TRIF and LC-MS of the TRIF 
immunocomplex. Proteins including ADAM metallopeptidase domain 15 (ADAM15), 
multiple endocrine neoplasia I (MEN) adenomatous polyposis coli (APC), IQ motif -
containing GTPase activating protein1 (IQGAP1), phosphoinositide-3-kinase, 
regulatory subunit 2 beta (PIK3R2), CREB regulated transcription coactivator 
1(CRTC1) and Probable ATP-dependent RNA helicase DDX28 were specifically 
identified as TRIF interactors (Figure 3.12). Some of these proteins have been 
previously shown to interact with one another as illustrated in the direct interaction 
network (Figure 3.12). IQGAP1 binds directly to APC, CLIP and Menin (MEN1).  
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Figure 3.11: Cell processes of poly(I:C)-dependent TRIF interacting proteins. 
HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
20 μg/ml poly(I:C) for 40 min. Then, IP of HA-TRIF was performed and the IP-
complex was analysed by LC-MS. The newly identified protein interactors were 
uploaded to Pathway Studio software analysis program and cell processes network was 
constructed. Red entities indicate proteins that were identified in TRIF IP-complex. 
Yellow entities indicate cellular processes that are co-regulated by the identified 
proteins and TRIF. TRIF (Ticam-1) is indicated in red with yellow surround. Grey 
dotted lines indicate regulation. 
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Figure 3.12: Direct interactions network of poly(I:C)-dependent TRIF interacting 
proteins. HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cell were 
stimulated with 20 μg/ml poly(I:C) for 60 min. Then, IP of HA-TRIF was performed 
and IP-complex was analysed by LC-MS. The newly identified protein interactors were 
uploaded to Pathway Studio software analysis program and direct interaction network 
was constructed. Red entities indicate proteins that were identified in TRIF IP-complex. 
TRIF (Ticam-1) is indicated in red with yellow surround. Purple line indicates direct 
binding. Grey solid lines indicate direct regulation. Grey dotted lines indicate 
regulation. 
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IQGAP1 is a scaffolding protein composed of multiple protein recognition motifs 
through which it interacts with a wide spectrum of binding partners, including CLIP-
170, epidermal cadherin (E-cadherin), β-Catenin, APC, components of the mitogen-
activated protein kinase pathway and RAP1 (Jeong et al., 2007). Interestingly, both β-
Catenin and APC are key components of the canonical wnt signalling pathway, and Wnt 
signalling and TLRs have been shown to intersect in Drosophila. Also, growing 
evidence supports the notion that Wnt signalling may be involved in orchestrating the 
immune response in response to microbial stimulation of innate immune cells of 
vertebrate origin (Neumann
 
et al., 2009; Schaale et al., 2011). Importantly, E-cadherin 
which was reported to bind IQGAP1 is known to be cleaved by the newly identified 
protein ADAM15 (Najy et al., 2008). E-cadherin is involved in cell-cell interaction, 
embryonic development, organ morphogenesis, tissue integrity, and wound healing, and 
disruption of E-cadherin has been observed in multiple pathophysiological conditions, 
including inflammation and cancer (Yasmeen et al., 2006; Wever et al., 2007). Notably, 
ADAM15, which belongs to the disintegrin and metalloprotease family, was also shown 
to be involved in different inflammation diseases such as atherosclerosis, rheumatoid 
arthritis (RA) and intestinal inflammation (Charrier-Hisamuddin et al. 2008).  
 Moreover, common targets network showed that the newly identified proteins 
are involved in regulation of different MAPKs, JUN, Nuclear factor NF-kappa-B p100 
subunit (NFKB2), epidermal growth factor (EGF) and EGF receptor (EGFR) (Figure 
3.13). More specifically, the newly identified MEN1 was shown to be involved in 
MAPK1, 3 and 8 and NFKB2 regulation (Figure 3.13). MEN1 is a tumor suppressor 
protein and was identified as the gene responsible for the disease multiple endocrine 
neoplasia type 1 (Yazgan and Pfarr, 2002). Heperen et al. (2001) also showed that the 
NF-κB proteins p50, p52 and p65 interact specifically and directly with Menin in vitro 
and in vivo. Overexpression of Menin repressed p65-mediated transcriptional activation 
on NF-κB sites and MAPK-induced phosphorylation of nuclear factors such, as c-JUN 
without altering ERK2 or JNK1 activity (Gallo et al., 2002). Importantly, it was found 
that TRIF and the newly identified proteins serve to modulate various cellular processes 
such as inflammatory response, immune response, immune invasion phagocytosis, T-
cell activation, cell differentiation and cell proliferation (Figure 3.14). Notably, many of 
the newly identified proteins are strongly linked with the modulation of apoptosis, cell  
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Figure 3.13: Common targets network of poly(I:C)-dependent TRIF interacting 
proteins. HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 20 μg/ml poly(I:C) for 60 min. Then, IP of HA-TRIF was performed 
and IP-complex was analysed by LC-MS. The newly identified protein interactors were 
uploaded to Pathway Studio software analysis program and common targets network 
was constructed. Red entities indicate proteins that were identified in HA-TRIF IP-
complex. Yellow entities indicate the proteins that are co-regulated by the newly 
identified proteins and TRIF. TRIF (Ticam-1) is indicated in red with yellow surround. 
Grey solid and dotted lines indicate direct regulation and regulation, respectively. 
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Figure 3.14: Cell processes of poly(I:C)-dependent TRIF interacting proteins. 
HEK293-TLR3 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
20 μg/ml poly(I:C) for 60 min. Then, IP of HA-TRIF was performed and IP-complex 
was analysed by LC-MS. The newly identified protein interactors were uploaded to 
Pathway Studio software analysis program and cell processes network was constructed. 
Red entities indicate proteins that were identified in TRIF IP-complex. Yellow entities 
indicate cellular processes that are co-regulated by the identified proteins and TRIF. 
TRIF (Ticam-1) is indicated in red with yellow surround. Grey dotted lines indicate 
regulation. 
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differentiation and cell proliferation. It should be noted that TLRs are also linked to 
cancer. Recently, Umemura et al. (2011) investigated the role of TLR3 in metastatic 
progression. It was found that metastatic tumor cells were highly sensitive to TLR3-
mediated apoptosis after double-stranded RNA treatment when compared to primary 
tumor cells. Enhanced apoptosis in metastatic cells was dependent on double-stranded 
RNA, TLR3 and also TRIF. Thus, interaction of these proteins with TRIF may affect 
TRIF activity during apoptosis or other processes regulated by TRIF (Umemura et al. 
2011). Moreover, Galli et al. (2010) showed that TLR3 and TLR5 stimulation of human 
prostate cancer cells triggers the production of chemokines, which, in turn, favor the 
attraction of immune effectors, thereby representing a tool to enhance the efficacy of 
conventional therapies by stimulating anticancer immune responses. 
 
3.2.3.5    LPS-independent TRIF interactors 
HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were collected and IP 
of HA-TRIF was performed followed by LC-MS analysis of the TRIF IP-complex. A 
significant numbers of proteins were identified as TRIF interacting partners. As 
predicted following analysis of the TRIF interaction network (Figure 3.15), there is no 
previous report of direct binding between these identified proteins and TRIF or between 
each other. However, the DBF4 homolog A (DB4) protein is directly regulated by 
MEN1. Interestingly, MEN1 was also identified in HEK-TLR3 upon poly(I:C) 
stimulation for 60 min. Thus, MEN1 is associated with TRIF in HEK-TLR3 and 
HEK293-TLR4 cells. The DBF4 is a kinase subunit that is essential for regulating the 
initiation of DNA replication in Saccharomyces cerevisiae. The human homologue of 
DBF4 (HsDBF4) was shown to be directly involved in regulating the initiation of DNA 
replication by targeting minichromosome maintenance (MCM2) protein in mammalian 
cells (Jiang et al., 1999). Importantly MCM2 was also identified in HEK293-TLR3 
upon poly(I:C) stimulation for 20 min. This may suggest an involvement of these 
proteins in TRIF-mediated apoptosis. Moreover, the common targets network for the 
newly identified proteins and TRIF include MAPKs, IRF3, TGFB1, EGFR, NFKB2, 
ESR1 and Tyrosine kinase-type cell surface receptor HER2 (ERBB2), SMAD3 and 
SMAD4 (Figure 3.16). Interestingly, TRIF, MEN1 and ADAM15 have been linked with 
MAPK1 regulation (Figure 3.16). This correlates with a study which showed that 
ADAM15 expression decreased the phosphorylation of ERK1/2 (Chen et al., 2008). 
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Figure 3.15: Direct interaction network of LPS-independent TRIF interacting 
proteins. HEK293-TLR4 cells were transfected with HA-TRIF. After 20 h, cells were 
collected and IP of HA-TRIF was performed and TRIF IP-complex was analysed by 
LC-MS. The newly identified protein interactors were uploaded to the Pathway Studio 
software analysis program and direct interaction network was constructed. Red entities 
indicate proteins that were identified in TRIF IP-complex. TRIF (Ticam-1) is indicated 
in red with yellow surround. Grey solid line indicates direct regulation. 
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Figure 3.16: Common targets network of LPS-independent TRIF interacting 
proteins. HEK293-TLR4 cells were transfected with HA-TRIF. After 20 h, cells were 
collected and IP of HA-TRIF was performed followed by IP-complex analysis by LC-
MS. The newly identified protein interactors were uploaded to the Pathway Studio 
software analysis program and common targets network was constructed. Red entities 
indicate proteins that were identified in TRIF IP-complex. Yellow entities indicate the 
proteins that are co-regulated by the newly identified proteins and TRIF. TRIF (Ticam-
1) is indicated in red with yellow surround. Grey solid and dotted lines indicate direct 
regulation and regulation, respectively. 
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Interestingly, whereas MEN1 was shown also to suppress ERK phosphorylation (Gallo 
et al., 2002), activation of the TRIF pathway resulted in activation of p38 and ERK 
MAPK pathways (Qi and Shelhamer., 2005). This suggests that ADAM15 and MEN1 
may regulate TRIF-mediated MAPK activation.  Furthermore, the identified proteins 
were strongly associated with the regulation of cell differentiation, cell migration, cell 
proliferation, cell adhesion, apoptosis and immunity (Figure 3.17). Some of these 
processes were also modulated by TRIF (Figure 3.17) indicating that these proteins may 
cooperate with each other to modulate the cellular processes. 
3.2.3.6    TRIF interactors 20 min following LPS stimulation 
HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
LPS for 20 min and IP of HA-TRIF was performed followed by LC-MS analysis of the 
TRIF IP-complex. A significant numbers of proteins were identified as TRIF interacting 
partner. Interestingly, a number of the newly identified hits previously have been 
reported to bind or regulate one another as illustrated in the interaction network (Figure 
3.18). For example importin-β1 (KPNB1) binds directly to proliferating cell nuclear 
antigen (PCNA) and GAPDH regulates both KPNB1 and PCNA (Figure 3.18). PCNA 
was first identified as an autoantigen that reacts with autoantibodies in patients with 
systemic lupus erythematosus (SLE) (Miyachi et al., 1978). PCNA plays an essential 
role in DNA replication, repair and methylation, chromatin assembly, cell cycle 
regulation, and ribosomal DNA transcription (Kaneda et al., 2004). These findings are 
supported by studies showing TLR involvement, particularly the nucleic acid-sensing 
TLR3, 7, 8 and 9 in SLE (Montero and Martin, 2009; Horton et al., 2010).    
 Moreover, the common target network showed that both TRIF and the newly 
identified protein macrophage migration inhibitory factor (MIF) were involved in the 
regulation of Caspase-3 and 8, macrophage colony stimulating factor 1 (CSF1) and 
interleukin 18 (IL-18) (Figure 3.19). Macrophage migration inhibitory factor (MIF) is a 
pro-inflammatory cytokine produced by human pulmonary artery endothelial cells 
(HPAECs). Its expression increases in response to various death-inducing stimuli, 
including LPS (Damico et al., 2008; Zhang et al., 2012). Studies have showed that MIF 
functions as an endogenous pro-survival factor in HPAECs through regulation of the 
FLICE-like inhibitory protein (FLIP). FLIP modulates or blocks death receptor- 
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Figure 3.17: Cell processes network of LPS-independent TRIF interacting 
proteins. HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were 
collected and IP of HA-TRIF was performed followed by analysis of the IP-complex by 
LC-MS. The newly identified protein interactors were uploaded to Pathway Studio 
software analysis program and cell processes network was constructed. Red entities 
indicate proteins that were identified in TRIF IP-complex. Yellow entities indicate 
cellular processes that are co-regulated by the identified proteins and TRIF. TRIF 
(Ticam-1) is indicated in red with yellow surround. Grey dotted lines indicate 
regulation. 
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Figure 3.18: Direct interaction network of LPS-dependent TRIF interacting 
proteins. HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were  
stimulated with 1 μg/ml LPS for 20 min followed by IP of HA-TRIF and LC-MS  
analysis of the TRIF-IP-complex. The newly identified protein interactors were 
uploaded to Pathway Studio software analysis program and cell processes network was 
constructed. Red entities indicate proteins that were identified in TRIF IP-complex.  
TRIF (Ticam-1) is indicated in red with yellow surround. Purple line indicates binding 
Grey dotted lines indicate regulation. Grey solid line indicates direct regulation. 
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Figure 3.19: Common targets network of LPS-dependent TRIF interacting 
proteins. HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 1 μg/ml LPS for 20 min followed by IP of HA-TRIF and LC-MS 
analysis of the TRIF-IP-complex. The newly identified protein interactors were 
uploaded to Pathway Studio software analysis program and common targets network 
was constructed. Red entities indicate proteins that were identified in TRIF IP-complex. 
Yellow entities indicate proteins that are co-regulated by the identified proteins and 
TRIF. TRIF (Ticam-1) is indicated in red with yellow surround. Grey dotted lines 
indicate regulation. 
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stimulated cell death by competing with Caspase-8 for binding to FADD (Damico et al., 
2008). Importantly, TRIF is known to mediate apoptosis through activation of caspase-8 
(Han et al., 2004). This suggests that MIF may affect TRIF-mediated Caspase-8 
activation and thereby affect TRIF-mediates apoptosis. Another interesting protein 
identified as a TRIF interactor is Segment polarity protein dishevelled homolog 
(DVL3), which was shown to be involved in MAPK8 and MAPK14 regulation (Figure 
3.19). DVL3 play important role in both the canonical wnt-β-catenin pathway and the 
planar cell polarity (PCP) pathway (Lee et al., 2008). Bikkavilli et al. (2008) 
demonstrated that in the canonical Wnt-β-catenin signalling pathway, DVL3 is critical 
for Wnt3A-induced p38 MAPK activation. As mention earlier, the TRIF pathway 
induces MAPK activation, thus linking the TLR and wnt signalling pathways 
(Bikkavilli et al., 2008; Neumann
 
et al., 2009). Furthermore, the cellular processes 
network showed that MIF was involved in the regulation of many of the cellular 
processes that were also regulated by TRIF including apoptosis, autophagy, immune 
response, phagocytosis, cytokine production, inflammatory responses and viral 
reproduction (Figure 3.20). It was reported that MIF acts as an important mediator of 
the inflammatory response in alcoholic liver disease. Moreover, it has been reported that 
the plasma from HIV-1-infected patients contains elevated levels of MIF and that 
peripheral blood mononuclear cells (PBMCs) from HIV-infected patients release a 
greater amount of MIF. Furthermore, HIV-1 replication in PBMCs declines when these 
cells were treated with anti-MIF antibodies (Regis et al., 2010). Thus, MIF may be an 
interesting protein to characterise in the context of TRIF signalling. 
3.2.3.7   TRIF interactors 40 min following LPS stimulation  
HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
LPS for 40 min and IP of HA-TRIF was performed followed by LC-MS analysis of the 
TRIF IP-complex. A numbers of proteins were identified as TRIF interacting partners. 
A direct interaction network showed that PHB bound to apoptosis inducing factor 1 
(AIFM1) and this protein directly regulates PHB2 expression (Figure 3.21).  It should 
be mentioned that PHB was also identified in HEK-TLR3 upon poly(I:C) stimulation 
for 20 min. PHB is present in various cellular compartments, including mitochondria, 
nucleus, and plasma membrane. It function as a potential tumor suppressor, an anti-  
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Figure 3.20: Cell processes network of LPS-dependent TRIF interacting proteins. 
HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
1 μg/ml LPS for 20 min followed by IP of HA-TRIF and LC-MS analysis of the TRIF-
IP-complex. The newly identified protein interactors were uploaded to Pathway Studio 
software analysis program and cell processes network was constructed. Red entities 
indicate proteins that were identified in TRIF IP-complex. Yellow entities indicate 
cellular processes that are co-regulated by the identified proteins and TRIF. TRIF 
(Ticam-1) is indicated in red with yellow surround. Grey dotted lines indicate 
regulation. 
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proliferative protein and a regulator of cell-cycle progression and apoptosis (Theiss et 
al., 2007). PHB in the gastrointestinal tract has been implicated in protection against 
infection and inflammation and the induction of apoptosis in other tissues (Mishra et al., 
2005). Furthermore, it was found that PHB overexpression decreased the accumulation 
of reactive oxygen metabolites, as well as increasing the permeability induced by 
oxidative stress in intestinal epithelial cells, suggested that PHB plays a role in the 
cellular defense against oxidant injury (Theiss et al., 2007). Importantly, deregulation of 
TLRs has been reported during intestinal inflammation and an essential role for TLR 
signalling in the pathogenesis of inflammatory bowel diseases (IBD) has been 
established through many studies (Harris, et al,. 2006; Cario, 2010). Together, these 
data suggest that the counterregulation of PHB via TRIF (or vica versa) may modulate 
inflammatory condition in the bowel. 
 Moreover, many of the newly identified proteins and TRIF have previously been 
reported to be involved in the regulation of proteins such as MAPK1 and 8, BCL2, 
ESR1, Glycogen synthase kinase-3 beta (GSK3B) and JUN as shown in the common 
targets network (Figure 3.22). It should be mentioned that two of the newly identified 
proteins namely, PHB and AIFM1 regulates GSK3B. GSK3 is a component of many 
diverse signalling pathways, including insulin/insulin-like growth factor (IGF-1) 
signalling and the Wnt signalling pathways (Gould and Manji, 2005). Regarding the 
Wnt/β-catenin pathway, active GSK-3 phosphorylates β-catenin leading to its ubiquitin-
dependent degradation. However, when GSK-3 is inhibited, β-catenin is not degraded, 
and this permits the interaction of β-catenin with T-cell-specific transcription factor 
(TCF) leading to transcriptional activation of target gene (Cadigan and Peifer, 2009). 
The link between TLRs and Wnt signalling was mentioned earlier. Another interesting 
finding is that both TRIF and the newly identified protein Scribbled (SCRIB) regulate 
MAPK1 and 8 and JUN. The cell polarity regulator, human Scribble (hSCRIB), is a 
potential tumour suppressor whose loss is a frequent event in late stage cancer 
development. In mammals, SCRIB regulates cell migration and wound healing in vivo 
(Dow et al., 2008). Moreover the suppression of MAPK signalling reported to be a 
highly conserved function of Scribble and that hSCRIB interacts with ERK and loss of 
hSCRIB results in elevated phospho-ERK levels (Nagasaka et al., 2010).  
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Figure 3.21: Direct interaction network of LPS-dependent TRIF interacting 
proteins. HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 1 μg/ml LPS for 40 min followed by IP of HA-TRIF and LC-MS 
analysis of the IP-complex. The newly identified protein interactors were uploaded to 
Pathway Studio software and direct interaction network was constructed. Red entities 
indicate proteins that were identified in TRIF IP-complex. TRIF (Ticam-1) is indicated 
in red with yellow surround. Purple line indicates binding, grey solid and dotted lines 
indicate direct regulation and regulation respectively. 
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Figure 3.22: Common targets network of LPS-dependent TRIF interacting 
proteins. HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 1 μg/ml LPS for 40 min followed by IP of HA-TRIF and LC-MS 
analysis of the TRIF-IP complex. The newly identified protein interactors were 
uploaded to Pathway Studio software and common targets network was constructed. 
Red entities indicate proteins that were identified in TRIF IP-complex. Yellow entities 
indicate proteins that are co-regulated by the identified proteins and TRIF. TRIF 
(Ticam-1) is indicated in red with yellow surround. Grey solid and dotted lines indicate 
direct regulation and regulation respectively. 
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Furthermore, cellular processes such as apoptosis, endocytosis, complement activation, 
immune responses, cytokinesis and cytokine production were all regulated by TRIF and 
the and the newly identified proteins (Figure 3.23). Most of the identified protein hits 
are strongly involved in apoptosis regulation. An important protein identified is Low-
density lipoprotein receptor-related protein 2 (LRP2), which showed to be involved in 
endocytosis, and cytokine production (figure 3.23). LRP2 is an endocytic receptor 
expressed on the apical surface of several epithelial cells that internalizes a variety of 
ligands including nutrients, hormones and their carrier proteins, signalling molecules 
and extracellular matrix proteins (Marzolo and Farfán, 2011). A GSK3 site was 
described in the intracellular cytoplasmic tail of LRP2. This site appears constitutively 
to be phosphorylated by GSK3 and regulates the cell membrane location of LRP2 
(Bolós et al., 2010). Interestingly, as mentioned earlier GSK3 is involved in wnt/β-
catenin pathway and was reported to be regulated by the two identified proteins namely, 
PHB and AIFM1.  
 
3.2.3.8   TRIF interactors 60 min following LPS stimulation  
HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
LPS for 60 min and IP of HA-TRIF was performed followed by LC-MS analysis of 
TRIF IP-complex. A significant numbers of proteins were identified as TRIF interacting 
proteins. Directed interaction network showed only one regulation between GAPDH 
and triosephosphate isomerase 1 (TPI1) (Figure 3.24). TPI and GAPDH are glycolytic 
enzymes essential for efficient energy production. Importantly, anti-TPI and GAPDH 
antibodies were found in the cerebrospinal fluid and in lesions of patients with the 
autoimmune disease multiple sclerosis (MS) suggested that TPI and GAPDH may be 
recruited into the immune cascade at different stages of the disease. (Kölln et al., 2010). 
Moreover, IgM antibodies against TPI were detected in the patient's serum from the 
acute phase of the Hepatitis A virus infection (Ritter et al., 1994). Furthermore the 
newly identified proteins and TRIF share regulation of proteins such as Caspase-1, 3 
and 8, MAPK1 eukaryotic translation initiation factor 2-alpha kinase 2 (EIF2AK), 
IKBKB, IFN-β and BCL2  as illustrated in the common targets network (Figure 3.25). 
For example, Absent in melanoma 2 (AIM2) share with TRIF the regulation of caspase-
1 and 3 and also involved in IFN-β regulation (Figure 3.25). AIM2 also known as 
Interferon-inducible protein is a member of the interferon (IFN)- inducible p200-protein  
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Figure 3.23: Cell processes network of LPS-dependent TRIF interacting proteins. 
HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
1 μg/ml LPS for 40 min followed by IP of HA-TRIF and LC-MS analysis of the TRIF-
IP complex. The newly identified protein interactors were uploaded to Pathway Studio 
software analysis program and cell processes network was constructed. Red entities 
indicate proteins that were identified in TRIF IP-complex. Yellow entities indicate 
cellular processes that are co-regulated by the identified proteins and TRIF. TRIF 
(Ticam-1) is indicated in red with yellow surround. Grey dotted lines indicate 
regulation. 
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Figure 3.24: Direct interaction network of LPS-dependent TRIF interacting 
proteins. HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 1 μg/ml LPS for 60 min followed by IP of HA-TRIF and LC-MS 
analysis of the TRIF-IP complex. The newly identified protein interactors were 
uploaded to Pathway Studio software programme and direct interaction network was 
constructed. Red entities indicate proteins that were identified in TRIF IP-complex. 
TRIF (Ticam-1) is indicated in red with yellow surround. Grey dotted line indicates 
regulation. 
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Figure 3.25: Common targets network of LPS-dependent TRIF interacting 
proteins. HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were 
stimulated with 1 μg/ml LPS for 60 min followed by IP of HA-TRIF and LC-MS 
analysis of the TRIF-IP complex. The newly identified protein interactors were 
uploaded to Pathway Studio software programme and common targets network was 
constructed. Red entities indicate proteins that were identified in HA-TRIF IP-complex. 
Yellow entities indicate proteins that are co-regulated by the identified proteins and 
TRIF. TRIF (Ticam-1) is indicated in red with yellow surround. Grey dotted lines 
indicate regulation. 
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family. It can sense double-stranded DNA (dsDNA) in the cytoplasm and through its 
pyrin domain (PYD) can form an inflammasome to activate caspase-1 and induce cell 
death (Hornung et al., 2009; Jones et al., 2010; Panchanathan et al., 2010). Moreover, 
knockdown of AIM2 abrogates caspase-1 activation in response to cytoplasmic double-
stranded DNA and the double-stranded DNA vaccinia virus (Hornung et al., 2009). 
Interestingly, different studies showed that TRIF is involved in caspase-1 activation and 
the processing of IL-1β (Harder et al., 2009; Lamkanifi et al., 2009). AIM2 is the 
second inflammasome component to be identified in TRIF IP-complex. As mentioned 
earlier, NLRP1 was also identified in HEK-TLR3 independent of poly(I:C) stimulation. 
Collectively, these data suggest a potential role for TRIF in inflammasome activation. 
Importantly, cell processes network analysis showed that most of the newly identified 
proteins and TRIF were involved in regulation of apoptosis, innate immune response, 
cytokine production, inflammatory response, virulence, immunity and autophagy 
(Figure 3.26). The newly identified protein α-Enolase shared with TRIF the regulation 
of inflammatory response, virulence, apoptosis cellular immune response (Figure 3.26). 
Interestingly, α-Enolase and TRIF was also showed to be involved in regulation of 
MAPK1 and Caspase-3 (Figure 3.25). α-Enolase is an abundantly expressed glycolytic 
enzyme that is expressed in most tissues. High level α-Enolase expression has been 
demonstrated in the plasma of patients with lung, breast and prostate carcinomas 
(Georges et al., 2011). Moreover, an anti-α-Enolase antibody were found in in various 
systemic autoimmune diseases such as SLE, mixed and cryoglobulinemia (MC) and 
RA, suggesting that the alpha-Enolase autoantigen may drive these chronic 
inflammatory diseases (Andrew et al., 2005; Prastesi et al., 2000). Interestingly, it has 
been reported that the TLRs signalling pathways intensively contribute to the 
pathogenesis of RA and SLE (Montero and Martin, 2009; Roelofs et al., 2005; 
Wähämaa  et al., 2011). In addition, immune reactivity of TLR2, TLR3, TLR4 and 
TLR7 was demonstrated in RA synovial lining (Takagi et al., 2011). Moreover, TLR 
ligands, such as PGN, CpG DNA, heat shock proteins and RNA from both infectious 
organisms and endogenous necrotic cells, have been identified in the joints of RA 
patients (Van der heijden et al., 2000; Brentano et al., 2005).  
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Figure 3.26: Cell processes network of LPS-dependent TRIF interacting proteins. 
HEK293-TLR4 were transfected with HA-TRIF. After 20 h, cells were stimulated with 
1 μg/ml LPS for 60 min followed by IP of HA-TRIF and LC-MS analysis of the TRIF-
IP complex. The newly identified protein interactors were uploaded to Pathway Studio 
software analysis program and cell processes network was constructed. Red entities 
indicate proteins that were identified in TRIF IP-complex. Yellow entities indicate 
cellular processes that are co-regulated by the identified proteins and TRIF. TRIF 
(Ticam-1) is indicated in red with yellow surround. Grey dotted lines indicate 
regulation. 
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Collectively, these data showed that both TRIF and the newly identified proteins share 
the regulation and modulation of many proteins and cellular processes respectively and 
that these proteins may positively or negatively modulate TRIF activity during these 
cellular processes.  
3.2.4    Co-immunoprecipitation of TRIF and novel interactors 
Using proteomics, it is clear that a number of potentially interesting proteins and 
signalling pathways that may modulate TRIF functionality were identified. To validate 
whether TRIF and the newly identified protein interact, co-immunoprecipitation 
experiments were performed. Interactions were confirmed by co-immunoprecipitation 
of epitope-tagged TRIF and the selected protein of interest in HEK293-TLR3 or 
HEK293-TLR4 cells. Thereafter, endogenous co-immunoprecipitation experiments 
were performed in the human astrocytoma cell line U373-CD14. The proteins selected 
for further study were disintegrin and metalloproteinase domain-containing protein 15 
(ADAM15) and segment polarity protein dishevelled homolog (DVL) 3. The 
interactions between TRIF and these two proteins were confirmed by overexpression 
and endogenously. ADAM15 was selected for further study as is well known as 
inflammatory mediator and reported to play important role in RA, Osteoarthritis (OA) 
and cancer (Charrier-Hisamuddin et al., 2008; Böhm et al., 2010). The link between 
TLRs, RA and cancer was already mentioned. Moreover, our group are interested in 
investigating the role of TLRs in RA and OA. Thus, it was of interest to us to further 
examine the role of ADAM15 in TRIF-mediated TLR signalling. As already discussed, 
DVL3 is important activator of Wnt signalling pathways and intersections between TLR 
and Wnt signalling pathways have been reported. (Blumenthal et al., 2005; Staal et al., 
2008; Neumann
 
et al., 2009). Therefore, the regulatory role of DVL3 in TLR signalling 
was investigated. Also, as already indicated, proteomic analysis showed that AIM2 was 
present in the TRIF immunocomplex following stimulation of HEK293-TLR4 cells 
with LPS for 60 min. Thus, co-immunoprecipitation experiments were performed to 
further explore whether TRIF and AIM2 interact. However, for some reason 
overexpression of AIM2 was not possible. Different concentrations of AIM2 were used 
in combination with TRIF. Also, expression of AIM2 alone did not result in its 
expression. Thus, further validation of the interaction between TRIF and AIM2 will be 
needed to establish whether they interact. Also, the ability of many of the other proteins 
identified using the proteomics approach, to interact with TRIF and to modulate TLR3 
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and TLR4 signalling requires further research. Regarding ADAM15 and DVL3, it was 
found that both of these proteins co-immunoprecipitate with TRIF and modulate TLR3 
and TLR4 signalling. Their functional involvement in TRIF dependent signalling will 
be discussed in Chapters 4 and 5. 
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3.3   Discussion  
In this study immunoprecipitation of overexpressed human HA-TRIF in HEK293-TLR3 
and HEK293-TLR4 was performed and a multi-TRIF protein complex was analysed 
using LC-MS. Many novel protein hits have been identified, but unfortunately, TRIF 
and its known binding partners e.g. TLR3, TBK1, TRAF6, and IRFs, were not 
identified. However, these proteins maybe present in the IP complex but their 
concentrations were less than the detectable level. Another issue regarding the use of 
LC-MS technique is the reproducibility of sample analysis. Additionally, the 
complexity of this technique leads to variation in the peptides and proteins identified. 
Nevertheless, these variations could be due to different factors including the biological 
nature of the samples and minor differences in liquid- chromatography (Pelikan et al., 
2007; Tabb et al., 2010). These heighlight the limitations of the LC-MS technique. It 
must be emphasised that whilst HA-TRIF was not detected by LC-MS, it was detected 
by immunoblot analysis. Regarding the detection of HA-TRIF by LC-MS, further 
optimisation may be required. For example, different IP conditions or digestion of the 
proteins using enzymes other than trypsin. Additionally, more sensitive proteomics 
approaches may be utilised e.g. using an OrbiTRAP mass analyser. It is possible that 
TRIF itself may not be suitable for in-gel proteomics analysis for various reasons such 
as an inability to migrate through the gel at sufficient levels to permit detection by LC-
MS. Thus, gel-free proteomics approaches may be used in the future. Concerning the 
above mentioned issues regarding the use of this approach all of the protein interactors 
identified in this study require additional validation by more direct experiments.   
Though many of the proteins identified in the current study did not show a direct 
interaction with TRIF (as per Pathway Studio networks), they are commonly regulated 
by many proteins and many cellular processes. Recently, Zhang et al. (2011) identified 
DDX1, DDX21 and DHX36 as dsRNA sensors that use the TRIF pathways to activate 
type I IFN responses independently of TLR3 in myeloid dendritic cells (mDCs). Using 
a proteomics approach, DDX3X and DDX28 were identified in the current study 
following poly(I:C) stimulation of cells for 40 and 60 min, respectively. 
Phosphoinositide-3-kinase catalytic beta polypeptide (p85β), a subunit of 
Phosphoinositide 3-kinases (PI3K), was identified in HEK293-TLR3 at time point zero 
and 60 min following poly(I:C) stimulation. PI3K has been shown to physically interact 
with TRIF.  Interestingly, pharmacological inhibition of PI3K in monocyte-derived 
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dendritic cells (DCs) was found to enhance IFN-β expression upon TLR3 or TLR4 
engagement (Aksoy et al., 2005). However, in the same models of DCs activation, PI3K 
inhibition increased DNA-binding activity of NF-κB, but not IRF (Aksoy et al., 2005). 
Another interesting protein identified is the NF-κB repression factor (NRF), which was 
identified in HEK293-TLR3 independent of poly(I:C) stimulation. NRF is a nuclear 
inhibitor of NF-κB protein that can silence the IFN-β promoter via binding to negative 
regulatory element (NRE) (Nourbakhsh et al., 1999). This provides a link between NRF 
and the NF-κB pathway. Identification of NLRP1 and AIM2, the core components of 
caspase-1-activating inflammasomes (Faustin et al., 2009), in this screening suggest that 
TRIF may play a role in inflammasomes activation and so, further investigation of 
NLRP1and AIM2 in the context of TRIF signalling is essential.  
 Interestingly, in HEK293-TLR4 at time point zero, the adapter TBK1-binding 
protein 1 (TBKBP1) was identified in the TRIF IP-complex. TBKBP1 is an adapter 
protein which constitutively binds TBK1 and the inhibitor of nuclear factor kappa-B 
kinase subunit epsilon (IKBKE). TBKBP1 was thought to play a role in antiviral innate 
immunity but it is exact functions are still not well known (Bouwmeester et al., 2004). 
Another interesting hit to look at is the Macrophage migration inhibitory factor (MIF) 
which was identified in HEK293-TLR4 cells following LPS stimulation for 20 min. 
MIF was originally identified as a T-cell-derived cytokine that inhibits the random 
migration of macrophages. MIF is proved to be an important pro-inflammatory cytokine 
secreted by most of the cells including T cells, macrophages, endothelial cells and 
smooth muscle cells. It induces the production of a large number of inflammatory 
mediators such as TNF-α, IL-1β, IL-6, and IL-8 (Calandra et al., 1994; Onodera et al., 
2004). MIF was found to be involved in regulation of many and diverse immunological 
cellular processes as shown in Figure 3.20. 
 Nibrin which was identified in the TRIF immunocomplex in HEK293-TLR3 
independent of poly (I:C) plays a critical role in the cellular response to DNA damage 
and the maintenance of chromosome integrity. Mutations in Nibrin cause the Nijmegen 
breakage syndrome (NBS), which is an autosomal recessive syndrome characterized by 
chromosomal instability, radiation sensitivity, immunodeficiency and predisposition to 
cancer, particularly to lymphoid malignancies (Varon et al., 1998; Kondratenko et al., 
2007). This may link TRIF to diseases such as cancer. 
 Menin is another interesting protein to explore in the context of TRIF signalling. 
It is a tumour suppressor gene that its mutation causes the familial cancer syndrome 
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multiple endocrine neoplasia type 1 (MEN1) (Poisson et al., 2003). Heppner et al. 
(2001) found that NF-κB proteins p50, p52 and p65 were capable of directly interacting 
with Menin in vitro and in vivo. They suggested that Menin repressed p65-mediated 
transcriptional activation on NF-κB sites in a dose-dependent and specific manner.  
In conclusion, this study has provided an insight into the TRIF interactome and 
to the best of my knowledge this is the first study performed to investigate the TRIF 
protein complex. Many of the proteins identified in the study are involved in the 
regulation of immunity, apoptosis, cell differentiation, viral reproduction, and cytokine 
production. However, more validatory experiments are needed to confirm their 
interaction with TRIF and the role that these proteins may play in regulating TLR 
signalling. 
Chapter 4 
 
 
Investigating the novel role of human ADAM15 
in TLR3 and TLR4 signalling 
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4.1    Introduction  
 
4.1.1    Background 
Metalloproteases are a large family of important proteases that include matrix 
metalloproteases (MMPs) and proteins with a disintegrin and metalloproteinase domain 
(ADAM). They
 
are also referred to as MDC (Metallo-protease, Disintegrin, Cysteine-
rich) proteins (Rosenberg, 2009). ADAMs are members of the zinc protease 
superfamily and may be subdivided according to the primary structure of their catalytic 
sites. ADAMs belong to the metzincin subgroup which may be further divided into 
serralysins, astacins, matrixins, and adamalysins (Seals and Contrtneidge, 2003). Thus, 
ADAMs are MMPs which belong to the the matrixin subgroup of metzincin proteins. 
These enzymes are responsible for extracellular matrix degradation and remodelling and 
play important roles in development, wound healing, and in the pathology of diseases 
such as Rheumatoid arthritis (RA) and cancer (Visse and Nagase, 2003). ADAMs are 
found in vertebrates, as well as in Caenorhabditis elegans, Drosophila, and Xenopus. In 
contrast, ADAMs are not expressed in Escherichia coli, Saccharomyces cerevisiae, or 
plants (Seals and Contrtneidge, 2003). Several ADAMs are expressed as multiple splice 
variants e.g., ADAM22, ADAM29 and ADAM30 exist as two to three splice variants 
that vary in terms of the length of their cytoplasmic tails, although no functional 
differences in these isoforms have been reported. In other cases, alternative splicing 
produces proteins with markedly different activity (Sagane et al., 1998; Cerretti et al., 
1999). 
 
4.1.2    ADAM Domain structure and function 
To date, about 40 members of the ADAMs family have been described in many 
different species (Paulissen et al., 2009). The domain structure of the ADAMs consists 
of a prodomain, a metalloprotease domain, a disintegrin domain, a cysteine-rich 
domain, an EGF-like domain, a transmembrane domain and a cytoplasmic tail (Figure 
4.1). 
 
4.1.2.1    The Prodomain  
The signal sequence at the N-terminus directs ADAMs to the secretory pathway and the 
prodomain functions to facilitate the maturation of ADAMs. The prodomain keeps the 
metalloprotease site of ADAMs inactive through a cysteine switch. Several ADAMs are  
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Figure 4.1: Domain structure of ADAMs and MMPs. The figure shows general 
domain structure of ADAMs compared to snake venom metalloproteases (SVMP), 
ADAMs with thrombospondin-like motif (ADMTS) and MMP. The MMP shown is of 
the gelatinase class. Other subclasses of MMPs lack hemopexin-like sequences and/or 
fibronectin type II-like sequences. It should be noted that alternative splicing results in 
some ADAMs lacking one or more domain. (Adapted from Seals and Contrtneidge, 
2003). 
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kept inactive state through the interaction of a cysteine residue at the prodomain with 
the zinc in the metalloprotease domain. During maturation which takes place in the 
endoplasmic reticulum, the prodomain is cleaved by furin or furin-like proprotein 
convertases, and the resulting protein constitutes the mature form with an active 
metalloprotease domain. However, maturation of some ADAMs such as ADAM8 and 
ADAM28 occurs as an autocatalytic process (Primakoff and Myles, 2000; Paulissen et 
al., 2009). The prodomain appears to be necessary for the correct folding of the ADAMs 
metalloprotease domain and to facilitate the transport of ADAMs through the secretory 
pathway (Blobel, 2005).  
 
4.1.2.2    The metalloprotease domain 
The metalloprotease domain contains zinc and water atoms that are necessary for the 
hydrolytic processing of protein substrates, and which are coordinated by three 
conserved histidine residues and a downstream methionine. Whilst all ADAMs possess 
a metalloprotease domain, only about 50 % exhibit protease activity. ADAMs which 
display protease activity include ADAM 8, 9, 10, 12, 15, 17, 19, 28, and 33 (Duffy et 
al., 2011). Once activated, ADAMs regulate many biological functions, including 
proteolysis, cell adhesion, cell fusion, inflammation, angiogenesis and intracellular 
signalling. Several ADAM family members have been found to mediate the release of 
cytokines, growth factors, receptors, adhesion molecules and other membrane bound 
proteins from the cell surface, a process termed ectodomain shedding (Nath et al., 1999; 
Zhong et al., 2008). Examples of cell surface proteins shed by ADAMs include the IL-6 
receptor, FAS-ligand, transforming growth factor α (TGFα) and TNFα, (Zigrino et al., 
2007). Inhibitors of ADAMs metalloprotease activity fall into four broad classes: those 
that inhibit by denaturation, those that inhibit by Zn-chelation, small molecule inhibitors 
and tissue inhibitors of metalloproteases (TIMPs). The first two categories represent 
non-selective inhibitors such as reducing agents or zinc chelating agents. The third class 
arose from efforts to develop inhibitors of both MMPs and ADAMs, and include 
hydroxamate-based inhibitors that bind competitively to the active site. Tissue inhibitors 
of metalloproteases, or TIMPs, are endogenous regulators of MMPs and ADAMs. Four 
TIMPs are now known and they cause inactivation by binding to the catalytic site of 
MMPs. However, the TIMPs are not totally selective for MMPs, TIMP3 also inhibits 
ADAM17 and ADAM12. ADAM10 is inhibited by both TIMP1 and TIMP3 but not all 
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ADAMs are sensitive to TIMP3. ADAM8 and ADAM9 processing of myelin basic 
protein is not inhibited by any TIMP (Amour et al., 2000; Loechel et al., 2000). 
 
4.1.2.3    The disintegrin domain  
The disintegrin domain within ADAMs is approximately 90 amino acids in length and 
displays sequence similarity to the disintegrin domain in snake venom metalloproteases 
(SVMPs).
 
Disintegrins have an arginine-glycine-aspartic acid (RGD) integrin-binding 
site, bind to the platelet integrin GPIIb-IIIa (αIIbß3) and inhibit platelet aggregation 
(Primakoff and Myle, 2000; Seal and Contrtneidge, 2003). Human ADAM15 is the only 
known ADAM to contain a RGD binding site in the disintegrin domain. (Chen et al., 
2008; Zhong et al., 2008).  
 
4.1.2.4    The cysteine-rich and EGF-like domains 
The function of the cysteine-rich and EGF-like domains is not fully understood. 
Structurally, the cysteine-rich and EGF-like domains are approximately 160 amino 
acids in length. The two domains may be important for interaction or cell fusion of 
ADAMs with other proteins such as chaperons. In some cases, the cysteine-rich region 
has been implicated in regulating protease activity and controlling substrate specificity 
(Reiss et al., 2006). It is also believed that the cysteine-rich domain complements the 
binding capacity of the disintegrin domain (Serrano et al., 2005). Surprisingly, 
ADAM10 and ADAM17, the only known ADAMs lacking the EGF-like domain, are 
the most effective at ectodomain shedding. This suggests that the EGF-like-domain may 
hinder the ectodomain shedding (Page-McCaw et al., 2007).  
 
4.1.2.5    The cytoplasmic tail 
The cytoplasmic tail of the ADAMs family is highly variable both in length and in 
sequence and serves to transduce signals between the interior and exterior of cells. 
Phosphorylation dependent and independent protein interactions with the cytosolic tail 
of ADAMs have been shown to regulate their maturation, subcellular localization and 
metalloprotease activation (Seal and Contrtneidge, 2003). The domain contains 
specialized motifs. The most common motifs are PxxP binding sites for SH3 domain-
containing proteins. These SH3-binding sites are present in human ADAMs 7, 8, 9, 10, 
12, 15, 17, 19, 22, 29, and 33. Several ADAMs also have potential phosphorylation sites 
for serine-threonine and/or tyrosine kinases. Consequently, ADAMs may serve as 
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adaptors to facilitate the assembly of protein complexes at critical functional locations 
(Yong et al., 2001; Seal and Contrtneidge, 2003). 
 
4.1.3    Subcellular localisation of ADAM 
Data indicate that ADAMs are probably synthesized in the rough endoplasmic reticulum 
and mature in the late Golgi compartment. Maturation involves the removal of the 
prodomain from the ADAM precursor protein, which facilitates the activation of the 
metalloprotease domain of ADAMs (Roghani et al., 1999; Hougaard et al., 1999). Some 
studies have showed that certain ADAMs reside in a region near the nucleus. However, 
ADAMs can also be detected on the cell surface. For example, ADAMs 9, 10, 15 and 
17 are expressed on the cell surface in a processed catalytically active form (Black et 
al., 1997; Hougaard et al., 1999; Lammich et al., 1999). Thus, the subcellular 
localization and activity of ADAMs depends on the specific ADAM, the cell type and 
the substrate involved. 
 
4.1.4    ADAM-mediated shedding 
ADAMs facilitate the shedding of cytokines, cytokine receptors and growth factors 
(Herren et al., 2002). One of the most well-studied members of the ADAMs family, 
TNF converting enzyme (TACE) also called ADAM17 (Black et al., 2002). It has been 
implicated in the release of multiple transmembrane molecules including TNFα, 
TNFRII (p75) and L-selectin. It was shown that TNFα processing was significantly 
inhibited in ADAM17 knockout mice, though limited processing of TNFα can still 
occur in cells derived from ADAM17-deficient mice. This residual sheddase activity is 
inhibited by the metalloprotease inhibitor IC-3, suggesting that other ADAMs family 
members may also process TNFα (Reddy et al., 2000). A dominant negative form of 
ADAM17, which lacks a metalloprotease domain, blocked the proteolysis of the TNF 
receptor (Solomon et al., 1999). Also, IL-1 receptor-II shedding does not occur in 
ADAM17-deficient fibroblasts. In fact, reconstitution of these cells with ADAM17, but 
not ADAM10 was capable of restoring shedding (Reddy et al., 2000). Other molecules 
that have been reported to be cleaved by ADAMs are the extracellular matrix proteins, 
type IV collagen, gelatine and fibronectin (Millichip et al., 1998; Alfandari et al., 2001; 
Martin et al., 2002). It is speculated that such activity may assist in cell migration.  
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4.1.5    ADAMs and human diseases  
ADAMs have been implicated in a variety of human disease processes, such as cancer, 
neuroinflammation, Alzheimers’s disease and RA. Studies from cell lines grown in 
culture, animal models and human malignancies suggest that a number of ADAMs are 
involved in cancer formation and/or progression, for example, ADAM9, 10, 12, 15 and 
17 (Duffey et al., 2009). ADAMs could potentially promote cancer formation/ 
progression through several different mechanisms e.g., release or activation of growth 
factors. Many growth factors are initially synthesised as inactive transmembrane 
precursor proteins that require conversion and the best-studied of these are the 
EGFR/HER family of ligands. All of these receptors, apart from HER2, can be directly 
activated following ligand binding leading to activation of several different signalling 
pathways including the MAPK, the PI3K and the janus kinase/signal transducer and 
activator of transcriptional (JAK/STAT) pathways. Activation of these signalling events 
results in activation of the classical hall markers of malignancy such as enhanced cell 
proliferation and increased cell survival (Bublil et al., 2007). 
 
4.1.6 The ADAM15 gene 
ADAM15 is a type I transmembrane glycoprotein belonging to the ADAMs proteins 
family and is widely expressed in different tissues and cell types with high level in 
vascular cells, the endocardium bone and some region in the brain (Zhong et al., 2008; 
Klino et al., 2009). Human ADAM 15 is located at 1q21.3 of chromosome 1, and was 
cloned in 1996 from MDA-MB-468 adenocarcinoma cells (Krätzschmar et al., 1996). 
The chromosomal region 1q21.3 has been reported to contain genes amplified in breast 
cancer and sarcomas, thus suggesting an association between ADAM15 and cancer 
(Kuefer et al., 2006). Human ADAM15 gene contains 23 exons varying in length from 
63 to 316 bp, and 22 introns (from 79 to 1283 bp). Exons 19-21 are used alternatively in 
human tissues (Kleino et al., 2007; Lu et al., 2010). Alternative mRNA splicing 
generates several ADAM15 isoforms which contain different combinations of putative 
Src homology-3 (SH3) domain binding sites in their cytosolic tails. A total of 6 
isoforms of ADAM15 have been described, and an alternative use of ADAM15 exons 
was found to profoundly influence selection of SH3-containing cellular partner proteins. 
Also, the amino acid sequence of the cytoplasmic tail of ADAM15 contains potential 
tyrosine phosphorylation sites, suggesting that ADAM15 could interact with SH2 
domain-containing proteins via phosphotyrosines, as well as potential serine and 
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threonine phosphorylation sites. Indeed, interaction of ADAM15 with Src, growth 
factor receptor binding protein2 (Grb2), endophilin, p85 (the regulatory subunit of 
Phosphatidylinositol-3 kinases) and mitotic arrest deficient2 (MAD2) has been reported 
(Howard et al., 1999; Poghosyan et al., 2002; Zhong et al., 2008). Thus, ADAM15 is 
involved in regulating many cellular signalling pathways. Also, alternative mRNA 
splicing provides a useful mechanism through which ADAM15 may regulate 
intracellular protein interactions which may help explain the association of some, but 
not all, ADAM15 isoforms with cancer (Yasui et al., 2004; Kleino et al 2009). 
The human ADAM15 has also been termed metargidin (for metalloprotease-
RGD disintegrin) as it is the only ADAM which contains an RGD sequence in a similar 
position to that in snake venom disintegrins. Interestingly, the mouse and rat 
orthologues of ADAM15 lack an RGD sequence. The presence of the RGD sequence 
suggests a specific role for ADAM15 in integrin binding and therefore, in cell-cell 
interactions (Lum et al., 1998; Horiuchi et al, 2003). Although human ADAM15 can 
indeed interact with RGD-binding integrins αvβ3 and α5β1, the mouse ADAM15 does 
not. Instead, the mouse ADAM15 has been implicated as a ligand for integrin α9β1. 
Both the human and mouse ADAM15 contain a catalytic site consensus sequence for 
zinc-dependent metalloproteases and purified recombinant ADAM15 is catalytically 
active. Known ADAM15 substrates include FGFR2iiib and N- and E-cadherin, the 
shedding of which has been implicated in prostate and breast cancer pathogenesis 
(Klino et al., 2009).   
Atherosclerosis is a chronic inflammatory disorder that is the underlying cause 
of most cardiovascular diseases. Interestingly, ADAM15 expression was detected in the 
macrophage-rich regions of atherosclerotic lesions (Herren et al., 1997). This work 
demonstrated that ADAM15 was upregulated during atherosclerosis suggesting a 
potential involvement of ADAM15 in this pathology. Also, upregulation of α5β1 and 
αvβ3 integrins was detected in atherosclerosis (Al-Fakhri, et al., 2003). These integrins 
bind to ADAM15 and have been shown to be involved in the development and 
progression of atherosclerosis. These findings suggest that ADAM15 expressed on 
endothelial cells could act as a receptor for platelets or as a receptor involved in the 
recruitment of immune cells during inflammation (Al-Fakhri et al., 2003; Nath et al., 
1999). Also, upregulation of ADAM15 mRNA and protein levels during inflammatory 
bowel disease (IBD) was detected, suggesting a role of ADAM15 in intestinal 
inflammation (Mosnier et al., 2006). ADAM15 has been also shown to be involved in 
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RA, an inflammatory degenerative joint disease, whereby ADAM15 may be involved in 
cleaving extracellular matrix (ECM) components such as gelatin and IV collagen 
(Martin et al., 2002).  
Herein, following the immunoprecipitation of TRIF and analysis of interacting 
partners using LC-MS techniques, ADAM15 was identified as a novel TRIF interacting 
partner following stimulation of HEK293-TLR3 cells with poly(I:C) for 60 min. 
Interestingly, TRIF and ADAM15 coimmunoprecipitated in a ligand-independent 
manner in HEK293-TLR4 cells. The aim of this chapter was to investigate the role 
played by ADAM15 in TRIF mediated TLR3 and TLR4 signalling. 
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4.2    Results 
 
4.2.1 ADAM15 interacts with TRIF 
Analysis of TRIF interacting partners using a proteomics approach revealed that TRIF 
interacted with ADAM15. Thus, to confirm the interaction, co-immunoprecipitation of 
epitope-tagged TRIF (HA-TRIF) with epitope tagged ADAM15 (V5-ADAM15) was 
performed in HEKT293-TLR3. Cells were transfected with HA-TRIF and EV, or HA-
TRIF and V5-ADAM15 and treated as indicated. Thereafter, immunoprecipitation of 
HA-TRIF was performed as described (Materials and methods, section 2.2.9). As shown 
in Figure 4.2 panel A, ADAM15 co-immunoprecipitated with TRIF following 
stimulation of cells with poly(I:C) for 60 min and there is no association in the absence 
of poly(I:C). It should be mentioned that downregulation of TRIF expression was 
observed when co-expressed with ADAM15 and that ADAM15 probably causing TRIF 
processing (discussed in more details in section 4.2.9).  Interestingly, in HEK293-TLR4 
cells, proteomics analysis showed that ADAM15 interacted with TRIF in a ligand 
independent manner and suggests that TLR4 or another auxiliary molecule may 
facilitate ligand-independent interaction of ADAM15 with TRIF when TLR4 is 
overexpressed in the cell. Many different anti-human TRIF antibodies were tested for 
their ability to detect TRIF, especially at the endogenous level. It was found that an anti-
TRIF polyclonal antibody obtained from Exalpha detected endogenous TRIF and was 
chosen for IP and western blot (discussed further in chapter 6). Thereafter, IP of 
endogenous TRIF from human astrocytoma cell line U373-CD14 was performed as 
described (Materials and methods, section 2.2.10). These cells were used as a model 
since they express TLR3 and TLR4 mRNA and respond well to poly(I:C) and LPS. As 
illustrated in Figure 4.2, panel B, endogenous ADAM15 interacted with endogenous 
TRIF following stimulation of U373-CD14 cells with poly(I:C) and LPS for 60 and 20 
min, respectively. The interaction of TRIF with ADAM15 upon LPS stimulation for 20 
min was also confirmed by LC-MS analysis of the endogenous TRIF immunocomplex 
(discussed further in chapter 6). 
 
4.2.2 ADAM15 inhibited TRIF-dependent reporter gene assays  
Initially, the ability of ADAM15 to modulate TRIF-mediated luciferase reporter gene 
activity was investigated. Thus, HEK T293 cells were transiently transfected with the 
NF-κB, IFN-β and CCL5 (Rantes) reporter gene constructs and increasing amounts of  
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Figure 4.2: Co-immunoprecipitation of human TRIF and human ADAM15.  (A). 
HEK293-TLR3 were seeded into 6 well plates. When the cells become confluent (80 
%), cells were co-transfected with 2 μg of HA-TRIF and 1 μg of EV or co-transfected 
with 2 μg of HA-TRIF and 1 μg of V5-ADAM15. 20 h after transfection, cells were left 
unstimulated or stimulated with 20 μg/ml poly(I:C) for 60 min. Thereafter cells were 
lysed in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM EDTA, pH 8.0, 1 % 
NP-40, 0.5 % sodium deoxycholate supplemented with 1 mM PMSF, 1 mM DDT, 1 
mM NaVO3, 5 mM EGTA and protease inhibitor cocktail). Cleared cell lysates were 
incubated with 1 μg of anti-HA monoclonal antibody precoupled to 50 μl of Protein 
A/G Plus-Agarose beads for 2 h at 4 
o
C with gentle shaking. Immunoprecipitation 
complexes were washed 4 times with lysis buffer and then released from the beads by 
addition of 40 μl of Laemmli loading buffer, followed by boiling for 5 min. Proteins 
were separated by SDS-PAGE gel electrophoresis and subjected to immuno-blotting 
using anti-HA and anti-V5 monoclonal antibodies. (B) U373-CD14 cells were cultured 
into T175 flasks. When the cells were 90-95 % confluent, they were stimulated with 
either 20 μg/ml poly(I:C) or 1 μg/ml LPS for time indicated. Thereafter cells were 
scrapped into 10 ml ice cold PBS and spun down for 10 min at 4
 o
C at 220 g. Cell 
pellets were lysed as per panel A and cleared cell lysates were incubated with 2 μg of 
anti-hTRIF polyclonal antibody precoupled to 50 μl of Protein A/G Plus-Agarose beads 
for 2 h at 4 
o
C with gentle shaking. Proteins were separated by SDS-PAGE gel 
electrophoresis and immunoblot analysis was performed using anti-hTRIF (Exalpha) 
and anti-hADAM15 (R&D) antibodies. Rabbit IgG (Sigma) was used as negative 
control. Images were captured using the G: box system (Syngene). Results represent at 
least three independent experiments. 
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ADAM15 in the presence of a constant concentration of TRIF or MyD88.  
Overexpression of ADAM15 significantly inhibited TRIF-dependent activation of the 
NF- κB, IFN-β (p125-luc) and Rantes reporter genes (Figure 4.3 panels A, B and C). 
Moreover, overexpression of ADAM15 also significantly inhibited TRIF-dependent 
activation of the NF-B-driven PRDII and IRF3/IRF7-dependent PRDIII-I reporter 
genes (Figure 4.3 panels D and E). As a control, the effect of ADAM15 on MyD88 
driven NF-B, IFN-β and Rantes promoter activity was also tested. Overexpression of 
ADAM15 significantly inhibited MyD88-dependent activation of the NF-B and Rantes 
promoter (Figure 4.3 panels F and H). However, overexpression of low levels of 
ADAM15 (5-20 ng) increased MyD88 dependent activation of the IFN-β (p125-luc) 
reporter gene (Figure 4.3 panel G).  
 
4.2.3 ADAM15 inhibited TLR3 and TLR4-mediated reporter gene activity 
 
AS TRIF mediates TLR3 and TLR4 signalling, the effect of ADAM15 on TLR3 and 
TLR4-dependent NF-κB, IFN-β and Rantes activation was investigated using HEK293 
cells stably expressing either TLR3 or TLR4. In HEK293-TLR3 cells, overexpression 
of ADAM15 significantly inhibited TLR3-dependent activation of NF-κB, IFN-β and 
Rantes reporter genes (Figure 4.4). Interestingly, the inhibition effect on the reporter 
gene activation of NF-κB and Rantes was stronger than the effect on IFN-β reporter 
gene activity (Figure 4.4 panels A-C). Furthermore, in HEK293-TLR4 cells, 
overexpression of ADAM15 significantly reduced TLR4-dependent NF-κB, IFN-β 
reporter gene activation (Figure 4.4 panels D and E). In our hands, HEK293-TLR4 cells 
did not induce LPS mediated activation of the Rantes reporter gene. Also, there was 
difficulty using HEK293-TLR4 for reporter gene assays as the fold induction of NF-κB, 
IFN-β relative luciferase activity (RLA) was always low when compared to HEK293-
TLR3.  
 
4.2.4    Poly(I:C) increased ADAM15 transcription     
Some MMPs including MMP9 and MMP3 contain an NF-κB binding site in their 
promoter region that regulates their expression (Mishra et al., 2011). Moreover, it has 
been demonstrated that poly(I:C) induces MMP9 expression in HaCat keratinocytes 
through NF-κB, p38 MAPK and PI-3K signal transduction pathways (Voss et al., 2011).   
Therefore, the effect of poly(I:C) and LPS on ADAM15 transcription was investigated. 
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Figure 4.3: ADAM15 inhibited TRIF-dependent reporter gene activity. (A-E) 
HEKT293 cells were plated into 96 well plates at a density of 5 x 10
4
 cells/well. After 
24 h, cells were transfected with expression vectors encoding either the reporter genes 
NF-B (A), IFN-β promoter p125 (B), Rantes (C), IFN-β PRDII (D) or IFN-β PRDIII-I 
(E) and co-transfected with either EV or expression vectors encoding the full length 
human HA-TRIF (20 ng) and increasing amounts of expression vectors encoding full 
length human V5-ADAM15 (5, 20, 30 and 40 ng) as indicated. After 24 h, cells were 
harvested and lysed. The cell lysates were stored at -80 
o
C for at least 24 h, followed by 
assessment of luciferase reporter gene activity. (F-H) HEKT293 cells were plated into 
96 well plates at density of 5 x 10
4
 cells/well. After 24 h, cells were transfected with 
expression vectors encoding either reporter genes for the NF-B (F), full-length IFN-β 
promoter (p125) (G) and Rantes (H) as indicated, and co-transfected with either EV or 
an expression vector encoding full length human Myc-MyD88 (20 ng) and increasing 
amounts of an expression vector encoding full length human V5-ADAM15 as indicated. 
After 24 h, cells were lysed and the cell lysates were stored at -80 
o
C for at least 24 h. 
Thereafter, luciferase reporter gene activity was assessed using the dual luciferase 
system (Promega). The results presented are representative of at least three independent 
experiments, each experiment was done in triplicate. * P < 0.05, ** P < 0.01 and *** P 
< 0.001. 
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Figure 4.4: Overexpression of ADAM15 inhibited TLR3 and TLR4 mediated 
reporter gene activity. (A-C) HEK293-TLR3 cells were plated into 96 well plates at 
density of 5 x 10
4
 cells/well. After 24 h, cells were transfected with expression vectors 
encoding either the NF-B (A), full-length IFN-β promoter (p125) (B), or Rantes 
promoter (C) reporter gene plasmids, and co-transfected with either an EV or and 
increasing amounts of V5-ADAM15. After 24 h, cells were left untreated (control) or 
stimulated with 20 μg/ml poly (I:C) for an additional 24 h, followed by harvesting of 
cell lysates.  Cell lysates were left at -80 
o
C for at least 24 h and assessment of 
luciferase reporter gene activity was performed. (D and E) HEK293-TLR4 were 
transfected with reporter genes for the NF-B (D) or full-length IFN-β promoter (p125) 
(E), and co-transfected with either an EV or increasing amount of expression vector 
encoding full length human V5-ADAM15 as indicated. After 24 h, cells were left 
untreated (control) or stimulated with 1 μg/ml LPS for 24 h, followed by harvesting and 
cell lysis. Cell lysates were left at -80 
o
C for at least 24 h, followed by assessment of 
luciferase reporter gene activity using dual luciferase system (Promega). The results 
presented are representative of at least three independent experiments each experiment 
was done in triplicate.  *** P < 0.001. 
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using the human astrocytoma cell line U373-CD14 as a model. Cells were stimulated 
with either poly(I:C) or LPS for different time points followed by RNA isolation, cDNA 
synthesis and Q-RT-PCR. Poly(I:C) stimulation modestly increased ADAM15 mRNA 
compared to the control, while LPS did not have an effect on ADAM15 mRNA 
expression (Figure 4.5  panel A and B). 
 
4.2.5    Downregulation of ADAM15 by esiRNA. 
To investigate the role played by ADAM15 in TLR3 and TLR4 signalling, knockdown 
of ADAM15 was performed using MISSION esiRNA technology in U373-CD14 cells. 
MISSION esiRNA are end-ribonuclease prepared siRNA. They are a heterogeneous 
mixture of siRNAs that all target the same mRNA sequence. These multiple silencing 
triggers lead to highly specific and effective gene silencing. To monitor the knockdown, 
U373-CD14 cells were transfected with esiRNA-control or esiRNA against human 
ADAM15, then ADAM mRNA and protein levels were measured by using RT-PCR 
and immunoblotting, respectively. It was found that esiRNA significantly decreased 
ADAM15 mRNA compare to the control (Figure 4.6, panel A and B). In addition, the 
ADAM15 protein expression was also downregulated by the ADAM15 esiRNA 
compared to the control as measured by western blot (Figure 4.6, panel C). 
 
4.2.6    Suppression of ADAM15 expression enhanced IFN-β, TNF-α and Rantes 
mRNA expression.  
To investigate the potential role of ADAM15 in TLR3 and TLR4 signalling, levels of 
IFN-β, TNF-α and Rantes mRNAs were measured in U373-CD14 cells transfected with 
esiRNA control or esiRNA against ADAM15. After 48 h, cells were stimulated with 
either poly(I:C) or LPS for 3 h. Downregulation of ADAM15 significantly increased 
poly(I:C) and LPS induce IFN-β, TNF-α and Rantes transcription compared to the 
control (Figure 4.7, panels A, B, C and F, G, H). Also knockdown of ADAM15 
increased slightly the basal level of IFN β mRNA compared to the control (Figure 4.7 
panel A and F). It has been reported that MMP9 secretion and activity was abolished in 
PC-3 cell line in response to ADAM15 reduction by short hairpin RNA technology 
(Najy et al., 2008). Furthermore ADAM15 has been shown to cleave the ectodomain of 
MMP10 (Tousseyn et al., 2009; Friedrichet et al., 2011). Therefore, the effect of 
ADAM15 knockdown on the transcription of these two MMPs was studied. 
Surprisingly, reduction of ADAM15 significantly increased poly(I:C) induced MMP9  
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Figure 4.5: poly (I:C) increased ADAM15 mRNA. U373-CD14 cells were plated into 
6-well plates. When cells were 80 % confluent, they were left un-stimulated (control) or 
stimulated with either 20 μg/ml poly(I:C) (A) or 1 μg/ml LPS (B) for the time indicated. 
Thereafter, total RNA was isolated, and reverse transcribed into cDNA. The cDNA 
were used as a template whereby it was diluted 25 times and ADAM15 mRNA was 
measured by Q-RT-PCR using primer specific to human ADAM15. GAPDH was used 
as housekeeping gene. The results presented are representative of at least three 
independent experiments each experiment was done in duplicate.  * P < 0.05. 
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Figure 4.6: Suppression of ADAM15 in human astrocytoma U373-CD14 cells. (A) 
Cells were seeded into 6-well plate. When cells were 80 % confluent, they were 
transfected with 20 nM esiRNA control or 20 nM esiRNA against human ADAM15.  
Cells were harvested 24 h after transfection and total RNA was isolated and reverse 
transcribed into cDNA. The cDNA template was diluted 25 times and ADAM15 mRNA 
was measured by Q-RT-PCR using primer specific to human ADAM15. GAPDH was 
used as housekeeping gene. (B) The cDNAs were diluted 100 times and RT-PCR was 
performed using specific primer for human ADAM15. GAPDH was used as 
housekeeping gene. RT-PCR products were separated by agarose gel electrophoresis for 
1 h at 100 V. Images were captured using the G:box documentation system (Syngene). 
(C) Cells were plated into 6-well plates. After 24 h, cells were transfected with 20 nM 
esiRNA control or esiRNA against human ADAM15. Cells were collected 48 h after 
transfection in 1 ml cold ice PBS and centrifuged for 10 min at 380 g at 4 
o
C. Cells were 
lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40, 1 % sodium 
deoxycholate, 0.1 % SDS, supplemented with protease inhibitor cocktail, 1 mM PMSF 
1 mM Na3VO4 , and 1 mM DDT). Proteins were separated by SDS-PAGE gel 
electrophoresis and subject to immunoblotting. ADAM15 was detected using anti-
human ADAM15 monoclonal antibody (R&D). β-Actin was used as loading control. 
Images were captured using the G:box documentation system (Syngene). **P < 0.01. 
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Figure 4.7: Suppression of ADAM15 expression enhanced IFN-β, TNF-α and 
Rantes mRNA transcripts (A and C) U373-CD14 cells were seeded into 6 well plates. 
When the cells were 80 % confluent, they were transfected with 20 nM esiRNA control 
or esiRNA directed against ADAM15. After 48 h, cells were stimulated with either 20 
μg/ml poly(I:C) (panel A) or 1 μg/ml LPS (panel C) for 3 h. Thereafter, cells were 
harvested and total RNA was isolated and reverse transcribed into cDNA.  The cDNA 
was used as template and then diluted 25 times. Next, levels of IFN-β, TNF-α and 
Rantes mRNAs were measured by Q-RT-PCR using specific human IFN-β, TNF-α and 
Rantes primers. (Panels, B and D) Cells were seeded into a 6-well plate and when cells 
become 80 % confluent, cells were transfected with 20 nM esiRNA control or esiRNA 
against ADAM15. After 24 h, cells were stimulated with either 20 μg/ml poly(I:C) 
(panel B) or 1 μg/ml  LPS (panel D) for an additional 24 h. Thereafter cells were 
collected, total RNA was isolated and reverse transcribed into cDNA.  cDNA was used 
as template and then diluted 25 times. Levels of mRNA for MMP9 and MMP10 were 
measured by Q-RT-PCR using specific human MMP9 and MMP10 primers. GAPDH 
was used as housekeeping gene. Data are representative of two independent experiments 
each experiment was done in duplicates. * P < 0.05 and ** P < 0.01. 
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and MMP10 mRNA compared to the control (Figure 4.7 panels D and E). However, 
reduction of ADAM15 slightly decreased LPS induced MMP9 and MMP10 mRNA 
Compared to the control (Figure 4.7, panels I and J). Suppression of ADAM15 had no 
effect on basal MMP9 transcription however it decreased slightly the MMP 10 mRNA 
compared to the control (Figure4.7, panels I and J).  
 
4.2.7    Downregulation of ADAM15 increased cytokine and chemokine secretion  
Next, the effect of ADAM15 on TLR3 and TLR4 mediated cytokine and chemokine 
induction was assessed. To this end, U373-CD14 cells were transfected with esiRNA 
control or esiRNA against ADAM15 for 24 h, followed by stimulation with either 
poly(I:C) or LPS for additional 24 h. Thereafter, cell free supernatants were collected 
and cyto/chemokine secretion was measured using the human Meso ELISA system as 
described (Materials and methods section 2.2.21). Suppression of ADAM15 expression 
significantly increased poly(I:C) induced IFN-β, IFN-γ, IL- 12p70, Rantes and TNF-α 
(Figure 4.8 panels A-E) secretion compared to the control.  Furthermore, down-
regulation of ADAM15 enhanced LPS induced IFN-β and IFN-γ, IL-12p70 and Rantes 
(Figure 4.8, panel E), secretion compared to the control (Figure 4.8, panels I-L). TNF-α 
is slightly increased but the difference is not significant (Figure 4.8, panel M). 
The transcription of many MMPs is promoted by inflammatory cytokines and 
chemokines (Yong et al et al., 2001). Also Voss et al. (2011) reported that  poly(I:C) 
stimulation in chondrocytes leads to TRIF-dependent induction of MMP1 and MMP13 , 
thus the levels of MMP 1, 3 and 9 in cell free supernatants was also measured using the 
human Meso ELISA system. Reduction of ADAM15 significantly enhanced poly(I:C) 
induced MMP1 MMP3 and MMP9 compared to the control (Figure 4.8, panels F-H). 
Alternatively, knockdown of ADAM15 significantly decreased/increased LPS induced 
MMP9/MMP3 secretion compared to the control, MMP1 was not affected (Figure 4.8, 
panels N-P). It should be mentioned that knockdown of ADAM15 had negligible effect 
on cytokines/chemokine and MMPs basal levels.   
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Figure 4.8: Suppression of ADAM15 enhanced TLR3 and TLR4 mediated cytokine 
and chemokine induction. U373-CD14 cells were plated into 6-well plates. When the 
cells were 80 % confluent, cells were transfected with 20 nM esiRNA control or 
esiRNA against ADAM15. After 24 h, cells were stimulated with either 20 μg/ml 
poly(I:C) (panels A, B, C, D) or 1 μg/ml  LPS (panels E, F, G, H) for an additional 24 h. 
Thereafter, cell free supernatants were collected and ELISA was performed using the 
Meso system. IFN-γ, IL-12p70, IL-6, TNF-α were measured in the cell free 
supernatants using human Pro-Inflammatory 7-plex Meso kit. Rantes and IFN-β were 
measured using the human single plex Meso kit. MMP 1, 3 and 9 were measured using 
the human 3 plex Meso kit.  * P < 0.05, ** P < 0.01 and *** P < 0.001.   
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4.2.8    Knockdown of ADAM15 increased the phosphorylation of p65 
As TRIF mediates NF-κB activation and phosphorylation of both p65 and IRF3, it was 
of interest to investigate whether ADAM15 reduction affected IκBα degradation, 
phosphorylation of p65 and IRF3. To this end, U373-CD14 cells were transfected with 
esiRNA control or esiRNA against ADAM15 for 48 h followed by stimulation with 
either poly(I:C) or LPS at the indicated time points. Then, IκBα degradation, phospho-  
rylation of p65 and IRF3 was investigated in whole cell lysates. Suppression of 
ADAM15 expression increased delayed IB degradation and phosphorylation of p65 
(120 min) upon LPS stimulation (Figure 4.9) compared to the control. However, 
suppression of ADAM15 expression had no effect on IB degradation and 
phosphorylation of p65 upon poly(I:C) (data not shown). Additionally, phosphorylation 
of IRF3 was not detected in this cell line.  
 
4.2.9    ADAM15 mediates TRIF degradation 
In an effort to define the mechanism that underlying ADAM15 negatively regulates 
TRIF mediated TLR3 and TLR4 signalling and as ADAM15 exhibits protease activity 
(Martin et al., 2002; Duffey et al., 2011), the ability of ADAM15 to mediate the 
degradation of TRIF was investigated. To this end, HEK293-TLR3 were transfected 
with HA-TRIF and EV or HA-TRIF and V5-ADAM15. Thereafter, cells were left 
untreated (control) or stimulated with poly(I:C) as indicated. It should be mentioned that 
during co-immunoprecipitation of TRIF and ADAM15 in HEK293-TLR3, degradation 
of TRIF was observed. To inhibit the catalytic activity of ADAM15, ethylene glycol 
tetraacetic acid (EGTA) and EDTA were used. Chen et al. (2007) reported that ADAM 
and MMP family members are Zn-dependent proteinases. Thus, their activities were 
reported to be inhibited by the metal ion chelators such as EDTA and EGTA. Results 
showed that ADAM10 and ADAM17 sheddase activity was inhibited by both EDTA 
and EGTA (Chen et al., 2007). For this reason EGTA and EDTA were not used in this 
experiment to keep ADAM15 in its catalytic active form. As shown in Figure 4.10 
panel A, overexpression of 1 μg ADAM15 caused TRIF degradation in HEK293-TLR3 
even in the absent of poly(I:C) stimulation. As a control and to eliminate the possibility 
that the degradation effect could be caused by overexpression of two proteins within a 
cell at the same time, the modulatory effect of ADAM15 on MyD88 was tested. 
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Figure 4.9: Attenuation of ADAM15 increased phosphorylation of p65. U373-
CD14 cells were seeded into 6-well plates. When the cells were 80 % confluent, they 
were transfected with 20 nM esiRNA control or esiRNA against ADAM15. After 48 h, 
cells were stimulated with 1 μg/ml LPS for the indicated time points. Thereafter, cells 
were collected in 1 ml PBS and centrifuged for 10 min at 4 
o
C at 380 g. Cell pellets 
were lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40, 1 % 
sodium deoxycholate, 0.1 % SDS, supplemented with protease inhibitor cocktail, 1 
mM PMFS 1 mM Na3VO4 and 1 mM DDT). Next, cell lysates were mixed with 
Laemmli loading buffer and boiled for 5 min. Proteins were separated by SDS-PAGE 
and subjected to immunoblot analysis using mouse anti-IκBα and rabbit anti pp65 
monoclonal antibodies. β-actin was used as loading control. Images were captured 
using the G:Box system (Syngene). Results represent three independent experiments. 
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Figure 4.10 : ADAM15 mediates TRIF degradation.  (Panel A), HEK293-TLR3, 
(Panel B), HEK293-TLR4 were seeded into 6-well plates. When the cells were 80 % 
confluent, HEK293-TLR3 were co-transfected with either 2 μg of HA-TRIF and 1 μg 
of EV or with 2 μg of HA-TRIF and 1μg of V5-ADAM15. HEK293-TLR4 were co-
transfected with 2 μg of Myc-MyD88 and 1 μg of EV or with 2 μg of Myc-MyD88 and 
1 μg of V5-ADAM15. After 20 h, cells were left unstimulated or treated with 20 μg/ml 
poly(I:C) (HEK293-TLR3) or 1 μg/ml LPS (HEK293TLR4) for the indicated times. 
Thereafter, cells were harvested and lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 
150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % SDS, supplemented with 
protease inhibitor cocktail, 1 mM PMSF, 1 mM Na3VO4 and 1 mM DDT). Proteins 
were separated by SDS-PAGE and immunoblotting was performed using anti-HA, 
anti-Myc and anti-V5 monoclonal antibodies whereby β-actin was used as loading 
control.  (Panel C) U373-CD14 cells were seeded into 6 well plates. When the cells 
were 80 % confluent, they were transfected with 20 nM esiRNA control or 20 nM 
esiRNA against ADAM15. After 24 h, cells were stimulated with either 20 μg/ml 
poly(I:C) or 1 μg/ml LPS for  3 or 24 h as indicated. Thereafter, total RNA was isolated 
and reverse transcribed into cDNA which was diluted 25 times and then used as a 
template for Q-RT-PCR. TRIF mRNA was measured by Q-RT-PCR using specific 
primer to human TRIF.  (Panel D) U373-CD14 cells were seeded into 6-well plates. 
When cells were 80 % confluent, they were transfected with 20 nM esiRNA control or 
20 nM esiRNA against ADAM15. After 24 h, cells were stimulated with either 20 
μg/ml poly(I:C) or 1 μg/ml LPS for additional 24 h. Thereafter, cells were collected in 
1 ml PBS and centrifuged for 10 min at 4 
o
C at 380 g. Cell pellets were lysed in RIPA 
buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 
0.1 % SDS, supplemented with protease inhibitor cocktail, 1 mM PMSF, 1 mM 
Na3VO4 and 1 mM DDT). Cell lysates were mixed with Laemmli loading buffer and 
boiled for 5 min. Proteins were separated by SDS-PAGE and subjected to 
immunoblotting using a rabbit anti-TRIF polyclonal antibody (Exalpha). β-actin was 
used as loading control. Images were captured using the G:Box system (Syngene). 
Results represent two independent experiments. 
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It was found that ADAM15 overexpression in HEK293-TLR4 had no effect on MyD88 
expression (Figure 4.10 panel B). To support these findings, levels of endogenous TRIF 
mRNA and protein level were measured following suppression of endogenous 
ADAM15 by esiRNA. Suppression of ADAM15 resulted in a significant increase of 
TRIF mRNA 24 h upon poly(I:C) stimulation compared to the control. However, 
suppression of ADAM15 only slightly increased LPS induces TRIF transcription upon 
LPS stimulation at 3 h compared to the control (Figure 4.10 panel C). Next, TRIF 
protein expression was detected by western blot using a specific anti human-TRIF 
antibody. Suppression of ADAM15 resulted in the upregulation of TRIF protein 
expression upon poly(I:C) and LPS stimulation (Figure 4.10 panel and D). 
 
4.2.10     Cellular localization of ADAM15 
It has been reported that some ADAMs may be cleaved and subsequently translocate to 
the nucleus (Friedrich et al., 2011; Mishra et al., 2011). For that reason, the subcellular 
distribution of ADAM15 was investigated following stimulation of cells with poly(I:C). 
To this end, ADAM15 was overexpressed in HEK293-TLR3. Thereafter, cells were 
stimulated with poly(I:C) and subcellular localisation was investigated by confocal 
microscopy. To avoid potential artifacts due to high levels of overexpression, the 
amount of plasmid DNA transfected into the cells was maintained at low levels (200 
ng). As illustrated in Figure 4.11, ADAM15 showed perinuclear distribution and poly 
(I:C) stimulation had no effect on it cellular location. 
 
4.2.11    Interaction network 
To investigate whether ADAM15 and TRIF are involved in the co-regulation of similar 
proteins or share some common targets, ADAM15 and TRIF were inputted into the 
Pathway Studio Software and a search was performed to identify common targets and 
common regulator networks. As illustrated in Figure 4.12, TRIF regulates IFN-γ 
expression which is indirectly regulated by ADAM15. TNFα is directly regulated by 
TRIF and its expression is also regulated by ADAM15. Also, it was found that 
ADAM15 and TRIF indirectly regulate MAPK1 and MMP9 and MAPK3 is regulated 
by ADAM15. Interestingly, ADAM15 expression was previously reported to be 
upregulated in cells treated with pro-inflammatory cytokines and in tissues of 
inflammatory diseases (Charrier-Hisamuddin et al., 2008). Also, overexpression of 
ADAM15 causes increased ERK1/2 activation in endothelial (Sun et al., 2010). It is 
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known that TRIF induces proinflammatory cytokine which is dependent on NF-κB and 
MAPK activation (Qi et al., 2005). This indicates that both ADAM15 and TRIF are 
involve in MAPK activation and is possible they may counterregulate each other. Ras 
GTPase-activating-like protein (IQGAP1) was another protein that was identified by 
LC-MS in HEK293-TLR3 together with ADAM15 upon poly(I:C) stimulation for 60 
min. IQGAP1 is also involved in MAPK activation and has been reported to play a 
positive role in viral replication (Leung et al., 2006). Research has shown that IQGAP1 
binds to and modulates the activity of multiple proteins that participate in bacterial 
invasion (Hugh et al., 2012). Interestingly, this protein has been reported to be involved 
in invadopodial matrix degradation (Sakurai-Yageta et al., 2008). Invadopodial are 
actin-based membrane protrusions with a matrix degradation activity and represent sites 
where cell signalling, proteolytic, adhesive, cytoskeletal, and membrane trafficking 
pathways physically converge (Weaver, 2006). Actin regulatory proteins participate in 
invadopodia formation whereas the matrix degradation activity requires MMPs.  
Stimulation of invadopodial activity by constitutively active IQGAP1 requires the 
CLIP170 and adenomatous polyposis coli (APC) (Sakurai-Yageta et al., 2008). These 
two proteins were also identified in the TRIF protein complex upon stimulation of 
HEK293-TLR3 with poly(I:C) for 60 min. Both CLIP170 and APC bind to IQGAP1 as 
shown in chapter 3 Figure 3.12. This may indicate that ADAM15 could causes TRIF 
degradation through IQGAP and their binding partners CLIP170 and APC. To 
investigate whether TRIF, ADAM15 and IQGAP share similar regulation of cellular 
processes, TRIF, ADAM15 and IQGAP were uploaded to the Pathway Studio Software 
and a cellular processes network was created. TRIF and IQGAP1 share the regulation of 
viral reproduction, phagocytosis and endothelial cell proliferation. Interestingly 
IQGAP1 regulates almost all cellular processes regulated by ADAM15. These include 
leukocyte migration, cell proliferation, cell migration, cell differentiation, 
vascularization, cell motility and cell invasion (Figure 4.13). Thus, there is a strong 
association between ADAM15 and IQGAP1. Therefore, IQGAP1 could be a target of 
choice in investigating the mechanism by which ADAM15 causes TRIF degradation 
and thereby negatively regulates TLR3 and TLR4 signalling.   
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Figure 4.11: Cellular distribution of ADAM15 upon TLR engagement. HEK293-
TLR3 were seeded on pre-collagen coated coverslip in 6-well plates. When the cells 
become 80 % confluent, they were transfected with 200 ng of V5-ADAM15. After 24 h, 
cells were left untreated or treated with 20 μg/ml poly(I:C) for 40 or 90 min as 
indicated. Thereafter, cells were fixed in 4 % parafomaldehyde in PBS, permeabilized 
in 0.5 % triton X-100 in PBS and blocked for 1 h in 1 % BSA in PBS. Next, cells were 
incubated with 200 μl of anti-V5 monoclonal primary antibody (diluted 1:50 in blocking 
buffer) for 2 h at RT with gentle shaking. Thereafter, cells were washed for 10 min with 
0.05 % Tween 20 in PBS three times. Then, cells were incubated with Alexa fluro 568 
secondary antibody (diluted 1:200 in blocking buffer) for 1 h at RT in the dark, 
followed by three washes with 0.05 % Tween 20 in PBS.  The nucleus was stained with 
DAPI (10 μg/ml in PBS). Then, cells were washed twice in PBS and the coverslips were 
mounted on glass slide using mounting medium and kept in the fridge until analysed. 
Images were captured using Olympus 1000 confocal microscopy and Flouview 
Software.   
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Figure 4.12: Common targets/regulator network of ADAM15 and TRIF as 
constructed using Pathway Studio Software. In HEK293-TLR3 cells, following 
immunoprecipitation of HA-TRIF and LC-MS analysis of TRIF interactors, ADAM15 
was identified upon stimulation of cells with poly(I:C) for 60 min. TRIF (Ticam-1) is 
indicated in red with yellow surround. ADAM15 is indicated in red with green 
surround. Yellow entities indicate the proteins that are co-regulated by TRIF and 
ADAM15, as derived from the software programme. Grey dotted line indicates 
regulation, grey solid line indicates direct regulation and purple solid line indicates 
expression.  
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Figure 4.13: Cell processes regulated by TRIF, ADAM15 and IQGAP1. In 
HEK293-TLR3 cells, following IP and LC-MS of HA-TRIF immunocomplexes, 
ADAM15 and IQGAP1 were identified upon stimulation of cells with poly(I:C) for 60 
min. Newly identified protein interactors were uploaded to Pathway Studio software 
analysis program. Next, cell processes that were commonly modulated by TRIF and the 
newly identified proteins were identified by Software analysis. Yellow entities indicate 
the cellular processes that are co-regulated by the identified proteins and TRIF. The red 
entity with yellow surround indicates TRIF (Ticam-1), red entity with green surround 
indicates ADAM15 and red entity with blue surround indicates IQGAP1. Grey dotted 
lines indicate regulation.  
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4.3    Discussion  
This study has shown for the first time that TRIF interacts with the disintegrin 
metalloprotease ADAM15 upon stimulation of the cells with poly(I:C) and LPS. 
ADAM15 was found to function as a negative regulator of TRIF mediated activation of 
NFκB, IFN-β and Rantes promoter activity. Also, efficient suppression of ADAM15 
expression was achieved by using esiRNA technology. Knockdown of ADAM15 
resulted in enhanced TLR3 and TLR4 signalling leading to the enhanced production of 
pro-inflammatory cytokines and chemokines and increased TRIF mRNA and protein 
levels compared to the control. Several MMPs including MMP3 and 9 contain NF-κB 
binding site within their promoter region that regulate their expression (Overall et al., 
2002). In this study, it was found that reduction of ADAM15 significantly enhanced 
poly(I:C) induced MMP1, 3 and 9 secretion. In agreement with this finding Zhang et al. 
(2008) reported TRIF-dependent induction of MMP1 and MMP13 in chondrocytes 
upon poly(I:C) stimulation. This induction was dependent on the NF-κB pathway, but 
was differentially inhibited by various mitogen-activated protein kinase inhibitors. 
Moreover, MMP9 has been shown to be upregulated upon poly(I:C) stimulation in 
HaCaT keratinocytes (Voss et al., 2011). It has previously been reported that LPS 
induces MMP9 expression in macrophages through a ROS-p38 kinase dependent 
pathway (Woo et al., 2004). Interestingly, we show that whilst LPS induced MMP9 
induction, suppression of ADAM15 expression significantly decreased LPS induced 
MMP9 secretion. MMP9 expression appears to be regulated by a number of different 
signalling pathways in different cell types. For example, protein kinases, MAPKs, 
transcription factors such as NF-κB, and AP-1 have all been reported to involve in the 
induction of MMP9 (Gum et al., 1996). Thus, the differences in terms of the role played 
by ADAM15 may be due to differences in signalling pathway that are instigated.  
Despite the potentially important role that ADAM15 may play in cancer, little is 
known about the regulation of ADAM15 activity, though many studies suggest that 
ADAM15 could play a role in cell signalling events. The intracellular domain of 
ADAM15 contains proline-rich sequences, suggesting possible interaction with Src 
homology (SH) 3 domain-containing proteins. Poghosyan and colleagues showed that 
the cytoplasmic domain of ADAM15 can form specific, phosphorylation-dependent 
interactions with Src family protein-tyrosine kinases and with the Grb2 adaptor protein 
in hematopoietic cell lines (Poghosyan et al., 2002).  
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ADAM15 expression has also been detected in atherosclerotic lesions, indicating its 
involvement in this pathology (Herren et al., 1997). In RA, an inflammatory 
degenerative joint disease involving tissue remodeling, increased ADAM15 expression 
was found in rheumatoid synovial tissue compared with normal synovial tissue or even 
osteoarthritic synovial tissue. The expression of ADAM15 in endothelial cells and 
immune cell infiltrates in RA synovium implies a role for ADAM15 in RA via immune 
cell recruitment (Komiya et al., 2005 and Böhm et al., 2001). It was also speculated that 
in RA ADAM15 could degrade the extracellular matrix (ECM) directly through it 
metalloprotease activity or indirectly through proteolytic activation of MMPs (Charrier-
Hisamuddin et al., 2008). Upregulation of ADAM15 was also reported during intestine 
bowl disease, suggested its involvement in intestinal inflammation.  
Whilst most of the published data suggest that ADAM15 is a mediator of 
inflammation, the possibility that ADAM15 could present both pro-and anti-
inflammatory activities cannot be precluded (Charrier-Hisamuddin et al., 2008; kleino et 
al., 2008). Wound healing experiments showed that overexpression of ADAM15 inhibit 
the mechanisms of wound repair in Caco2-BBE cells (Charrier et al., 2005; Charrier et 
al., 2007). That is supported by Herren and colleagues showing that ADAM15 inhibits 
wound healing mechanisms in the fibroblastic cell line NIH3T3 (Herren et al., 2001). 
Recently Friedrich et al. (2011) reported that knockdown of ADAM15 significantly 
reduced HIV-1 replication in U373-MAGI-CCR5 cells, through a mechanism involving 
cleavage of ADAM10 by ADAM15. This indicates that ADAM15 is involved in viral 
replication. 
Notably, a total of 6 isoforms of ADAM15 have been described, thus different 
expression of ADAM15 could result in different cells events (Yasui et al., 2004). 
Herein, we have shown that full length ADAM15 binds to TRIF, however, the ability of 
the other ADAM15 splice variants to bind TRIF and to modulate TLR signalling remain 
to be investigated. Also, the availability of a specific ADAM15 inhibitor will greatly 
enhance the capability to study the effect of ADAM15 on other TLRs in various cell 
types. 
 In conclusion, this study shows for the first time that ADAM15 interacts with 
TRIF upon poly (I:C) and LPS stimulation, and that ADAM15 functions as a negative 
regulator of  TLR3 and TLR4 signalling by a mechanisms involve TRIF degradation.  
 Chapter 5 
 
 
Role of Dishevelled in TLR signalling 
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5.1    Introduction 
 
5.1.1    Wnt signalling pathway 
The Wnt signalling pathway is a well conserved signalling pathway necessary for 
embryonic development, tissue self-renewal, cellular proliferation and homeostasis. 
Dysregulation of Wnt signalling has been linked to cancer (Wang et al., 2010; Bernatik 
et al., 2011). Wnts are secreted glycoproteins that can activate several downstream 
signalling pathways including the canonical Wnt/β-catenin pathway and other non-
canonical pathways. These non-canonical pathways include the planar cell polarity 
(Rho/c-Jun N-terminal kinase), the Wnt/Ca
2+
 pathway, and other less-known signalling 
cascades (Uemastsu et al., 2007; Gao et al., 2010). The canonical Wnt signalling 
pathway is the most well studied of the pathways and is involved in regulating diverse 
cellular processes, such as cell embryonic development, tissue homeostasis, stem cell 
maintenance, tumor suppression and oncogenesis (Logan et al., 2004). Many genes such 
as cyclin D1, c-myc, fibronectin, matrix metalloproteases (MMPs) and vascular 
endothelial growth factor (VEGF) have been identified as Wnt target genes (Staal et al., 
2004; Ziegler et al., 2005). 
 
5.1.2    Canonical Wnt Signalling  
In the absence of a Wnt signal, cytoplasmic β-catenin is recruited into a destruction 
complex that contains adenomatous polyposis coli (APC) and Axin which facilitates the 
phosphorylation of β-catenin by Casein kinase I (CKI) and Glycogen synthase kinase 
(GSK3β). Phosphorylated β-catenin is then ubiquitinated and destroyed by the 
proteasome (Figure 5.1, panel A). When a Wnt ligand binds to a Frizzled (Fzd) family 
of receptors and a low density lipoprotein (LRP) co-receptor of the LRP-5/6, the 
destruction complex is inhibited and the signalling cascade is initiated. LRP is 
phosphorylated by CKI and GSK3β, and Axin is then recruited to the plasma 
membrane. The kinases in the β‑catenin destruction complex are then inactivated and β-
catenin translocates to the nucleus. In the nucleus, β-catenin interacts with the T cell 
factor (TCF)/lymphoid enhancer factor (LEF) family transcription factors and activates 
the transcription of various target genes (Eisenmann et al., 2005; Choi et al., 2007; Zhou 
et al., 2009) (Figure 5.1, panel B).  
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Figure 5.1: Schematic representation of the canonical Wnt/β-catenin pathway. (A) 
In the absence of the Wnt protein ligands, the destruction complex (Axin, APC and 
GSK3β) facilitates β-catenin phosphorylation and its ubiquitination and degradation by 
the proteasome. (B) Binding of the Wnt ligand to a Frizzled/LRP-5/6 receptor complex 
activates the downstream signalling components including the G-proteins, Gαo and 
Gαq, and the phosphoprotein, DVL. DVL reduces GSK3β kinase activity, which lead to 
β-catenin stabilisation and its translocation to the nucleus, where it interacts with 
TCF/LEF proteins in the nucleus to activate transcription. (Adapted from Bikkavilli and 
Malbon, 2009). 
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To date, 19 different Wnt ligands have been identified in humans and all are lipid-
modified glycoproteins (Liang et al., 2007; Muralidharan et al., 2011). The -catenin 
pathway is mainly activated by the ligands Wnt1, Wnt3A and Wnt8. 
 
5.1.3    Non-canonical WNT signalling. 
There are many non-canonical Wnt signalling pathways, but the two best-studied 
pathways are the Planar Cell Polarity (PCP) and Wnt/Calcium pathways Staal et al., 
2008) (Figure 5.2, panel A and B). Activation of the non-canonical Wnt signalling 
pathway is initiated by the ligands Wnt4, Wnt5A and Wnt11 which interact with 
Frizzled and DVL (Grumolato et al., 2010). In the PCP pathway, which does not 
involve β-catenin, LRP or TCF molecules, ligand binding to the receptor recruits 
Dishevelled (DVL), which forms a complex with Daam1. Daam1 then activates the 
small G-protein Ras homologue gene-family member A (Rho A) through a guanine 
exchange factor. Rho A then activates Rho-associated kinase (ROCK), a cytoskeletal 
regulator. DVL also forms a complex with Ras-related C3 botulinum toxin substrate 1 
(Rac 1) and mediates profilin binding to actin. Rac1 activates JNK and can also lead to 
actin polymerization. Profilin binding to actin results in restructuring of the 
cytoskeleton and changes in cell adhesion and motility. Through largely unknown 
mechanisms, canonical β-catenin signalling can be inhibited by the PCP signalling 
pathway (Staal et al., 2008; Liang et al., 2007).  
 In the Wnt/Calcium pathway, Wnt5A and Fzd regulate intracellular calcium 
levels. Ligand binding initiates activation of the coupled G-protein to activate 
phospholipase C (PLC), leading to the generation of Diacyl glycerol (DAG) and Inositol 
1,4,5-trisphosphate (IP3). When IP3 binds to its receptor on the ER, levels of 
intracellular calcium increase. Ligand binding also activates cGMP-specific 
phosphodiesterase (PDE), which depletes cGMP and leads to further increases in 
intracellular calcium. The increased concentrations of calcium and DAG then activate 
cell division control protein 42 (cdc42) through PKC (Habas and Dawid, 2005; Staal et 
al., 2008). Cdc42 itself serves to regulate cell adhesion, migration, and tissue separation. 
Increased calcium also activates calcineurin (Calc) and CamKII (calcium/calmodulin-
dependent kinase). Whereas Calc induces activation of transcription factor NFAT, 
which regulates ventral patterning, CamKII activates TAK1 and Nemo-like kinase 
(NLK) which interferes with TCF/β-catenin signalling in the canonical pathway. Thus, 
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Figure 5.2: A schematic representation of the non-canonical Wnt signalling 
pathways. (A) For planar cell polarity (PCP) signalling, Wnt signalling is transduced 
through Frizzled independent of LPR5/6. Utilizing the PDZ and DEP domains of DVL, 
this pathway mediates cytoskeletal changes through activation of the small GTPases 
Rho and Rac. (B) The Wnt-Ca
2+ 
pathway, Wnt signalling via Frizzled mediates 
activation of heterotrimeric G-proteins, which engage DVL, calcium-calmodulin kinase 
2 (CamK2) and protein kinase C (PKC). This pathway also uses the PDZ and DEP 
domains of DVL to modulate cell adhesion and motility (Adapted from Habas and 
Dawid, 2005).  
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The Wnt/Calcium pathway can influence the activity of both the non-canonical and 
canonical Wnt signalling pathways (Habas and Dawid, 2005; Liang et al., 2007; staal et 
al., 2008).   
 
5.1.4    Wnt signalling in immune system 
In blood and immune cells, Wnt signalling controls the proliferation of progenitor cells. 
Wnt proteins also regulate effector T-cell development, regulatory T-cell activation and 
dendritic cell maturation (Staal et al., 2008). The Wnt/β-catenin signalling pathway 
plays an important role in thymocyte development and induces T cell production of 
MMPs which are required for T cell migration (Wu et al., 2007). However, 
Muralidharan and colleagues have since reported that activation of the Wnt/β-catenin 
signalling pathway inhibits human peripheral T cell differentiation (Muralidharan et al., 
2011). Interestingly, Wnt protein production by macrophages has been shown to depend 
on microbial stimulation. For example, stimulation of macrophages and monocytes with 
LPS or Pam3CSK4 (TLR2 ligand) induced the production of Wnt5A (George, 2011). It 
was noted that TLR ligand induced Wnt5A induction was restricted to macrophages, 
DCs and monocytes, as T cells, B cells and natural killer (NK) cells did not express 
Wnt5A after TLR stimulation. TLR-induced Wnt5A production was dependent on the 
NF-κB pathway and it was also reported that microbe-induced Fzd1 mRNA was TLR2, 
TLR4, MyD88 and NF-κB pathway dependent (Neumann et al., 2009). 
 
 
5.1.5   Dishevelled 
The segment polarity genes dishevelled (DVLs) are key components in the Wnt 
signalling pathways.  Mammalian cells express 3 isoforms of the phosphoprotein DVL, 
namely DVL1, DVL2 and DVL3. All three human DVL genes are expressed in foetal 
and adult tissues, including lung, kidney, heart, brain and skeletal muscle (Shan et al., 
2005). The DVLs are composed of three well known conserved domains (Figure 5.3), a 
N-terminal DIX (Dishevelled-Axin) domain, a central PDZ (post synaptic density-95, 
disc large and zonular occludens-1) domain and a C-terminal DEP (Dishevelled-
EGL10-Pleckstrin) domain (lee et al., 2008). The DIX domain is necessary for DVL-
DVL or DVL-Axin dimerization. The PDZ domain is essential for Wnt canonical and 
non-canonical signalling pathways. The DEP domain is essential for the PCP pathway. 
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Figure 5.3: Dishevelled domain structure. DVL proteins possess three conserved 
domains an amino terminal DIX domain of 80 amino acids, a central PDZ domain of 
about 90 amino acids, and a carboxyl-terminal DEP domain of 80 amino acids. In 
addition, another two conserved regions, the basic region and the proline-rich region, 
are also implicated to mediate protein-protein interaction and/or phosphorylation 
(Adapted from Gao and Chen, 2010). 
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Deletion of either the DIX or PDZ domain of DVL blocks the Wnt canonical pathway 
(Gao and Chen, 2010). Mammalian DVLs are approximately 70 % homologous and 
appear to function cooperatively as well as uniquely (lee et al., 2008; Śmietana et al., 
2011) DVLs act as scaffolding proteins which interact with many proteins and serve as 
key signalling intermediate between the Wnt receptor Fzd and downstream components 
in the Wnt/β-catenin and non-canonical Wnt signalling pathways (Bernatik et al., 2011). 
The current model of Wnt/β-catenin signal transduction proposes that DVLs are a core 
protein of dynamic protein assemblies called signalosomes. The signalosome hypothesis 
proposes that upon stimulation of the Wnt pathway, the DVL proteins multimerise via 
the DIX domains and form a platform which then recruits other proteins including Axin, 
which is required for the phosphorylation of LRP6 (Bilic et al., 2007; Romond et al., 
2007). When DVL is overexpressed in mammalian cells, it is present in dynamic protein 
aggregates and is visible as DVL punctuate structures, which most likely represent DVL 
multimers. Wnt induced activation of DVL is visible as a Wnt-induced shift in the 
electrophoretic mobility of all three DVL isoforms, forming the so called 
phosphorylated and shifted-(PS) DVL. It has been clearly demonstrated that both the 
activation of DVL in the Wnt/β-catenin pathway and Wnt-induced PS-DVL formation 
is dependent on CK1 (Jose´ et al 2004; Bryja et al., 2007). The fact that there are three 
DVLs in mammals and that they interact with a great variety of proteins suggest that 
DVLs may have other functions in addition to Wnt signalling. Recently, it was found 
that all three DVLs isoforms directly interact with NF-κB (p65) and overexpression of 
DVLs inhibit TNF-α-induce activation of the NF-κB transcriptional activity (Deng et 
al., 2010).  
As mentioned in Chapter 3, using proteomics, DVL3 was identified as a TRIF 
interacting partner upon stimulation of HEK-TLR4 with LPS for 20 min. Another Wnt 
pathway protein, APC, was also identified as a TRIF interacting partner following 
stimulation of HEK293-TLR3 with poly(I:C) for 60 min. As mention earlier (section, 
5.1.4) WNT signalling reported to play different roles in immune system. Interestingly 
recently TLR4 has been reported to negatively regulate WNT signalling in enterocytes 
in the ileum of new born mice and suppressed Wnt signalling in Muller glia by reducing 
phosphorylation and therefore activation of LRP6 (Yi et al., 2012, sodhi et al., 2010). 
As DVLs are essential proteins in the WNT signalling pathway and shown to bind 
NFκB it was of interest to study the role of DVLs in TLR3 and TLR4 signalling and the 
counterregulation of DVLs/Wnt-β-catenin signalling by TLR ligands in this Chapter. 
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5.2    Results 
 
5.2.1    DVLs interact with TRIF  
Using a proteomics approach, DVL3 was identified as a TRIF interacting partner upon 
stimulation of HEK-TLR4 with LPS for 20 min. To confirm the interaction between 
DVL3 and TRIF, HEK293-TLR4 were co-transfected with HA-TRIF and Myc-DVL3 
and IP of HA-TRIF was implemented as described (Materials and methods, section 
2.2.9). As shown in Figure 5.4 panel A, Myc-DVL3 co-immunoprecipitated with HA-
TRIF even in a ligand independent manner. Next, an IP of endogenous TRIF from 
U373-CD14 cells following stimulation with either poly(I:C) or LPS was performed as 
described (Materials and methods, section 2.2.10). Herein, we show that endogenous 
DVL3 interacts with endogenous TRIF following stimulation with LPS for 20-40 min. 
However, DVL3 did not interact with TRIF upon poly(I:C) stimulation (Figure 5.4 
panel B). Next, it was decided to examine whether DVL1 and DVL2 also interacted 
with TRIF. HEK293-TLR4 cells were co-transfected with either HA-TRIF and Myc-
DVL1 or HA-TRIF and Myc-DVL2 and IP of HA-TRIF was implemented as described 
(Materials and methods, section 2.2.9). As shown in Figure 5.5, panel A and B, Myc-
DVL1 and Myc-DVL2, respectively, both co-immunoprecipitated with HA-TRIF even 
in the absence of the ligand. These data indicate that co-overexpression of DVLs and 
TRIF facilitated their interaction in a ligand independent manner. It was previously 
reported that overexpression of TRIF resulted in its activation and concomitant 
induction of the IFN-β promoter in a receptor-independent manner (Funami et al., 2007; 
Funami et al., 2008). Thus, it may be implicated that activation of TRIF is required to 
facilitate its interaction with the DVLs.  
 
5.2.2 DVLs inhibited TRIF-dependent reporter gene activity  
The ability of the DVLs to modulate TRIF signalling cascades was investigated. 
Initially, luciferase reporter gene assays were performed using HEKT293 cells. 
Overexpression of all the DVLs isoforms significantly inhibited TRIF-dependent 
activation of NF-κB, IFN-β (p125-luc), Rantes, PRDII and PDRIII reporter gene 
activity (Figure 5.6). The results showed that DVL3 exhibited a strong inhibitory effect 
on TRIF mediated reporter activity when cells were transfected with as little as 1ng of 
DVL3 (Figure 5.6, panel A-E). Overexpression of DVL1 and DVL2 also strongly 
reduced  
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Figure 5.4: Co-immunoprecipitation of human TRIF and human DVL3.  (A), 
HEK293-TLR4 were seeded into 6 well plates. When the cells become confluent (80 %) 
they were transfected with 3 μg of EV (control) or co-transfected with 2 μg of HA-TRIF 
and 1 μg of Myc-DVL3. Next, 20 h after transfection cells were left un-stimulated or 
stimulated with 1 μg/ml LPS for 20 and 60 min as indicated. Thereafter, cells were 
lysed in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM EDTA, pH 8.0, 1 % 
NP-40, 0.5 % sodium deoxycholate supplemented with 1 mM PMSF, 1 mM DDT, 1 
mM NaVO3 and protease inhibitor cocktail). Cleared cell lysates were incubated with 1 
μg of anti-HA monoclonal antibody precoupled to 50 μl of Protein A/G Plus-Agarose 
beads for 2 h at 4 
o
C with gentle shaking. Immuno-precipitation complexes were 
washed 4 times with lysis buffer and then released from the beads by addition of 
Laemmli loading buffer, followed by boiling for 5 min. Proteins were separated by 
SDS-PAGE gel electrophoresis and subjected to immunoblotting using anti-HA and 
anti-Myc monoclonal antibodies. (B) U373-CD14 cells were cultured into T175 flasks. 
When the cells were 90-95 % confluent, they were stimulated with either 20 μg/ml 
poly(I:C) or 1 μg/ml LPS for times indicated. Thereafter, cells were scrapped into 10 ml 
ice cold PBS and spun down for 10 min at 4
 o
C at 220 g. Cell pellets were lysed as 
described in panel A. Cleared cell lysates were incubated with 2 μg of anti-hTRIF 
polyclonal antibody precoupled to 50 μl of Protein A/G Plus-Agarose beads for 2 h at 4 
o
C with gentle shaking. Proteins were separated by SDS-PAGE and immunoblot 
analysis was performed using rabbit polyclonal anti-hTRIF and anti-hDVL3 antibodies. 
Rabbit IgG was used as negative control. Images were captured using the G: box system 
(Syngene). Results represent at least two independent experiments. 
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Figure 5.5: DVL1 and DVL2 interact with TRIF. HEK293-TLR4 cells were seeded 
into a 6 well plate. When the cells become confluent (80 %), they were transfected with 
either 3 μg of EV (control) or co-transfected with 2 μg of HA-TRIF and 1 μg of Myc-
DVL1 (A) or 2 μg of HA-TRIF and 1 μg of Myc-DVL2 (B). After 20 h, cells were left 
unstimulated or stimulated with 1 μg/ml LPS for 20 and 60 min as indicated. Thereafter, 
cells were lysed in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM EDTA, 
pH8.0, 1 % NP-40, 0.5 % sodium deoxycholate supplemented with 1 mM PMSF, 1 mM 
DDT, 1 mM NaVO3 and protease inhibitor cocktail). Cleared cell lysates were 
incubated with 1 μg of anti-HA monoclonal antibody precoupled to 50 μl of Protein 
A/G Plus-Agarose beads for 2 h at 4 
o
C with gentle shaking. Immuno-precipitation 
complexes were washed 4 times with lysis buffer and then released from the beads by 
addition of Laemmli loading buffer, followed by boiling for 5 min. Proteins were 
separated by SDS-PAGE and subjected to immunoblot analysis using anti-HA and anti-
Myc monoclonal antibodies. Images were captured using the G: box system (Syngene). 
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Figure 5.6: DVL3 inhibited TRIF-dependent reporter gene activity. HEKT293 cells 
were plated into 96 well plates at a density of 5 x 10
4
 cells/well. After 24 h, cells were 
transfected with expression vectors encoding either NF-κB (A), full-length IFN-β 
promoter p125 (B), Rantes promoter (C), IFN-β PRDII (D) or IFN-β PRDIII-I (E) 
luciferase reporter gene plasmids and co-transfected with either EV or expression vector 
encoding full length human HA-TRIF (20 ng) and increasing amounts of expression 
vector encoding full length human Myc-DVL3 (1, 5, 20 and 40 ng) as indicated. After 
24 h, cells were harvested and lysed and the cell lysates were kept at -80 
o
C for at least 
24 h, followed by assessment of luciferase reporter gene activity using dual luciferase 
system (Promega). The results presented are representative of at least three independent 
experiments, each experiment was done in triplicate. * P < 0.05, and *** P < 0.001. 
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TRIF-mediated NF-κB and Rantes reporter gene activity (Figure 5.7, panel A, C, D and 
F). However, both DVL1 and DVL2 reduced TRIF mediated IFN-β (p125-luc) reporter 
gene activation at a higher concentration (20 ng) (Figure 5.7, panel B and E). In an 
agreement with these results, Deng et al. (2010) showed that overexpression of DVLs 
dramatically reduced TNF-α-induced NF-κB transcriptional activity.   
 
5.2.3    DVLs inhibited TLR3-dependent reporter gene activity 
To investigate the role of DVL3 in TLR3 signalling, HEK293-TLR3 were transfected 
with NF-κB, IFN-β and Rantes reporter gene constructs and increasing amount of full 
length human Myc-DVL3. Despite the fact that DVL3 did not co-immunoprecipitate 
with TRIF in U373-CD14 cells uopon poly(I:C) stimulation, surprisingly, its  over-
expression in HEK293-TLR3 resulted in a markedly decrease in TLR3-dependent 
transcription of NF-κB, IFN-β and Rantes (Figure 5.8, panel A-C). This could be due to 
cell lines used or the possibility that DVL3 may exert its effects on TLR3 signalling 
through another intermediate protein molecule involved in the pathway and not directly 
through TRIF. Thereafter, the effect of DVL1 and DVL2 on TLR3 signalling was 
studied. Results showed that DVL1 and DVL2 function as potent inhibitors of TLR3 
signalling pathway as they significantly reduced TLR3-dependent activation of NF-κB, 
IFN-β and Rantes promoter (Figure 5.8, panels D-I). Reporter gene assays in HEK293-
TLR4 were not possible as the cells that were available had lost their responsiveness to 
LPS.  
 
5.2.4    Effect of DVLs on MyD88-dependent reporter activity   
As both TRIF and MyD88 mediate TLR4 signalling the ability of DVLs to modulate 
MyD88 mediated reporter gene activity was investigated. Cells were co-transfected with 
either NF-κB, and IFN-β (p125) constructs and MyD88 and increasing amounts of 
DVL1, DVL2 and DVL3. Overexpression of DVL1 had a negligible effect on MyD88-
induced NF-κB reporter gene activity. However, DVL1 significantly decreased MyD88-
induced IFN-β reporter gene activity at concentrations of 20-40 ng (Figure 5.9, panel A 
and B). Interestingly, DVL2 overexpression significantly enhanced MyD88-dependent 
activation of NF-κB, and IFN-β reporter genes at a concentration of 1-20 ng (Figure 5.9, 
panel C and D). On the other hand, overexpression of DVL3 significantly inhibited 
MyD88-induced NF-κB transcriptional activity even at very low concentration (1 ng) 
(Figure 5.9, panel E). 
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Figure 5.7: DVL1 and DVL2 reduced TRIF-dependent reporter gene activity. 
HEKT293 cells were plated into a 96 well plate at a density of 5 x 10
4
 cells/well. After 
24 h, cells were transfected with expression vectors encoding either NF-κB (A and D), 
IFN-β promoter (p125) (B and E), Rantes promoter (C and F) luciferase reporter gene 
plasmids and co-transfected with either EV or expression vector encoding full length 
human HA-TRIF (20 ng) and increasing amounts of expression vector encoding full 
length human Myc-DVL1 (A-C) or DVL2 (D-F) as indicated. After 24 h, cells were 
harvested and lysed and the cell lysate were kept at -80 
o
C for at least 24 h, followed by 
assessment of luciferase reporter gene activity using dual luciferase system (Promega). 
The results presented are representative of at least two independent experiments, each 
experiment was done in triplicate. * P < 0.05, ** P < 0.01 and *** P < 0.001. 
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Figure 5.8: DVLs represses TLR3-dependent reporter gene activity. HEK293-
TLR3 cells were plated into a 96 well plate at a density of 5 x 10
4
 cells/well. After 24 h, 
cells were transfected with expression vectors encoding NF-κB (A, D, G), IFN-β (p125) 
(B, E, H) and Rantes promoter (C, F, I) reporter gene constructs and co-transfected with 
either EV or increasing amounts of expression vector encoding full length human Myc-
DVL3 (A-C) or expression vector encoding full length human Myc-DVL1 (D-F) 
expression vector encoding full length human or Myc-DVL2 (G-I) as indicated. After 
24 h, cells were stimulated with 20 μg/ml poly(I:C) for an additional 24 h. Thereafter, 
cells were harvested and lysed and cell lysate were kept at -80 
o
C for at least 24 h, 
followed by assessment of luciferase reporter gene activity using dual luciferase system 
(Promega). The results presented are representative of at least two independent 
experiments, each experiment was done in triplicate. * P < 0.05, ** P< 0.01 and *** P < 
0.001. 
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Figure 5.9: Effect of DVLs on MyD88-dependent reporter gene activity.  HEKT293 
cells were plated into 96 well plates at a density of 5 x 10
4
 cells/well. After 24 h, cells 
were transfected with expression vectors encoding either a reporter gene NF-κB (A, C 
and E), IFN-β promoter (p125) (B, D and F), and co-transfected with either EV or 
expression vector encoding full length human Myc-MyD88 (20 ng) and increasing 
amounts of expression vector encoding full length human Myc-DVL1 (A, and B) or 
expression vector encoding full length human Myc-DVL2 (C and D) or expression 
vector encoding full length human Myc-DVL3 (E and F) as indicated. After 24 h, cells 
were harvested and lysed and cell lysates were kept at -80 
o
C for at least 24 h, followed 
by assessment of luciferase reporter gene activity using dual luciferase system 
(Promega). The results presented are representative of at least two independent 
experiments, each experiment was done in triplicate. * P < 0.05, ** P < 0.01 and *** P 
< 0.001. 
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Nevertheless, its overexpression significantly decreased MyD88-induced IFN-β reporter 
gene activity at concentration of 20-40 ng (Figure 5.9, panel F). Collectively, these 
results indicate that DVLs are capable of regulating NF-κB and IFN-β transcription, and 
among all DVLs isoforms DVL3 strongly represses TRIF and MyD88-dependent 
activation of NF-κB and IFN-β. 
 
5.2.5    Inhibition of DVLs attenuates TLR3 and TLR4 signalling 
As mentioned in sections 5.2.2 and 5.2.4, DVLs were capable of regulating TRIF and 
MyD88-dependent reporter gene activity. Therefore, it was of interest to study the effect 
of DVLs inhibition on TLR3 and TLR4-dpendent signalling in wild-type murine bone-
derived macrophages (wt-BMDMs). The DVLs were inhibited by the cell permeable 
amidobenzanilide. This compound targets the DVLs PDZ domain which is essential for 
DVLs mediated canonical and non-canonical WNT pathways. In addition, this 
compound has been reported to block WNT signalling in different biological systems. It 
suppresses WNT pathway-dependent growth of prostate cancer PC-3 cells by 16 % in 
72 h at ≥50 µM, it also inhibit WNT-pathway-mediated apoptosis of the hyaloid 
endothelial cells in the mouse eyes (Grandy et al., 2009). Next, wt-BMDMs were 
treated with DMSO or 100 μM DVL inhibitor (in DMSO solvent) for 48 h and 
subsequently stimulated with either 20 μg/ml poly(I:C) or 100 ng/ml LPS for 3 h. 
Thereafter, total RNA was isolated as described (Materials and methods, section 2.2.14) 
and cytokine mRNA was measured using Q-RT-PCR. Surprisingly, results showed that 
inhibition of DVLs significantly reduced poly(I:C) and LPS-induce TNF-α and Rantes 
transcription compared to the control. However, basal transcriptions of TNF-α and 
Rantes were slightly increased due to the DVL inhibition (Figure 5.10, panels, B, D, G, 
and I). IFN-β mRNA was also reduced but not statistical significant (Figure 5.10, panels 
A and F). Interestingly, DVL inhibition significantly increased LPS-induce IFN-α 
transcription but slightly decreased poly(I:C)-induce IFN-α transcription compared to 
the control (Figure 5.10, panels C and D). Nevertheless, overexpression of all DVLs in 
HEK293-TLR3 reduced TLR3-dependent gene transcription. Here, DVLs inhibition did 
not increase poly(I:C) induces signalling. This could be due to the fact that poly(I:C) 
can be sensed by RLRs such as MDA-5 (Siednienko et al., 2011) which may suggest the 
involvement of DVLs in other signalling pathways induced by poly(I:C). These results 
showed that DVLs are needed for poly(I:C) and LPS induce signalling in  murine 
BMDMs. 
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Figure 5.10: Inhibition of DVLs attenuated TLR3 and TLR4 signalling. Wt-
BMDMs were plated into 6 well plates. When cells became confluent (60 %), they were 
treated with either DMSO or 100 μM DVLs inhibitor for 48 h. Thereafter, cells were 
stimulated with either 20 μg/ml poly(I:C)  (A -D) or 100 ng/ml LPS (F - I) for 3 h. Next, 
total RNA was isolated and reverse transcribed into cDNA. The cDNA was used as a 
template and samples were diluted 25 times and cytokines were measured by Q-RT-
PCR using specific primer to murine IFN-β, IFN-α, TNFα, and Rantes. Mouse GAPDH 
was used as a housekeeping gene. Results are representing two independent 
experiments each done in duplicates. * P< 0.05, ** P < 0.01. 
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5.2.6    Inhibition of DVLs decreased IκBα degradation and phosphorylation of 
IRF3.  
To understand the molecular mechanism by which DVLs inhibition reduced the 
cytokines mRNA, their ability to modulate IκBα degradation and phosphorylation of 
p65 and IRF3 was investigated. To this end, Wt-BMDMs were pretreated with either 
the DVL inhibitor or DMSO and subsequently stimulated with either poly(I:C) or LPS 
for different time points. Then, IκBα degradation and phosphorylation of p65 and IRF3 
in whole cell lysates were studied by western blot. As shown in Figure 5.11 panel A, 
inhibition of DVL decreased IκBα degradation 60-120 min upon poly(I:C) stimulation 
compared to the control. Phosphorylation of p65 and IRF3 was not detected. On the 
other hand, inhibition of DVLs decreased IκB degradation and phosphorylation of IRF3 
upon LPS stimulation for 60 min compared to the control (Figure 5.11, panel B). Here, 
phosphorylation of p65 was not detected. It has been reported that, in human 
macrophages, LPS induced a strong IFN-β mRNA response within a short time frame. 
These responses were associated with NF-κB and IRF3 activation. However, poly(I:C) 
induced a strong and long-lasting IFN-β mRNA and protein response in the absence of 
detectable IRF3 and NF-κB signalling (Reimer et al., 2008). These results confirmed 
that DVLs are needed for NF-κB and IRF3 activation upon poly(I:C) and LPS 
stimulation in murine BMDMs. Whether DVLs inhibition promote stabilization and 
resynthesis of IκB protein following poly(I:C) and LPS stimulation respectively is  need 
to be investigated. 
 
5.2.7    Effect of β-catenin activation on TLR3 and TLR4 signalling  
Physically interaction between β-catenin and NF-κB has been reported in human colon 
and breast cancer cells. This interaction resulted in a reduction of NF-κB DNA binding 
(Deng et al., 2002). Sun and colleagues also reported that Salmonella-induced IL-8 
secretion is completely abolished by the activity of β-catenin in human intestinal 
epithelia (Sun et al., 2005). Thus, it was of interest to study whether activation of β-
catenin affects TLR3 and TLR4 signalling. It has been previously demonstrated that 
epidermal growth factor (EGF) treatment inactivates GSK-3β and thereby, activates β-
catenin and caused its nuclear translocation (Lee et al., 2010; Hu et al., 2010). 
Therefore, herein, EGF was used as a β-catenin activator. Initially, wt-BMDMs were 
pretreated with 10 μg/ml EGF for 24 h, followed by stimulation with either poly(I:C)  
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Figure 5.11: DVLs inhibition reduced IκBα degradation and phosphorylation of 
IRF3. Wt-BMDMS were seeded into 6 well plates when cell become confluent (60 %) 
cells were treated with either DMSO or 100 μM DVLs inhibitor for 48 h. Thereafter 
cells were treated with either 20 μg/ml poly(I:C) or 100 ng/ml LPS for times indicated. 
Then cells were collected in 1 ml PBS and spun down for 10 min at 4 
o
C at 380 g. Cell 
pellets were lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-
40, 1 % sodium deoxycholate, 0.1 % SDS, supplemented with protease inhibitor 
cocktail, 1 mM PMFS 1 mM Na3VO4 and 1 mM DDT). Cell lysates were mixed with 
Laemmli loading buffer and boiled for 5 minutes. Proteins were separated by SDS-
PAGE gel electrophoresis and subjected to immunoblotting using anti-IκBα, and anti-
phospho-IRF3 monoclonal antibodies. β-Actin was used as loading control. Images 
were captured using the G: Box system (Syngene). Results are representing of three 
independent experiments.  
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and LPS for 3 h. Thereafter, RNA was isolated and cytokines mRNA was measured 
using Q-RT-PCR. EGF treatment was found to increase IFN-β and Rantes, but decrease 
IFNα transcriptions upon poly(I:C) stimulation compared to the control (Figure 5.12). 
In contrast, expression of TNF-α mRNA was not affected. Furthermore, EGF treatment 
significantly increased IFN-β and Rantes and decreased IFN-α and TNF-α upon LPS 
stimulation compared to the control (Figure 5.12). To confirm these results HEK293-
TLR3 were transfected with NF-κB, IFN-β (p125), IFN-α and Rantes promoter reporter 
gene constructs in the presence of EGF. Then, cells were left untreated or stimulated 
with 20 μg/ml poly (I:C) followed by assessment of reporter gene activity. In 
accordance with the Q-RT-PCR data, results showed that EGF treatment significantly 
decreased TLR3-dependent NF-κB and IFN-α reporter gene activation (Figure 5.13, 
panels A and B). However, EGF increased slightly TLR3-dependent IFN-β and Rantes 
reporter gene activity (Figure 5.13, panels C and D).   
 
5.2.8   EGF stimulation decreased IκBα degradation and increased phospho-
rylation of IRF3 and p38 
Wnts are capable of activating p38 MAPKs and this activation dependent on the DVLs 
(Bikkavilli and Malbon, 2009). Activation of p38 MAPK by Wnt inhibits GSK3β and 
leads to an increase in cytosolic β-catenin levels and Wnt-sensitive gene transcription. 
Therefore, the effects of EGF-induced β-catenin activation on TLR-mediated IκBα 
degradation and phosphorylation of IRF3 and p38 was investigated. Wt-BMDMs were 
pretreated with 10 μg/ml EGF for 24 h followed by stimulation with either poly(I:C) or 
LPS for different time points as indicated. Thereafter, cells were collected and IκBα, 
phospho IRF3 and phosph p38 were detected in whole cell lysates. Results showed that 
pretreatment of cells with EGF inhibited poly(I:C) mediated IκBα degradation (60-120 
min) compared to the control. Moreover, EGF increased basal levels of phosph p38 but 
has a negligible effect on p38 phosphorylation upon poly(I:C) stimulation compared to 
the control (Figure 5.14, panel A). Phosphorylation of IRF3 was not detected. However, 
EGF stimulation reduced early and late IκBα degradation (15-60 min), and increased 
phosphorylation of IRF3 and p38 (30-60 min) upon LPS stimulation compared to the 
control (Figure 5.14, panel B). This suggests that the increase in IFN-β and Rantes 
transcription was due to increase IRF3 phosphorylation. However, as EGF reported to 
activates an extensive network of signal transduction pathways that include activation of  
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Figure 5.12: Effect EGF on TLR3 and TLR4 signalling. Wt-BMDMs were plated 
into a 6 well plate. When cells become confluent (80 %), they were left untreated or 
treated with 10 μg/ml EGF for 24 h. Thereafter, cells were stimulated with either 20 
μg/ml poly(I:C) or 100 ng/ml LPS for 3 h. Next, total RNA was isolated and reverse 
transcribed in to cDNA. cDNA was used as templates and samples were diluted 25 
times and cytokines were measured by Q-RT-PCR using specific primer to murine IFN-
β, IFN-α, TNF-α, Rantes and IL-6. Mouse GAPDH was used as housekeeping gene.  
Results are representing two independent experiments each done in duplicates. * P< 
0.05. 
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Figure 5.13: Effect of EGF activation on TLR3-dependent signalling. HEK293-
TLR3 were plated in to 96 well plate at density of 5x 10
4
 cells/well. After 24 h, the 
medium on the cells was removed and replaced by fresh medium containing 10 μg/ml 
EGF. After 3 h, cells were transfected with (80 ng) of reporter gene constructs encoding 
either NF-κB (A), IFN-α (B), IFN-β (p125) (C) and Rantes promoter (D). 24 h after 
transfection cells were left untreated or treated with 20 μg/ml poly(I:C) for additional 24 
h. Thereafter, cells were harvested and lysed, cell lysates were kept at - 80 
o
C for at least 
24 h. Then, luciferase assay was performed using dual luciferase system (Promega). The 
results presented are representative of at least two independent experiments, each 
experiment was done in triplicate. * P < 0.05, ** P < 0.01. 
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Figure 5.14: EGF stimulation inhibited IκBα degradation and increased 
phosphorylation of IRF3 and p38. Wt-BMDMs were seeded into 6 well plates. When 
cells became confluent (80 %), they were either left untreated or treated with 10 μg/ml 
EFG for 24 h. Thereafter, cells were treated with either 20 μg/ml poly(I:C) or 100 
ng/ml LPS for times indicated. Then, cells were collected in 1 ml PBS and spun down 
for 10 min at 4 
o
C at 380 g. Cell pellets were lysed in RIPA buffer (25 mM Tris-HCl 
pH 7.6, 150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % SDS, 
supplemented with protease inhibitor cocktail, 1 mM PMSF 1 mM Na3VO4 and 1 mM 
DDT). Cell lysates were mixed with Laemmli loading buffer and boiled for 5 min. 
Proteins were separated by SDS-PAGE and subjected to immunoblot analysis using 
anti-IκBα, anti phosph p38 and IRF3 monoclonal antibodies. β-Actin was used as 
loading control. Images were captured using the G:Box system (Syngene). Results 
represent two independent experiments.  
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the MAPK, PI3K/AKT, RAS/ERK and JAK/STAT pathways (Henson and Gibson, 
2006; Ji et al., 2009) more direct experiments are need to confirm the role of β-catenin 
in TLR signalling.  
 
5.2.9    Regulation of DVLs by the TLRs  
Autophagy is a newly recognised innate defence mechanism, acting as a cell-
autonomous system for the elimination of intracellular pathogens. TLRs have been 
shown to induce TRIF and MyD88-dependent autophagy in macrophages (Delgado et 
al., 2008; Shi et al., 2008). Interestingly, autophagy negatively regulates Wnt signalling 
by promoting the degradation of DVLs (Gao et al., 2010). Thus, we propose that TLR 
activation may lead to the degradation of DVL protein and concomitant inhibition of 
Wnt signalling. To test this hypothesis, the effect of poly(I:C), LPS and R848 (TLR7 
and 8 ligand) on DVLs mRNA expression levels was investigated. Wt-BMDMs were 
treated with either poly(I:C) or  LPS or R848 for different time points, followed by 
RNA isolation and measurement of DVL1, DVL2, and DVL3 mRNA by Q-RT-PCR. 
Results showed that poly(I:C) significantly increased all three DVLs mRNA at 3 and  
24 h compared to the control (Figure 5.15, panels A-C). LPS treatment significantly 
increased DVL1 and DVL3 mRNA at 90 min but significantly decreased DVL3 at 30 
min and at 24 h compared to the control (Figure 5.14, panels D and F). DVL2 mRNA 
significantly deceased at 90 min, at 3 and 24 h (Figure 5.15, panel E). On the other 
hand, R848 significantly induced DVL1 transcription at 30 and 90 min but decreased it 
at 3 h compared to the control (Figure 5.15, panel G). DVL2 mRNA was also 
significantly increased at 90 min and decreased at 24 h (Figure 5.15, panel H). DVL3 
transcription was significantly reduced at 24 h. This showed that TLRs differently 
regulated DVLs expression. 
 
5.2.10    TRIF and MyD88 inhibit β-catenin-induced Lef promoter activation 
It has been previously reported that downregulation of Wnt/β-catenin signalling 
occurred during Mycobacterium tuberculosis infection, characterised by TLR activation, 
in mice (Schaale et al., 2011). Therefore, the ability of TRIF and MyD88 to regulate β-
catenin induced Lef transcription was studied in HEKT293. Cells were co-transfected 
with Lef reporter construct, β-catenin and increasing amount of either TRIF or MyD88. 
It was found that TRIF significantly reduced β-catenin-induced Lef transcriptional 
activity even at a concentration of 1 ng (Figure 5.15, panel B).  
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Figure 5.15: Regulation of DVLs transcription by TLRs. Wt-BMDMs were plated 
into 6 well plates. When the cells were confluent, they were treated with either 20 μg/ml 
poly(I:C) (A, B and C) or 100 ng/ml LPS (D, E and F) or 1 μg/ml R848 (G, H and I) for 
times indicated. Thereafter, cells were collected and total RNA was isolated and reverse 
transcribed into cDNA. cDNA was used as templates and samples were diluted 25 times 
and DVLs mRNA were measured by Q-RT-PCR using specific primer to murine DVL1 
(A, D, G), DVL2 (B, E, H), and DVL3 (C, F, I). Mouse GAPDH was used as 
housekeeping gene.  Results are representing two independent experiments each done in 
duplicates. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 5.16: TRIF and MyD88 inhibited β-catenin-induces Lef transcription 
HEKT293 were plated into a 96 well plate at a density of 5 x10
4
 cells/well. After 24 h, 
cells were transfected with expression vectors encoding a reporter gene contruct for Lef 
and co-transfected with either EV or expression vector encoding full length human HA- 
β-catenin (20 ng) and increasing amounts of expression vector encoding full length 
human HA-TRIF (A), or an expression vector encoding full length human Myc-MyD88 
(B). After 24 h, cells were harvested and lysed and cell lysates were kept at -80 
o
C for at 
least 24 h, followed by assessment of luciferase reporter gene activity using dual 
luciferase system (Promega). The results presented are representative of at least two 
independent experiments, each experiment was done in triplicate. * P < 0.05, ** P < 
0.01 and *** P < 0.001. 
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MyD88 inhibited Β-catenin-induced Lef promoter activation at a concentration of 20 ng 
(Figure 5.15, panel B). This may suggest reciprocal regulation of the TLRs and the 
Wnt/β-catenin pathway. 
 
5.2.11    poly(I:C) and LPS inhibited β-catenin expression 
Following the finding that TRIF and MyD88 negatively regulate β-catenin-induce lef 
promoter transcription, the effect of poly(I:C) and LPS on β-catenin expression and its 
nuclear translocation was investigated. Hela cells were transfected with either β-catenin 
or β-catenin and DVL3. Thereafter, cells were treated with poly(I:C) or LPS for 60 min 
followed by immunostaining of β-catenin  and analyses by confocal microscopy. The 
expressed β-catenin was found to mostly co-localize in the cytoplasm but partially in the 
nucleus (Figure 5.17 panel A). DVL3 expression caused β-catenin nuclear translocation 
(Figure 5.17, panel B). However, poly(I:C) and LPS stimulation decreased β-catenin 
expression and partially inhibited DVL3-dependent β-catenin translocation (Figure 
5.17, panels C and D).    
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Figure 5.17: Poly(I:C) and LPS inhibited β-catenin expression. Hela cells were 
seeded on precollagen coated glass coverslip into 6 wells plate. After 24 h, cells were 
transfected with either 200 ng of expression vector encoding full length human HA-β-
catenin (A) or co-transfected with either 200 ng of expression vector encoding full 
length human HA-β-catenin and 200 ng of EV or 200 ng of expression vector encoding 
full length human HA-β-catenin and full length human Myc-DVL3 (B-D). After 24 h 
cells were left untreated (A, B) or treated with either 20 μg/ml poly (I:C) (C) or 1 μg/ml  
LPS (D) for 60 min as indicated. Thereafter, cells were fixed in 4 % paraformaldehyde 
in PBS, permeabilised in 0.5 % triton X-100 in PBS and blocked for 1 h in 1 % BSA in 
PBS. Then, cells were incubated with 200 μl of anti-HA monoclonal primary antibody 
(diluted 1:50 in blocking buffer) for 2 h at RT with gentle shaking. Thereafter, cells 
were washed with 0.05 % Tween 20 in PBS three times each 10 min. Then, cells were 
incubated with Alexa fluro 488 secondary antibody (diluted 1:200 in blocking buffer) 
for 1 h at RT in the dark, followed by three washes with 0.05 % Tween 20 in PBS.  
Nucleus was stained with DAPI (10 μg/ml in PBS). Then cell were washed twice in 
PBS and coverslip were mounted on glass slide using mounting medium and kept in the 
fridge until analysed. Images were captured using Olympus 1000 confocal microscopy 
and Flouview Software.   
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5.3    Discussion  
The fact that there are three DVLs in mammals and that they are found to interact with a 
great variety of proteins including NF-κB suggests that DVLs may have other functions 
in addition to their vital role in Wnt signalling. In this study, role of DVLs in the 
regulation of TLR3 and TLR4 was investigated. It was found for the first time that all 
DVLs isoforms interacted with TRIF. Overexpression of all DVLs isoforms negatively 
regulated TRIF and TLR3-induce NF-κB, IFN-β and Rantes promoter activation. 
However, only DVL2 had a positive effect on MyD88-dependent activation of NF-κB 
and IFN-β promoter at low concentration. Recently, it has been reported that DVLs 
interact with NF-κB in the nucleus and their overexpression dramatically reduced TNF-
α-induced NF-κB transcriptional activity (Deng et al., 2010). However, the inhibition of 
NF-κB by the DVLs was not dependent on Wnt signalling or β-catenin (Deng et al., 
2010). 
 Inhibition of DVLs reduced TLR3 and TLR4-induce IFN-β, TNF-α and Rantes 
transcription. This reduction could be explained by the decreased in IκBα degradation 
and the phosphorylation of IRF3 observed after DVLs inhibition. In contrast, the DVLs 
negatively regulated TRIF and TLR3 signalling in reporter gene assays. These 
differential effects could be due to the cell lines used in the study. Several studies 
suggested that different cell types may use different receptors to sense poly(I:C) or viral 
dsRNA. Although TLR3 was reported to play a key role in sensing poly(I:C) by 
epithelial cells (Guillot et al., 2005; Rudd et al., 2006; Matsukura et al., 2007), it only 
played a moderate or minor role in sensing poly(I:C) in macrophages (Alexopoulou et 
al., 2001; Yamamoto et al., 2003; López et al., 2004). Upregulation of Wnt5A in human 
macrophages stimulated with different mycobacterial species and conserved bacterial 
structures has been reported and the expression was dependent upon TLRs and NF-κB 
activation. Functional studies showed that Wnt5A is necessary for the regulation IL-12 
and interferon γ in response to infectious agents (Blumenthal et al., 2006). A potential 
regulatory function of Wnt5A on cytokine expression is further supported by the 
observation that in patients with rheumatoid arthritis, Wnt5A modulates IL-6 and IL-15 
expression in synoviocytes (Sen et al., 2001). Collectively, these data indicate the 
involvement of Wnt signalling in regulation of TLR signalling cascades. Our data 
showed that DVLs were needed for poly(I:C) and LPS induce cytokines transcription 
and may suggest that DVLs and Wnt5A activate the noncanonical pathway via calcium/ 
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calmodulin dependent kinase II (CAMKII) which results in sustained upregulation of 
inflammatory cytokines (Figure 5.18).  
  Stimulation with EGF which was used here as of β-catenin activator increased 
IFN-β and Rantes and decreased IFNα and TNFα transcription upon poly(I:C) and LPS 
stimulation. Also, it increased phosphorylation of IRF3 and p38 after LPS stimulation. 
However, IκBα degradation was reduced upon poly(I:C) and LPS stimulation. This may 
suggest that that β-catenin may play a positive and a negative role in regulating TLR 
signalling. In agreement with this result, β-catenin has been shown to interact with NF-
κB and this interaction inhibited NF-κB activation in human colon and breast cancer 
cells (Deng et al., 2002). In another study, overexpression of β-catenin inhibited NF-κB 
reporter gene activity in a dose-dependent manner (Du et al., 2009). Also, Sun and 
colleagues reported that in cell lines expressing constitutively active β-catenin, IκBα 
protein was indirectly stabilised and NF-κB activity was repressed after wild-type 
Salmonella colonisation (Sun et al., 2005).  
This study showed that DVLs transcriptions are differentially regulated by the 
TLRs, and that TRIF and MyD88 inhibited β-catenin-induces Lef transcription. Also, 
poly(I:C) and LPS stimulation decreased β-catenin expression in Hela cells and partially 
inhibited DVL3-dependent β-catenin translocation. TLR4 activation has been shown to 
inhibits enterocyte proliferation in vitro and in vivo via impaired β-catenin signalling 
through activation of the GSK3β (Sodhi et al., 2010). In mice infected with M. 
tuberculosis, while inducible nitric oxide synthase (iNOS) and IFN-γ formation were 
increased, the transcription of β-catenin dependent target genes were significantly 
reduced (Neumann et al., 2009; Schaale et al., 2011). 
 In conclusion this study demonstrates for the first time, that an interaction occurs 
between TRIF and the DVLs isoforms and shows that DVLs were needed for poly(I:C) 
and LPS induced cytokines transcription in wt-BMDMs. Specific DVL inhibitors or 
esiRNA against individual DVL may be useful to define the role that each DVL play in 
regulating TLR signalling. This study also demonstrated a cross regulation between β-
catenin and TLR/NF-κB-mediated signalling. 
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Figure 5.18: Working hypothesis of the role of Wnt5A in the inflammatory 
response. Activation of TLRs in macrophages by pathogens leads to activation of NF-
κB and upregulation of Wnt5A and cytokines. Wnt5A independently of β-catenin 
activates the noncanonical pathway via calcium/calmodulin dependent kinase II 
(CAMKII) which results in sustained upregulation of inflammatory cytokines including 
IL-12, IL-6, IL-8, IL-1β, and macrophage inflammatory protein-1β (MIP-1β) either in a 
nuclear factor of activated T-cells (NFAT)-dependent or independent manner. 
Additionally, increased levels of Wnt5A and cytokines may affect other mononuclear 
cells including T-cells and surrounding resident tissue cells. (Adapted from George, 
2008). 
 
 
  
  
Chapter 6 
 
 
Proteomic analysis of endogenous TRIF 
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signalling by Optineurin 
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6.1   Introduction 
 
Mammalian cell lines provide several advantages over other cellular systems for the 
production of recombinant proteins, most notably the correct processing and modification 
of mammalian proteins (Mallory et al., 2007). However, still several problems such as 
protein yield, protein solubility and toxicity are associated with protein expression in 
mammalian cells. To date, most, if not all, studies concerning the subcellular localization of 
TRIF use over-expression models (Funami et al., 2008). These systems, though inherently 
useful, may not accurately reflect the true in vivo status of TRIF. For example, the correct 
subcellular localization of TRIF may not be apparent due to the large fluorescent tag which 
may impede cellular trafficking. An important problem associated with TRIF 
overexpression is the fact that induction of RIP/FADD/caspase8-dependent apoptosis is 
apparent (Han et al., 2004). Also, the expression of TRIF protein was always very low 
when compared to cells that were similarly transfected with MyD88 or other proteins that 
were utilised used during this project. This finding is supported by work undertaken by 
Funami and colleagues who reported lower expression level of wild-type TRIF when 
compared to mutated forms of TRIF (Funami et al., 2008). They suggested that wild-type 
TRIF may be rapidly degraded via some protein modifications.  
Given the issues surrounding the overexpression of TRIF, the aim of the current 
chapter was to identify an anti-TRIF antibody that is capable of detecting endogenous 
human TRIF. Subsequently, the antibody will be used for pull-down assays and western 
blot analysis towards defining the time-dependent association of TRIF interacting proteins. 
Likewise, we aim to find a mammalian cell line that responds to both TLR3 and TLR4 
ligands. The cell line would then be used to investigate the role played by TRIF and novel 
TRIF interacting proteins in TLR3 and TLR4 signalling.  
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6.2    Results 
 
6.2.1    Characterisation of commercially available TRIF antibodies  
To find an antibody that specifically recognises endogenous TRIF, a number of different 
commercial anti-TRIF antibodies were characterised. The antibodies were tested for their 
specificity towards the detection of TRIF by using different approaches namely western 
blotting, immunoprecipitation and immunohistochemistry. The antibodies that were tested 
are as follows: 
Rabbit polyclonal anti-human TRIF (Alexis, Cat. no. AL227 ). 
Rabbit polyclonal anti-human and anti-mouse TRIF (Abnova, Cat. no. PAB0317). 
Rabbit polyclonal anti-human TRIF antibody (Exalpha, Cat. no. X1827P). 
Following transfection of HEKT293 cells with a plasmid encoding HA-TRIF, it was found 
that the anti-TRIF antibody that was purchased from Exalpha was capable of detecting HA-
TRIF. In contrast, the anti-TRIF antibodies that were purchased from Alexis and Abnova 
did not detect HA-TRIF, despite confirmation of HA-TRIF expression following western 
blotting using an anti-HA antibody (data not shown). Regarding the anti-TRIF antibody 
from Exalpha, the antibody was examined for its ability to detect epitope-tagged full length 
human HA-TRIF using whole cell lysate (WCL) from HEKT293 cells transfected with 3 
µg of HA-TRIF. To detect endogenous TRIF, whole cell lysate from un-transfected Hela 
cells was used as these cells have been reported to express TRIF mRNA (Nishimura et al., 
2005). Proteins were separated by SDS-PAGE electrophoresis. Immunoblotting was 
performed using either the anti-HA antibody or the anti-TRIF antibody (Exalpha). A band 
close to the 100 kDa molecular weight marker was detected in Hela WCL (Figure 6.1 panel 
A, lane 1) and this band was also detected in HEKT293 WCL following HA-TRIF 
overexpression (Figure 6.1, panel A, lane 2). To confirm that the antibody was capable of 
immunoprecipitating TRIF, HEKT293 cells were transfected with 3 µg  EV or 3 µg HA-
TRIF and IP of HA-TRIF was performed as described (Materials and methods, section 
2.2.9) using either an anti-HA or an anti-TRIF antibody (Exalpha). Immunoprecipitation of 
HA-TRIF using both the anti-TRIF antibody (Exalpha) and the anti-HA antibody was 
confirmed (Figure 6.1, panel B). These data confirm that the anti-TRIF antibody (Exalpha) 
can detect TRIF and be used in western blot and IP studies. As mentioned in Chapter 4 and  
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Figure 6.1: Characterisation of Exalpha anti-hTRIF polyclonal antibody.  (A, lane 1) 
Hela were seeded into T175 flasks and when the cells were 90-95 % confluent, they were 
collected in 10 ml ice cold PBS and spun down 10 min at 4 
o
C at 2000 rpm. Thereafter, the 
cell pellet was lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40, 
1 % sodium deoxycholate, 0.1 % SDS, supplemented with protease inhibitor cocktail, 1 
mM PMSF 1 mM Na3VO4 and 1 mM DDT). Cell lysates were mixed with Laemmli loading 
buffer and boiled for 5 min. Proteins were separated by SDS-PAGE and subjected to 
immunoblotting using anti-TRIF polyclonal antibody (Exalpha) and anti-HA antibodies. 
(A, lane 2) HEKT293 cell were seeded into 6 well plates. When cells were 80 % confluent, 
they were transfected with 3 µg of HA-TRIF. After 20 h, cells were lysed in RIPA buffer as 
mentioned in lane 1. Cell lysates were mixed with Laemmli loading buffer and boiled for 5 
min. Proteins were separated by SDS-PAGE and subjected to immunoblotting using anti-
HA and anti-TRIF(Exalpha) antibodies. (B) HEKT293 cells were seeded into 6 well plates. 
When the cells 80 % confluent, they were transfected with either 3 µg EV or 3 µg of HA-
TRIF. After 20 h, transfected cells were lysed in lysis buffer (50mM HEPES, pH 7.5, 150 
mM NaCl, 2 mM EDTA, pH8.0, 1 % NP-40, 0.5 % sodium deoxychloate supplemented 
with 1 mM PMFS, 1 mM DDT, 1 mM NaVO3, 5 and protease inhibitor cocktail). Cleared 
cell lysates were incubated with either 1 μg of anti-HA monoclonal or 2 μg  of anti-TRIF 
(Exalpha) antibodies precoupled to 50 μl of Protein A/G Plus-Agarose beads for 2 h at 4 oC 
with gentle shaking. IP complexes were washed 4 times with lysis buffer and then released 
from the beads by addition of 40 μl of Laemmli loading buffer, followed by boiling for 5 
min. Proteins were separated by SDS-PAGE and subjected to immunoblotting using anti-
HA monoclonal antibody. Images were captured G: box system (Snygene). Results 
represent at least two independent experiments. 
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5, the anti-TRIF antibody was used to confirm an interaction between ADAM15 and TRIF 
and DVL3 and TRIF, respectively.   
 
6.2.2   Examination of TLR3 and TLR4 responsiveness in U373-CD14 cells 
Having established that the TRIF antibody obtained from Exalpha can be used to detect 
endogenous TRIF, different cell lines were tested for their responsiveness to TLR3 and 
TLR4 ligands with the ultimate aim of the comparative characterisation of the endogenous 
TRIF immunocomplex following TLR3 and TLR4 engagement. Cells of relevance to innate 
immunity namely, human alveolar epithelial (A549) cells, bronchial epithelial (BEAS-2B) 
cells and human astrocytoma (U373-CD14) cells were tested. To test the cellular 
responsiveness, cells were stimulated with either poly(I:C) or LPS for different time points. 
Thereafter, cytokines were measured at both mRNA and protein level using by Q-RT PCR 
and ELISA, respectively. It was found that the U373-CD14 cell line was the only cell line 
that responded well to poly(I:C) and LPS as demonstrated by the upregulation of mRNA 
and secretion of cytokines and chemokines as measured by Q-RT-PCR and ELISA, 
respectively (Figure 6.2). Stimulation of U373 CD14 cells with poly(I:C) and LPS resulted 
in a significant upregulation of TNF-α, IFN-β, and Rantes mRNAs compared to the control 
(Figure 6.2, panels A-C). In agreement with the mRNA data, poly(I:C) and LPS stimulation 
significantly increased the TNF-α, IL-6, and Rantes secretion in the cell free supernatant 
when compared to the control (Figure 6.2, panels, D-F). These results indicate that U373-
CD14 respond to both TLR3 and TLR4 ligands, which make them suitable cell line for the 
proposed study. 
6.2.3    Immunoprecipitation of endogenous TRIF  
IP of endogenous TRIF using an anti-hTRIF antibody obtained from Exalpha was 
performed using U373-CD14 cells as a model. To ensure adequate protein recovery and to 
achieve optimal TRIF detection, the IP was performed using the protein obtained from 
T175 flasks which were 90-95 % confluent. To this end, U373-CD14 cells were treated 
with either poly(I:C) or LPS for different time points followed by IP of endogenous TRIF 
as described (Materials and methods, section 2.2.10). Proteins were separated by SDS- 
PAGE and subjected to immunoblotting. As shown in Figure 6.3, panel A, whilst immuno- 
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Figure 6.2: Examination of TLR3 and TLR4 responsiveness in U373-CD14 cells (A-C) 
U373-CD14 cells were seeded into 6 well plates. When the cells were 80 % confluent, they 
were stimulated with either 20 µg/ml poly(I:C) or 1µg/ml LPS for 3 h. Thereafter, cells 
were collected and total RNA was isolated and reverse transcribed into cDNA. The cDNA 
was then diluted 25 times and Q-RT-PCR was performed using primers specific for human 
TNF-α (A), IFN-β (B) and Rantes (C). Human GAPDH was used as housekeeping gene. 
(D-F) Cells were plated into 6 well plate. When the cells were 80 % confluent, they were 
stimulated with either 20 µg/ml poly(I:C) or 1µg/ml LPS for additional 24 h. Thereafter, 
cell free supernatants were collected and sandwich ELISA was performed to measure the 
protein level of TNF-α (D), IL-6 (E) and Rantes (F). Data are representative of three 
independent experiments.* P < 0.05, ** P < 0.01, and *** P < 0.001.    
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Figure 6.3: Immunoprecipitation of endogenous TRIF. (A) U373-CD14 cells were 
cultured into T175 flasks. When the cells were 90-95 % confluent, they were stimulated 
with either 20 μg/ml poly(I:C) or 1 μg/ml LPS for the times indicated. Thereafter, cells 
were scraped into 10 ml ice cold PBS and spun down for 10 min at 4
 o
C at 1200 rpm. Cell 
pellets were lysed in  of lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM EDTA, 
pH 8.0, 1 % NP-40, 0.5 % sodium deoxycholate supplemented with 1 mM PMSF, 1 mM 
DDT, 1 mM NaVO3 and protease inhibitor cocktail). Cleared cell lysates were incubated 
with 2 μg of anti-hTRIF polyclonal antibody precoupled to 50 μl of Protein A/G Plus-
Agarose beads for 2 h at 4 
o
C with gentle shaking. Proteins were separated by SDS-PAGE 
and immunoblot analysis was performed using anti-hTRIF (Exalpha). Rabbit IgG (Sigma) 
was used as negative control. To visualize protein bands for tryptic digestion and LC-MS 
analysis, gels were stained in instant blue overnight (B) Images were captured using the 
G:box system (Syngene).  
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precipitated endogenous TRIF was detected at all-time points, a band was not detected in 
the control IP using a rabbit IgG. It must be noted that whilst the predicted molecular 
weight of TRIF is 76-78 kDa, routinely, in the current study, endogenous TRIF was 
detected at approximately 95 kDa. This finding is supported by Qu and colleagues whom 
showed that endogenous TRIF was detected at ~ 90 kDa (Qu et al., 2011). Further, an 
aliquot of the protein sample was subjected to SDS-PAGE followed by instant blue staining 
to visualise the protein bands (Figure 6.3, panel B). Here, to avoid the loss of protein, the 
gel was not destained, although, it is a less sensitive detection method when compared to 
the silver staining method. 
6.2.4  Identification of endogenous TRIF interactors 
The aim of this aspect of the study was to identify the binding partners for endogenous 
TRIF, without putting the cells under stress associated with transfection or TRIF 
overexpression. As the study investigated TRIF interactors at the endogenous level, 
receptor-independent TRIF activation associated with TRIF overexpression was avoided 
(Funami et al., 2007; Funami et al., 2008). We aimed here to identify ligand and receptor-
dependent TRIF interacting proteins. Each gel lane was cut into 24 gel pieces, followed by 
in-gel tryptic digestion and LC-MS analysis as described (Materials and methods, section 
2.2.12). Samples were analysed using Agilent 6340 Ion trap LC-MS machine. The MS 
spectra of the peptide ions were identified using the Mascot software programme 
(www.matrixscience.com) to search against the publicly available NCBI nonredundant 
protein database (www.ncbi.nlm.nih.gov). The results generated at each time point was 
compared to the controls (un-stimulated and the IgG). Proteins which were similar to that 
identified in the controls were excluded from further analysis and considered as unspecific 
binding. Poly(I:C)-dependent TRIF interacting proteins are listed in Table 6.1 and LPS-
dependent TRIF interacting proteins were listed in Table 6.2. Following analysis of the 
TRIF interactors, it was found that Menin, adenomatous polyposis coli (APC), CAP-Gly 
domain-containing linker protein 1 (CLIP), Prohibitin, ADAM15, IQ motif containing 
GTPase activating protein1 (IQGAP1), and 14-3-3 protein Zeta/delta proteins interacted 
with endogenous TRIF upon poly(I:C) and LPS stimulation. All of these proteins were also 
identified following LC-MS analysis of the overexpressed TRIF immunocomplex (Chapter 
3). Together, these data confirm the association of these proteins with TRIF, both at 
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endogenous and at overexpressed level. Unfortunately, following analysis of the TRIF 
immunocomplex, TRIF itself was not identified, and as described in Chapter 3 (section 
3.3), this may be due to mobility issues relating to TRIF. It must be emphasised that whilst 
TRIF was not detected by LC-MS it was detected in the concomitant sample following 
immunoblot analysis.   
 A significant number of proteins were identified as TRIF interactors. Due to the 
time course of this project validation of these protein interactors by immunoprecipitation or 
other direct experiments was not possible. However, it was decided to establish the role of a 
novel TRIF interactor, Optineurin (OPTN), in TLR signalling. Optineurin was identified as 
being a TRIF interactor following stimulation of cells with poly(I:C) for 20 min and will be 
further discussed herein. In addition, another interesting TRIF interactor identified upon 
stimulation of cells with poly(I:C) and LPS for 60 min and 40-60 min, respectively, was 
Prolow-density lipoprotein receptor-related protein 1 (LRP1). The LRP1 is multifunctional 
cell surface receptor and member of the low density lipoprotein (LDL)-receptor family. 
LRP1 play and important role in endocytosis and phagocytosis of apoptotic cells and 
involves in the regulation of many signalling pathway including lipid metabolism, 
proliferation of vascular smooth muscle, neurodevelopment and cancer (Campana et al., 
2006; Francini et al., 2011). LRP1 induces the expression of matrix metalloproteinase 2 
(MMP2) and MMP9 and thereby promotes the migration and invasion of human 
glioblastoma U87 cells (Song, et al., 2009). Zurhove et al. (2008) showed that LRP1 
interacted with IRF3 in the nucleus and promotes its nuclear export and proteasomal 
degradation. Moreover, basal transcription of LPS target genes and LPS-induced secretion 
of proinflammatory cytokines are increased in the absence of LRP1. It has been reported 
that LRP1 sequesterd frizzled receptor and thereby disrupts the frizzled receptor-
LRP5/LRP6 complex and ultimately represses the canonical Wnt pathway (Lindner et al., 
2010). This may suggest that the LRP1 is involves in TLRs mediated negative regulation to 
the Wnt/β-catenin pathway.  
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Table 6.1    poly(I:C)-dependent TRIF interacting proteins. 
U373-CD14 cell line was stimulated with poly(I:C) for 20, 40 and 60 min, then TRIF immunoprecipitation was performed and 
proteins were separated by 1D SDS-PAGE gel electrophoresis followed by tryptic digestion and LC-MS analysis. 
 
Protein name NCBI 
accession no 
Mascot 
score 
PI MW Peptide 
Match 
Sequence 
Coverage 
% 
Time 
point 
Adenomatous polyposis coli protein 53759122 57 7.92 313659 3 1 20 min 
CAP-Gly domain-containing linker protein 1 109658674  51 5.29 162901 3 2 
 
20 min 
A disintegrin and metalloproteinase with thrombo-
spondin motifs 13  
21265034  51 6.96 158261 3 3 20 min 
Optineurin/FIP2  20149572 53 5.14 66286 2 3 20 min 
14-3-3 protein zeta/delta 4507953 134 4.73 26943 3 23 20 min 
Very low-density lipoprotein receptor 65301167 
 
249 
 
4.62 99856 
 
5 7 40, 60 
min 
NF-kappa-B-repressing factor  
 
63003897  
 
64 8.94 
 
78308 
 
2 3 40 min 
Pyruvate kinase isozymes M1/M2  
 
33286418  
 
127   3 5 40 min 
and 
60 min 
Prolow-density lipoprotein receptor-related protein 1 126012562  585 5.16 523476 
 
16 4 60 min 
Ras GTPase-activating-like protein IQGAP1 
 
4506787 78 6.08 189772 
 
2 1 60 min 
prohibitin  
 
4505773 
 
74 5.75 29843 
 
2 16 60 min 
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Table 6.2    LPS-dependent TRIF interacting proteins. U373-CD14 cells were stimulated with LPS for 20, 40 and 60 min, then 
TRIF immunoprecipitation was performed and proteins was separated by 1D SDS-PAGE followed by tryptic digestion and LC-MS 
analysis.  
Protein name NCBI 
accession no 
Mascot 
score 
PI MW Peptides 
Match 
Sequence 
Coverage 
% 
Time 
point 
Desmoplakin 58530840   88 6.44 334021 2 1 20 min 
Vascular endothelial growth factor receptor 1 156104876   53 8.66 152554 2 1 20 min 
Junction plakoglobin 4504811  134 5.75 82434 4 6 20 min 
Disintegrin and metalloproteinase domain-containing 
protein 15 
15778976 52 6.3 95636 2 2 20 min 
Growth factor receptor-bound protein 10  48762679  51 8.07 68158 2 5 20 min 
Lysozyme C  4557894 132 9.38 16982 2 16 20 min 
Prolow-density lipoprotein receptor-related protein 1 
 
12667788 
 
378 5.16 523150 12 3 40 min 
and  
60 min 
Very low-density lipoprotein receptor 65301167 147 4.62 99856 3 6 40 min 
and  
60 min 
Menin 1945390 
 
53 6.14 68380 5 2 40 min 
Monocyte differentiation antigen CD14 
 
4557417 72 5.84 40689 2 5 40 min 
and  
60min 
Granulins 4504151 49 6.43 6815 2 3 60 min 
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Another interesting TRIF interactor that was identified upon LPS stimulation for 20 min 
was growth factor receptor-bound protein 10 (GRB10). GRB10 encodes an intracellular 
adaptor protein that can interact with several receptor tyrosine kinases and downstream 
signalling molecules (Garfield et al., 2011). GRB10 has been shown to interact with insulin 
receptor (IR), insulin-like growth factor 1 receptor (IGF1R), Raf1 kinase, and MEK1 
kinase and to be involved in cell growth regulation. It is also negatively regulate insulin and 
IGF1 signalling by mediating insulin receptor and IGF1R degradation through 
ubiquitination (Huang et al., 2010; Doiron et al., 2012). In this regard, it has been reported 
that activation of the innate immune system via TLRs is implicated in the pathogenesis of 
insulin resistance and diabetes (Shi et al., 2006; Grishman et al., 2012). In accordance with 
this, Dasu and colleagues reported a significant increase in TLR2 and TLR4 expression in 
monocytes isolated from type 2 diabetes patients. They also showed increased 
phosphorylation of MyD88. TRIF, IRF3, IRAK1 and p65 in type 2 diabetes monocytes 
(Dasu et al., 2010).    
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6.3    Optineurin negatively regulates TRIF signalling     
 
6.3.1    Introduction  
Following the immunoprecipitation of endogenous TRIF using  anti-TRIF antibody (from 
Exalpha) and analysis of interacting partners using LC-MS techniques, Optineurin (OPTN) 
was identified as a novel TRIF interacting partner following stimulation U373-CD14 cells 
with poly(I:C) for 20 min. Therefore the aim of this part was to investigate the role played 
by OPTN in TRIF mediated TLR3 and TLR4 signalling. OPTN is a Golgi complex-
associated ubiquitous protein with high expression in skeletal muscle, heart, brain and 
pancreas (Sippl et al., 2011). It was first discovered as a binding partner of the adenoviral 
protein E3-14.7K and was shown to protect infected cells from TNF-induced cytolysis (Li 
et al., 1998). OPTN is a conserved 67-kD protein with multiple leucine zipper domains and 
a putative zinc finger domain at the C-terminus. OPTN shows strong homology (53 % 
identity) with NF-κB essential modulator and was therefore also called NEMO-related 
protein (Schwamborn et al., 2000).  
Mutations in OPTN have been observed in rare hereditary cases of glaucoma 
(neurodegenerative eye diseases that cause blindness) and therefore named Optic 
neuropathy-inducing protein (Chalasani et al., 2007). Recently, mutations in OPTN were 
identified in patients with familial amyotrophic lateral sclerosis (ALS) (Maruyama et al., 
2010). ALS is an adult onset progressive neurodegenerative disorder whose hallmark is the 
selective death of motor neurons of primary motor cortex, brainstem, and spinal cord. The 
mechanisms by which mutant OPTN causes glaucoma or ALS have not been clarified yet. 
However, overexpression of glaucoma-causing mutant of OPTN in culture cells causes 
apoptotic and Golgi fragmentation leads to cell death and receptor mediated endocytosis 
(Sippl et al., 2011). OPTN also bind to Rab8, a member of small GTPase family known to 
be involve in vesicular transport (Hattula and Peränen, 2000) and  link myosin VI to the 
Golgi complex and is involved in Golgi organization and exocytosis (Sahlender et al., 
2005).  
OPTN plays an important role in NF-κB regulation. Suppression of OPTN 
expression increases basal as well as TNF-α-induced NF-κB activity whereas 
overexpressed OPTN inhibits it. This negative regulation of NF-κB activity is believed to 
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be the result of competition of OPTN with NEMO for binding to polyubiquitinated RIP 
(Zhu et al., 2007). However, in human T-lymphotropic virus type1 (HTLV-1) infected 
cells, OPTN interacts with TAX1BP1 and a viral protein TAX1 resulting in sustained 
activation of NF-κB and ubiquitination of TAX1 (Journo et al., 2009). Importantly, OPTN 
was identified as TBK1 binding partner (Morton et al., 2008). Overexpression of OPTN 
inhibited Sendai virus (SeV) and dsRNA triggered induction of IFN-β, whereas depletion 
of OPTN with siRNA promoted virus-induced IFN-β production and decreased RNA virus 
replication. This signalling involves interaction of OPTN with the antiviral protein kinase 
TBK1 and ubiquitin ligase TRAF3 (Mankouri et al., 2010). However, Gleason and 
colleagues reported a significant reduction in TBK1 activity and decreased phosphorylation 
of IRF3 in response to activation of TLR3 and TLR4 in BMDMs expressing a 
polyubiquitin-binding defective OPTN mutant. The production of IFN-β mRNA and IFN-β 
secretion was also impaired (Gleason et al., 2011). 
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6.3.2    Results 
 
 
6.3.2.1    OPTN interacts with TRIF 
Analysis of endogenous TRIF interacting partners using a proteomics approach revealed 
that TRIF interacts with OPTN. Thus, to confirm the interaction, co-immunoprecipitation 
of epitope-tagged TRIF (HA-TRIF) with epitope tagged OPTN (Myc-OPTN) was 
performed in HEK293-TLR3. Cells were transfected with either HA-TRIF and EV, or HA-
TRIF and Myc-OPTN and treated as indicated. Thereafter, immunoprecipitation of HA-
TRIF was performed as described (Materials and methods, section 2.2.9). As shown in 
Figure 6.4, panel A, OPTN constitutively co-immunoprecipitated with TRIF. Interestingly, 
Mankouri and colleagues reported a constitutive interaction between OPTN and TBK1 in 
HEKT293 infected with Sendai virus or HEK293-TLR3 treated with poly(I:C) (Mankouri 
et al., 2010). This finding was recently supported by Gleason and colleagues who showed 
constitutive interaction between endogenous OPTN and endogenous TBK1 in BMDMs 
(Gleason et al., 2011). To investigate whether endogenous TRIF and OPTN interact 
constitutively with each other, IP of TRIF was performed in U373-CD14. Cells were 
treated with either poly(I:C) or LPS for 20 and 60 min followed by IP of endogenous TRIF 
as described (Materials and methods, section 2.2.10). Results showed that TRIF and OPTN 
interact in ligand-dependent manner. However, OPTN proved difficult to detect in whole 
cell lysates (Figure 6.4, panel, B).  
 
6.3.2.2    Poly(I:C) and LPS induce OPTN expression 
It has been reported that expression of OPTN is induced in response to viral infection 
(Mankouri et al., 2010). TNF-α stimulation in Hela and A549 cells also activates OPTN 
promoter activity in a NF-κB dependent manner (Sudhakar et al., 2009). Therefore, the 
effect of poly(I:C) and LPS on OPTN expression was investigated in U373-CD14. Cells 
were stimulated with either poly(I:C) or LPS for different time points followed by RNA 
isolation, cDNA synthesis and Q-RT-PCR. Poly(I:C) significantly increased OPTN mRNA 
after 24 h  compared to the control, LPS also increased OPTN expression at 24 h but the 
difference was not statistically significant (Figure 6.5, panels, A and B). 
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Figure 6.4: Co-immunoprecipitation of TRIF and OPTN.  (A) HEK293-TLR3 were 
seeded into 6 well plates. When confluent (80 %), cells were co-transfected with 2 μg of 
HA-TRIF and 1 μg of EV or co-transfected with 2 μg of HA-TRIF and 1 μg of Myc-OPTN. 
After 20 h, cells were left unstimulated or stimulated with 20 μg/ml poly(I:C) for 20 min. 
Thereafter, cells were lysed in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM 
EDTA, pH 8.0, 1 % NP-40, 0.5 % sodium deoxycholate supplemented with 1 mM PMSF, 1 
mM DDT, 1 mM NaVO3, and protease inhibitor cocktail). Cleared cell lysates were 
incubated with 1 μg of anti-HA monoclonal antibody precoupled to 50 μl of Protein A/G 
Plus-Agarose beads for 2 h at 4 
o
C with gentle shaking. Immunoprecipitation complexes 
were washed 4 times with lysis buffer and then released from the beads by addition of 40 μl 
of Laemmli loading buffer, followed by boiling for 5 min. Proteins were separated by SDS-
PAGE and subjected to immunoblotting using anti-HA and anti-Myc monoclonal 
antibodies. (B) U373-CD14 cells were cultured into T175 flasks. When the cells were 90-
95 % confluent, they were stimulated with either 20 μg/ml poly(I:C) or 1 μg/ml LPS for 
time indicated. Thereafter cells were scrapped into 10 ml ice cold PBS and spun down for 
10 min at 4
 o
C at 1200 rpm. Cell pellets were lysed as per panel A and cleared cell lysates 
were incubated with 2 μg of anti-hTRIF polyclonal antibody precoupled to 50 μl of Protein 
A/G Plus-Agarose beads for 2 h at 4 
o
C with gentle shaking. Proteins were separated by 
SDS-PAGE and immunoblot analysis was performed using anti-hTRIF (Exalpha) and anti-
hOPTN (Santa cruz) antibodies. Rabbit IgG (Sigma) was used as negative control. Images 
were captured using the G:box system (Syngene). 
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Figure 6.5: poly(I:C) and LPS induce OPTN expression. (A, B). U373-CD14 cells were 
plated into 6-well plates. When cells were 80 % confluent, they were left unstimulated 
(control) or stimulated with either 20 μg/ml poly(I:C)  (A) or 1 μg/ml LPS  (B) for the time 
indicated. Thereafter, total RNA was isolated, and reverse transcribed into cDNA. The 
cDNA were used as a template whereby it was diluted 25 times and OPTN mRNA was 
measured by Q-RT-PCR using primer specific to human OPTN. GAPDH was used as 
housekeeping gene. (C) U373-CD14 cells were plated in T175 flasks. When cells were 80 
% confluent, they were stimulated with either 20 μg/ml poly(I:C) or 1 μg/ml LPS for the 
time indicated. Thereafter, cells were collected in 10 ml ice cold PBS and spun down for 10 
min at 4
 o
C at 1200 rpm. Cell pellets were lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 
150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % SDS, supplemented with 
protease inhibitor cocktail, 1 mM PMSF, 1 mM Na3VO4 and 1 mM DDT). Next, cell 
lysates were mixed with Laemmli loading buffer and boiled for 5 min. Proteins were 
separated by SDS-PAGE and subjected to immunoblot analysis using mouse anti-OPTN 
monoclonal antibody and β-actin was used as loading control. Images were captured using 
the G:Box system (Syngene). The results presented are representative of at least two 
independent experiments.  *** P < 0.001. 
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However, poly(I:C) and LPS both increased OPTN protein expression levels after 24 h 
(Figure 6.5, panel C). 
 
6.3.2.3    OPTN inhibits TRIF and TLR3-dependent reporter gene activity.  
The ability of OPTN to modulate TRIF-mediated luciferase reporter gene activity was 
investigated. Thus, HEKT293 cells were transiently transfected with the NF-κB, IFN-β and 
CCL5 (Rantes) reporter gene constructs and increasing amounts of OPTN in the presence 
of a constant concentration of TRIF. OPTN significantly inhibited TRIF-dependent 
activation of the NF-κB, IFN-β (p125-luc) and Rantes reporter genes (Figure 6.6, panels, 
A-C). Furthermore, overexpression of OPTN also significantly inhibited TRIF-dependent 
activation of the NF-κB-driven PRDII and IRF3/IRF7-dependent PRDIII-I reporter genes 
(Figure 6.6, panels D and E).  As TRIF mediates TLR3 signalling, the effect of OPTN on 
TLR3-dependent NF-κB, IFN-β and Rantes activation was investigated using HEK293 
cells stably expressing TLR3. In HEK293-TLR3 cells, overexpression of OPTN 
significantly inhibited TLR3-dependent activation of NF-κB, IFN-β and Rantes reporter 
genes (Figure 6.6 panels F-H).   
 
6.3.2.4    Suppression of OPTN by esiRNA. 
To investigate the role played by OPTN in TLR3 and TLR4 signalling, knockdown of 
OPTN was performed used esiRNA technology in U373-CD14 cells. To monitor the 
knockdown, U373-CD14 cells were transfected with esiRNA control or esiRNA against 
human OPTN, then OPTN mRNA and protein levels were measured by using Q-RT-PCR 
and immunoblotting, respectively. It was found that esiRNA successfully reduced OPTN 
mRNA by at least 70 % compared to the control (Figure 6.7 panel, A). In addition, the 
OPTN protein expression was also downregulated following suppression of OPTN 
expression by esiRNA compared to the control as measured by western blot (Figure 6.6 
panel C). 
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Figure 6.6: OPTN inhibited TRIF and TLR3-dependent reporter gene activity. (A-
E) HEKT293 cells were plated into 96 well plates at a density of 5 x 10
4
 cells/well. After 
24 h, cells were transfected with expression vectors encoding either the reporter genes 
NF-κB (A), IFN-β promoter p125 (B), Rantes promoter (C), IFN-β PRDII (D) or IFN-β 
PRDIII-I (E) and co-transfected with either EV or expression vectors encoding the full 
length human HA-TRIF (20 ng) and increasing amounts of expression vectors encoding 
full length human Myc-OPTN (5, 20, 30 and 40 ng) as indicated. After 24 h, cells were 
harvested and lysed. The cell lysates were stored at -80 
o
C for at least 24 h, followed by 
assessment of luciferase reporter gene activity. (F-H) HEK293-TLR3 cells were plated 
into 96 well plates at a density of 5 x 10
4
 cells/well. After 24 h, cells were transfected 
with expression vectors encoding either the NF-κB (F), IFN-β promoter p125 (G), or 
Rantes promoter (H) reporter gene plasmids, and co-transfected with either an EV or and 
increasing amounts of OPTN. After 24 h, cells were left untreated (control) or stimulated 
with 20 μg/ml poly(I:C) for an additional 24 h, followed by harvesting of cell lysates. 
Cell lysates were left at -80 
o
C for at least 24 h and assessment of luciferase reporter 
gene activity was performed using the dual luciferase system (Promega). The results 
presented are representative of at least three independent experiments, each experiment 
was done in triplicate. ** P < 0.01 and *** P < 0.001. 
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Figure 6.7: Suppression of OPTN in human astrocytoma U373-CD14 cells. (A) Cells 
were seeded into 6-well plate. When cells were 80 % confluent, they were transfected with 
20 nM esiRNA control or 20 nM esiRNA against human OPTN.  Cells were harvested 24 h 
after transfection and total RNA was isolated and reverse transcribed into cDNA. The 
cDNA template was diluted 25 times and OPTN mRNA was measured by Q-RT-PCR 
using primer specific to human OPTN. GAPDH was used as housekeeping gene. (B). Cells 
were plated into 6-well plates. After 24 h, cells were transfected with 20 nM esiRNA 
control or esiRNA against human OPTN. Cells were collected 48 h after transfection in 1 
ml cold ice PBS and centrifuged for 10 min at 2000 rpm at 4 
o
C. Cells were lysed in RIPA 
buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 
% SDS, supplemented with protease inhibitor cocktail, 1 mM PMSF, 1 mM Na3VO4 , and 1 
mM DDT). Proteins were separated by SDS-PAGE and subjected to immunoblot analysis 
using an anti-human OPTN mouse monoclonal antibody (Santa Cruz) and β-Actin was 
used as loading control. Images were captured using the G:box documentation system 
(Syngene). *P < 0.05. 
 
 
 
 
169 
 
6.3.2.5   Downregulation of OPTN expression enhanced IFN-β, and Rantes mRNA 
expression.  
To investigate the potential role of OPTN in TLR3 and TLR4 signalling, levels of IFN-β, 
TNF-α and Rantes mRNAs were measured in U373-CD14 cells following transfection with 
esiRNA control or esiRNA against OPTN. After 48 h post transfection, cells were 
stimulated with either poly(I:C) or LPS for 3 h, followed by RNA isolation, cDNA 
synthesis and Q-RT-PCR. It was found that suppression of OPTN expression significantly 
increased poly(I:C)-induces IFN-β transcription compared to the control (Figure 6.8, panel 
A) Rantes mRNA was also increased but the difference is not statistically significant. 
However, suppression of OPTN expression had a negligible effect on TNF-α. (Figure 6.8 
panels B and C). Suppression of OPTN had a negligible effect on LPS-induces IFN-β, 
TNF-α and Rantes transcription (Figure 6.8 panels D-F). In general knockdown of OPTN 
increased slightly the basal levels IFN-β, TNF-α and Rantes transcriptions 
 
6.3.2.6    Effect of OPTN suppression on cytokine and chemokine secretion  
Next, the effect of OPTN on TLR3 and TLR4-mediated cytokine and chemokine secretion 
were assessed. To this end, U373-CD14 cells were transfected with esiRNA control or 
esiRNA against OPTN for 24 h, followed by stimulation with either poly(I:C) or LPS for 
additional 24 h. Thereafter, cell free supernatants were collected and cyto/chemokine 
secretion was measured in cell free supernatants using the Sandwich ELISA as described 
(Materials and method, section 2.2.20). Suppression of OPTN expression significantly 
increased poly(I:C) induced TNF-α, and Rantes compared to the control, IL-6 was slightly 
increased but the difference was not statistically significant, Surprisingly reduction of 
OPTN significantly decreased/increased LPS-induces TNF-α/Rantes, respectively (Figure 
6.9, panels, A-C). Basal induction of TNF-α and Rantes was slightly increased when OPTN 
was suppressed. 
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Figure 6.8: Suppression of OPTN expression enhanced IFN-β mRNA transcription. 
U373-CD14 cells were seeded into 6 well plates. When the cells were 80 % confluent, they 
were transfected with 20 nM esiRNA control or esiRNA directed against OPTN. After 48 
h, cells were stimulated with either 20 μg/ml poly(I:C) (panels, A-C) or 1 μg/ml LPS 
(panels D-F) for 3 h. Thereafter, cells were harvested and total RNA was isolated and 
reverse transcribed into cDNA.  The cDNA was used as template and then diluted 25 times. 
Next, levels of IFN-β (A, D), TNF-α (B, E) and Rantes (C, F) mRNAs were measured by 
Q-RT-PCR using specific human IFN-β, TNF-α and Rantes primers. GAPDH was used as 
housekeeping gene. Data are representative of two independent experiments each 
experiment was done in duplicates. * P < 0.05. 
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Figure 6.9: Effect of OPTN suppression on cytokine and chemokine secretion U373-
CD14 cells were plated into 6-well plates. When the cells were 80 % confluent, cells were 
transfected with 20 nM esiRNA control or esiRNA against OPTN. After 24 h, cells were 
stimulated with either 20 μg/ml poly(I:C) or 1 μg/ml LPS for an additional 24 h. Thereafter, 
cell free supernatants were collected and ELISA was performed to detect human TNF-α 
(A), Rantes (B) and IL-6 (C). Data are representative of two independent experiments each 
experiment was done in triplicates. * P < 0.05, ** P < 0.01. 
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6.4    Discussion 
The aim of this chapter was to characterise the endogenous TRIF immunocomplex 
following TLR3 and TLR4 ligand stimulation. To this end, we characterised a suitable 
antibody and cell line that facilitated the activation of TLR3 and TLR4 signalling and 
subsequent immunoprecipitation of endogenous TRIF. This study has showed that an anti-
TRIF antibody obtained from Exalpha can be used to detect and immunoprecipitate 
endogenous TRIF. The anti-TRIF antibody was used to confirm an interaction between 
endogenous TRIF and some novel TRIF interacting proteins such as ADAM15, DVL3 and 
OPTN. The human astrocytoma cell line U373-CD14 was found to be a good cell model to 
study TRIF mediated TLR3 and TLR4 signalling as they showed good response to 
poly(I:C) and LPS. This is in contrast to A549 cells which showed upregulation of TNF-α 
and IFN-β mRNA upon poly(I:C) and LPS stimulation. However, secretion of TNF- 
Rantes and IL-6 was not detected in cell free supernatant following stimulation with these 
ligands, as measured by ELISA (data not shown). In BEAS-2B cells, poly(I:C) stimulation 
resulted in increased TNF-α and IFN-β mRNA and, in agreement with the mRNA data, the 
BEAS-2B cells showed significant increase in IL-6 and Rantes secretion in cell free 
supernatant. However, LPS stimulation increased TNF-α mRNA, but not cytokine/ 
chemokine secretion in cell free supernatant (data not shown). MacRedmond et al. (2005) 
reported that expression of TLR4 in A549 cells showed that the cells respond to LPS. Hou 
et al. (2006) also reported that Poly(I:C) upregulated TLR3 mRNA, stimulated IL-8 
secretion and enhanced phosphorylation of NF-κB in A549 cells. Regarding the BEAS-2B, 
it has been reported that these cells express functionally active TLR3 and TLR4 (Sha et al., 
2004). The difference here, may be due the cells passage that used in this study or the cells 
may secret other cytokine/chemokine than what we measured in response to poly(I:C) and 
LPS. 
  Following immunoprecipitation of endogenous TRIF and subsequent LC-MS 
analysis a potential number of poly(I:C) and LPS-dependent TRIF protein interactors were 
identified in this study. Proteins such ADAM15, CLIP, APC, Menin, IQGAP1 and 
prohibitin were identified in this screening and also identified in the proteomic analysis of 
overexpressed TRIF protein complex (Chapter 3). These data confirm an association 
between these proteins and TRIF at the endogenous level. However, further validation by 
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direct experiments is required to study their potential role in TRIF signalling. New 
interesting TRIF interactors such as LRP1 and GRB10 were also identified, thus linking 
TRIF to other signalling pathways such as endocytosis and phagocytosis and diseases such 
as diabetes. As mentioned earlier LRP1 play an important role in endocytosis and 
phagocytosis (Campana et al., 2005; Francini et al., 2011) and GRB10 negatively regulates 
insulin and IGF1 signalling by mediating insulin receptor and IGF1R degradation through 
ubiquitination (Huang et al., 2010; Doiron et al., 2012). 
Results showed that OPTN, a TBK1 binding protein also interacted with TRIF 
constitutively when overexpressed in HEK293-TLR3. It also binds to endogenous TRIF 
upon poly(I:C) and LPS stimulation for 20-60 min in U373-CD14. It was found that OPTN 
expression was increased following stimulation with poly(I:C) and LPS for 24 h. In 
agreement with this result, Mankouri and colleagues reported that increased OPTN 
expression was evident in HEKT293 infected with Sendai virus, an activator of the RIG-I 
pathway and following stimulation of HEK293-TLR3 with poly(I:C) (Mankouri et al., 
2010). Activation of OPTN promoter upon TNF-α stimulation in Hela and A549 cells has 
also been reported (Sudhakar et al., 2009). 
Overexpression of OPTN in HEKT293 or HEK-TLR3 strongly inhibited TRIF and 
TLR3-dependent activation of NF-κB, IFN-β and Rantes promoter activity respectively. 
Moreover, overexpression of OPTN in HEKT293 also significantly inhibited TRIF-
dependent activation of the NF-κB-driven PRDII and IRF3/IRF7-dependent PRDIII-I 
reporter genes. Furthermore knockdown of endogenous OPTN using esiRNA technology in 
U373-CD14 significantly increased IFN-β mRNA and secretion of TNF-α and Rantes upon 
poly(I:C) stimulation. However, suppression of OPTN significantly increased LPS-induces 
Rantes and decreased LPS-induces TNF-α secretion. In this regard, Gleason and colleagues 
reported that OPTN is required for optimal activation of TBK1 and production of IFN-β in 
BMDMs upon TLR3 and TLR4 activation (Gleason et al., 2011). This is in contrast with 
another study which reported that poly(I:C) and virus-induced activation of IFN-β reporter 
gene and IFN-β secretion was inhibited upon OPTN overexpression and enhanced by 
siRNA knockdown of OPTN in HEK293-TLR3 (Mankouri et al., 2010). However, another 
study showed that overexpression of OPTN inhibited TNF-α-induced NF-κB activation in 
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Hela cells (Nagabhushana et al. 2011). Collectively, these data suggest that the role of 
OPTN in regulating NF-κB and IFN-β depends on the cell type and the stimulus. 
In conclusion, this study demonstrates that an anti-TRIF antibody obtained from 
Exalpha can be used to detect and immunoprecipitate endogenous TRIF, and 
characterisation of the TRIF immunocomplex has identified a number of TRIF interacting 
partners. OPTN has been identified as a negative regulator of TRIF and TLR3-mediated 
reporter gene activation. However, further future work is need to determine the mechanisms 
by which OPTN inhibits TRIF and TLR3 signalling.  
 
  
Chapter 7 
 
 
General Discussion 
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7.1    General discussion 
While it is well appreciated that the TLRs are responsible for the recognition of 
pathogens and emanation of the appropriate responses, increasing evidence suggests 
that the family of five cytosolic TIR-adaptor proteins also play a crucial role in the 
specificity of the response (Jenkenis and Mansell, 2010). The TRIF adaptor protein is a 
key adaptor for TLR3 and TLR4-mediated signalling. It was first shown to serve as an 
adaptor for the TLR3-mediated signalling pathway with studies showing an association 
between TRIF and TLR3 and the ability of a mutant form of TRIF to inhibit the TLR3-
dependent activation of NF-κB (Hardy et al., 2004). Further, studies using TRIF-
deficient mice have demonstrated that TRIF plays a key role in both TLR3- and TLR4-
mediated signal transduction via both NF-κB and IRF3, with the induction of IFN-β and 
inflammatory cytokines being severely impaired (Yammato et al., 2003). Recently, it 
was shown that TRIF also mediates TLR5 signalling in intestinal epithelial cells and 
that DDX1, DDX21 and DHX36 use TRIF to activate the NF-κB pathway and type I 
IFN responses (Choi et al., 2010; Zhang et al., 2011). 
Herein, proteomic analysis of overexpressed and endogenous TRIF interactomes 
was performed with a view to identifying novel TRIF interacting proteins towards a 
better understanding of how TRIF-mediates TLRs signalling. Proteomic analysis of 
overexpressed TRIF in HEK293-TLR3 and HEK293-TLR4 cells led to the 
identification of many novel TRIF interacting proteins. Interestingly, many of the newly 
identified TRIF interacting proteins have been previously reported to be involved in 
modulation of proteins such as MAPKs (MAPK1, 2, 3, 8, and 9), Caspases (Caspase 1, 
3, and 8), BCL2, JUN, IKBKB and NFKBIA. Moreover, they were reported to 
modulate cellular processes such as apoptosis, immune response, inflammatory 
response, autophagy, phagocytosis, endocytosis, cytokine production, cell 
differentiation, cell proliferation and a lot of more. However, there was no previous 
report showing interaction between TRIF and these new identified proteins. 
Unfortunately, TRIF itself was not identified in the overexpression and endogenous IP 
complex in the LC-MS analysis. However, the expression of TRIF was always 
confirmed by immunoblot analysis. Recently, Li et al. (2011) performed proteomic 
analysis of the human innate immunity interacome for type I interferon. Proteins such as 
Optineurin (OPTN), NFκB repressing factor (NFRF), and Growth factor receptor-bound 
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protein 2 (GRB2) were among the identified hits. OPTN and NFRF, GRB2- associated-
binding protein 3 and GRB10 were identified herein in TRIF IP complex this may 
confirm association of these proteins with TRIF. This approach, although useful, it may 
result in identification of false positive interacting protein hits. As the cells already 
expressed endogenous TRIF, overexpression of TRIF could increase the TRIF 
expression level in the cells, which may lead to induction of some proteins that are not 
present in its physiological condition. The overexpression of TRIF was also associated 
with apoptosis and cell death. Thus, the output from this approach requires intensive 
validations by direct experiments to filter out nonspecific binding proteins. Another 
method used to identify protein-protein interaction is the tandem affinity purification 
(TAP)-tags technique (Li et al., 2011; Pichlmair et al., 2012). The TAP tag is a 
composite tag consisting of two different epitope domains and a protease cleavage site, 
and it facilitates the purification of the tagged protein in two consecutive, high-affinity 
chromatography steps (Gunzl and Schimanski, 2009). An important advantage of the 
TAP-technique is that the amount of nonspecific binding is reduced compared to 
approach used in this study. Although the TAP-tag method is highly sensitive and 
selective, a potential problem with the method is that the increased purity leads to the 
loss of transient nature protein-protein interaction during the series of purification steps. 
Another problem is that a relatively large amount of starting material is required, which 
makes purification and identification of low abundance binding partners a difficult task 
(Berggård et al., 2007; Gunzl and Schimanski, 2009). 
Proteins such ADAM15, Menin, Prohibitin, 14-3-3 protein Zeta/delta, IQ motif 
containing GTPase activating protein1, NFκB repressing factor (NFKRF) and 
adenomatous polyposis coli were identified following the proteomic analysis of the 
overexpressed  and endogenous TRIF protein complex (Chapter 3 and 6). These data 
confirm an association between these proteins and TRIF at the endogenous level. 
However, further validation by direct experiments is required to study their potential 
role in TRIF signalling. Due to the time course of this project, three identified proteins 
namely ADAM15 and DVL3 and OPTN were selected for further study. These were 
selected because they have been shown to have potential role in inflammation, Wnt 
signalling pathway and antiviral signalling, respectively (Charrier-Hisamuddin, 2008; 
Mankouri et al., 2010; Bernatik et al., 2011). 
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In this study, it was found that ADAM15 interacted with TRIF upon poly(I:C) and LPS 
stimulation for 60 and 20 min, respectively. Moreover, ADAM15 acted as a negative 
regulator of TRIF, TLR3 and TLR4-mediated activation of the NF-κB, IFNβ (p125-luc) 
and Rantes reporter genes. In addition, overexpression of ADAM15 also significantly 
inhibited TRIF-dependent activation of the NF-κB-driven PRDII and IRF3/IRF7-
dependent PRDIII-I reporter genes. Importantly, downregulation of ADAM-15 by 
esiRNA significantly enhanced poly(I:C) and LPS-induced cytokine/chemokine 
secretion in cell free supernatant in U373-CD14. Furthermore, overexpression of 
ADAM15 in HEK293-TLR3 caused TRIF degradation and the use of EGTA in 
combination with EDTA partially inhibited this effect. ADAM and MMP family 
members are Zn-dependent proteinases. Thus, their activities were reported to be 
inhibited by the metal ion chelators such as EDTA and EGTA (Chen et al., 2007). In 
agreement with these results, knockdown of ADAM15 increased TRIF mRNA and 
protein levels upon poly(I:C) stimulation. This lead to the speculation that ADAM15 
inhibited TLR3 and TLR4 signalling by a mechanism involved TRIF degradation. In 
contrast to our finding, many of the published data consider ADAM15 as an 
inflammatory mediator (Herren et al., 1997; Al-Fakhri et al., 2003; Mosnier et al., 
2006). However, the possibility that ADAM15 could present both pro-and anti-
inflammatory activities cannot be precluded (Charrier et al., 2005; Charrier et al., 2007). 
 Furthermore, this study also investigated the role of DVL1, DVL2 and DVL3 in 
TRIF mediating TLRs signalling. It was found that all DVLs isoforms constitutively 
interacted with TRIF when overexpressed in HEK293-TLR4. However, immuno-
precipitation of endogenous TRIF showed that DVL3 interacted with TRIF only 
following stimulation with LPS for 20-40 min. Moreover, overexpression of all DVLs 
isoform inhibited TRIF and TLR3-mediated activation of the NF-κB, IFNβ (p125-luc) 
and Rantes reporter genes in HEK293 and HEK293-TLR3, respectively. In agreement 
with our results, Deng et al. (2010) showed that all three DVLs isoforms directly 
interact with NF-κB (p65), and overexpression of DVLs inhibited TNF-α induced 
activation of NF-κB transcriptional activity. Surprisingly, in wild-type murine BMDMs, 
the inhibition of DVLs reduced poly(I:C)-induced upregulation of TNF-α, IFN-β and 
Rantes mRNA as well as decreased IκB degradation. This could be due to the cells line 
used in this study. TLR3 was reported to play a key role in sensing poly(I:C) by 
epithelial cells (Guillot et al., 2005; Matsukura et al., 2007), but it played a moderate or 
minor role in sensing poly(I:C) in macrophages (Alexopoulou et al., 2001; Yamamoto 
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et al., 2003). Importantly, it was found that DVLs were also needed for LPS-induces 
upregulation of cytokine/chemokine transcription as well as phos-phorylation of IRF3. 
In agreement with our results, Blumenthal et al. (2006) showed that TLRs activation 
resulted in upregulation of Wnt5A in human macrophages and that Wnt5A is necessary 
for the regulation IL-12 and IFN-γ in response to infectious agents. In addition, our 
study showed that DVLs transcriptions differentially regulated by TLRs activation, and 
that both TRIF and MyD88 inhibited β-catenin-induces Lef transcription. Also, 
poly(I:C) and LPS stimulation decreased β-catenin expression in Hela cells and partially 
inhibited DVL3-dependent β-catenin nuclear translocation. Correlating with this data, it 
has been shown that TLR4 activation inhibits enterocyte proliferation in vitro and in 
vivo via the impairment of β-catenin signalling through activation of the GSK3β (Sodhi 
et al., 2010).  
Importantly, it has been demonstrated that that β-catenin-dependent Wnt 
signalling is also active in mature, peripheral blood T cells and that Wnts induce MMP 
expression and augment T cell transmigration (Wu et al., 2007) Masckauchán et al. 
(2006) showed that Wnt5A signalling induced proliferation and survival of endothelial 
cells in vitro and expression of MMP1. In addition, Blavier et al. (2006) reported that 
MMPs (MMP2, MMP3, MMP9, MMP13 and MMP14) play an active role in Wnt1-
induced tumorigenesis in mice. Interestingly, high expression of ADAM 15 has been 
reported in lung, gastric, ovarian breast and prostate carcinoma cell lines and tissues 
(Zhong et al., 2008). Moreover, ADAM15 expression was shown to be associated with 
aggressive prostate and breast cancer (Kuefer et al., 2006). Furthermore, both ADAM15 
and DVLs are involved in MAPK activation and in particular the extracellular signal 
regulated kinase 1/2 (ERK1/2) (Bikkavilli and Malbon, 2009; Sun et al., 2010). 
Schlange et al. (2007) showed that Wnt signalling activates the ERK1/2 pathway and 
suppression of the DVLs serves to decrease active β-catenin levels, lowering ERK1/2 
activity, blocking proliferation and inducing apoptosis in the human breast cancer cell 
line MCF-7. The effects of Wnt signalling are mediated partly by EGFR transactivation 
in human breast cancer cells in a metalloprotease- and Src-dependent manner (Schlange 
et al., 2007). Interestingly ADAMs, including ADAM15, have been reported to be 
involved in EGFR transactivation  (Seals and Courtneidge, 2003). Moreover in breast 
cancer cells, ADAM15 deletion decreases ERK1/2 phosphorylation impairing migration 
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and proliferation (Najy et al., 2008). Consistently, Sun et al. (2010) demonstrated that 
ADAM15 overexpression stimulates ERK1/2 phosphorylation in endothelial cells. 
As mentioned earlier, TRIF activation induces Caspase-8-dependent cell death 
and studies have shown that TLR3 activation can trigger apoptosis of human prostate 
cells and breast cancer cells  (Salaun et al., 2006; Paone et al., 2008). It plausible to 
speculate that ADAM15 and DVLs may inhibit TRIF-induced cell death and thereby 
promotes cell growth and tumor formation. As Wnts have been shown to induce MMPs 
expression (Blavier et al., 2006), it may be suggested that activation of Wnt signalling 
by DVLs may lead to ADAM15 expression which then can inhibit TLRs signalling in a 
negative feedback mechanism to prevent overproduction of pro-inflammatory cytokine 
and thereby, suppress the inflammation associated with bacterial and viral infections.  
 Herein, Optineurin (OPTN) was also identified as a TRIF interacting partner. 
OPTN constitutively interacted with TRIF when overexpressed in HEK293-TLR3. 
However, endogenously expressed OPTN and TRIF interacted in ligand dependent 
manner only (20 and 60 min upon poly(I:C) and LPS stimulation). OPTN is a 
multifunctional protein involved in several functions such as vesicular trafficking from 
the Golgi to the plasma membrane, NF-κB regulation, signal transduction, endocytosis 
and gene expression  (Nagabhushana et al., 2010). In this study, OPTN was found to act 
as negative regulator of TRIF and TLR3-mediated activation of the NF-κB, IFN-β 
(p125-luc) and Rantes reporter genes in HEK293 and HEK293-TLR3, respectively. 
Moreover, knockdown of endogenous OPTN using esiRNA technology in U373-CD14 
significantly increased IFN-β mRNA and secretion of TNF-α and Rantes upon poly(I:C) 
stimulation. However, suppression of OPTN significantly increased LPS-induces 
Rantes and decreased LPS-induces TNF-α secretion. The data regarding the role of 
OPTN in regulating NF-κB and IFN-β are controversial and seem to be dependent on 
the cell type and the stimulus. In agreement with our results, Mankouri et al. (2010) 
reported that poly(I:C) and virus-induced activation of IFN-β reporter gene and IFN-β 
secretion was inhibited upon OPTN overexpression and enhanced by siRNA 
knockdown of OPTN in HEK293-TLR3. However, Gleason et al. (2011) reported that 
OPTN is required for optimal activation of TBK1 and production of IFN-β in BMDMs 
upon TLR3 and TLR4 activation. Furthermore, Nagabhushana et al. (2010) 
demonstrated that OPTN is involved in endocytosis. It should be mentioned that 24 h 
poly(I:C) and LPS stimulation in U373-CD14 cell line resulted in increased OPTN 
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protein level, which may suggest that TLRs induced OPTN in a negative feedback 
mechanism to reduce the signal. Interestingly, Bryja et al. (2007) showed that 
endocytosis is important for DVL2 stability and blocking of endocytosis leads to rapid 
DVL2 degradation and prevents Wnt/β-catenin signalling. Importantly, the endocytosis 
receptor, low-density lipoprotein receptor-related protein 1 (LRP1) was also identified 
in the endogenous TRIF-IP complex following stimulation with poly(I:C) for 60 min 
and LPS for 40-60 min. Song et al. (2009) demonstrated that LRP1 induces the 
expression of MMP2 and MMP9 and thereby, promotes the migration and invasion of 
human glioblastoma U87 cells. Interestingly, it has been reported that LRP1 sequestered 
frizzled receptor and thereby, disrupts the frizzled receptor-LRP5/LRP6 complex and 
ultimately represses the canonical Wnt pathway (Lindner et al., 2010). Thus, it may be 
speculated that TLRs act through OPTN or LRP1 to regulate endocytosis and thereby, 
negatively or positively regulate Wnt signalling.   
 In conclusion, proteomic analysis of the overexpressed and endogenous TRIF 
immunocomplex led to the identification of many novel TRIF interacting proteins. 
These proteins indicate that TRIF may be linked to inflammasome activation, NOTCH 
signalling, Wnt signalling, cancer and diabetes. Overall, to our knowledge this is the 
first study performed to analyse whole TRIF-IP complex.   Future studies are needed to 
validate the potential role of many of the TRIF-interactor proteins in TRIF signalling 
and to investigate whether TRIF can be associated with signalling pathways that are 
distinct from its role as an activator of TLR signalling. 
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Table 3.1    Poly(I:C)-independent TRIF interacting proteins 
HEK293-TLR3 were transfected with HA-TRIF, after 20 h cells were collected and IP of HA-TRIF was performed, followed by LC-MS 
analysed of the IP-complex. The MS spectra of the peptide ions were identified using the Mascot software programme. 
Protein name NCBI 
accession no 
Mascot 
score 
PI MW Peptide Match Sequence 
Coverage % 
AF4/FMR2 family member 4 
 
7656879 
 
51 9.33 127788 
 
3 3 
Ran-binding protein 17 
 
12597633 55 
 
6.02 125977 
 
4 3 
NIK and IKK beta binding protein 
 
119612606 50 6.29 124293 
 
2 2 
EVH1 domain binding protein 7416993 33 6.48 90831 
 
1 2 
cAMP-specific 3',5'-cyclic phosphodiesteras 259906420 
 
55 4.84 85189 
 
1 1 
Semaphorin-3C 
 
5454048 58 8.96 86487 
 
3 4 
Nibrin 33356172 54 6.50 85602 
 
2 3 
Phosphatidylinositol-4,5-bis-phosphate 3-kinase 
catalytic subunit beta isoform 
4826908 46 6.03 81837 
 
1 2 
Leucine rich repeat neuronal 4 20381181 40 6.82 80395 1 2 
NF-kappa-B-repressing factor 
 
33860178 59 8.74 78320 
 
3 4 
E3 ubiquitin-protein ligase RNF6  5174653 55 9.16 
 
78451 
 
2 3 
Guanylate cyclase soluble subunit beta-2 14916977 42 8.84 70892 2 3 
Structure of The Nalp1 Pyrin Domain 17380146 52 6.68 50486 1 11 
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F-box/LRR-repeat protein 20 isoform 1 27734755 38 7.65 
 
50248 
 
1 4 
GA-binding protein subunit beta-1 isoform beta 1 8051593 50 4.77 44906 2 3 
ribosome biogenesis protein BRX1 homolog 55770900 
 
40 9.92 41990 
 
1 2 
cAMP-dependent protein kinase catalytic subunit 
alpha 
4506055 52 8.84 40678 
 
1 3 
Mis18-binding protein 1 (p243) 5101770 44 8.74 27686 
 
1 8 
T-box transcription factor  5689744 
 
37 9.23 23183 
 
1 8 
 
Table 3.2    TRIF interactors following 20 min poly(I:C) stimulation 
HEK293-TLR3 were transfected with HA-TRIF, after 20 h cells were stimulated with 20 μg/ml poly(I:C) for 20 min. Then IP of HA-TRIF was 
performed and IP-complex was analysed by LC-MS. The MS spectra of the peptide ions were identified using the Mascot software programme. 
Protein name NCBI 
accession no 
Mascot score PI MW Peptide 
Match 
Sequence 
Coverage % 
Cardiomyopathy-associated protein 5 62241003 
 
51 4.73 450792 4 1 
sacsin 6907042 51 6.81 441744 
 
3 1 
Ubiquitin carboxyl-terminal hydrolase 32 22550104 54 6.01 183861 
 
4 2 
Bifunctional aminoacyl-tRNA synthetase 62241042 110 7.02 172107 
 
4 4 
Erythroid differentiation-related factor 1 321117522 50 5.93 139833 4 4 
Cullin-associated NEDD8-dissociated protein 1 21361794  124 5.52 137999 3 3 
224 
 
Caspase recruitment domain-containing protein 11 
 
157743265 
 
54 5.78 134512 
 
4 3 
Vinculin 
 
7669550   
 
72 5.5 134962 1 1 
Protein AF-17   215273929  
 
57 8.93 119643 3 6 
Exportin-2(cellular apoptosis susceptibility protein ) 371502112 
 
218 5.5 111145 4 6 
Transportin-1 
 
133925811  
 
73 4.83 103797 2 2 
Replication licensing factor MCM 33356547  49 5.34 102528 1 1 
Plasminogen 38051823 
 
51 6.89 93310 2 3 
RUN and TBC1 domain containing 3 119580785 
 
54 8.08 74953 3 2 
Far upstream element-binding protein 2 
 
154355000 
 
104 6.84 73443 3 6 
Plastin-3 
 
7549809  103 5.41 71288 2 6 
SUMO-activating enzyme subunit 2 4885649  
 
74 5.15 71759 1 2 
Calnexin 
 
10716563  
 
115 4.47 67990 3 5 
Numb-like protein 10863899 
 
47 9.1 65605 1 2 
Fragile X mental retardation syndrome-related protein 1 
isoform c 
61835172 
 
51 6.34 63280 3 4 
 
Alpha adrenergic receptor subtype alpha  7690135 58 9.35 61305 2 4 
T-complex protein 1 subunit theta  
 
9988062 
 
89 5.42 60153 3 6 
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Telomeric repeat-binding factor 2 
 
21542277 
 
53 9.22 55688 3 8 
Secretogranin-3 
 
19557645 
 
61 4.94 52973 2 3 
Serine/threonine-protein phosphatase 2A 
 
4758954 
 
58 5.82 52182 1 3 
Ribonuclease inhibitor 
 
62087972 
 
66 4.71 51766 2 7 
M-phase phosphoprotein 4 1770456 
 
62 6.01 49148 3 12 
Peptidase M20 domain-containing protein 2 58082085 51 5.56 48094 1 2 
Lupus La protein 
 
125985 
 
71 6.68 46979 3 10 
Phosphoglycerate kinase 1 
 
52788229 
 
146 8.30 44992 2 6 
inactive caspase-12 
 
300360580 
 
51 5.63 39130 
 
2 9 
Poly(rC)-binding protein 2 
 
14141168 
 
147 6.33 38962 
 
4 13 
SUMO-activating enzyme subunit 1 4885585 125 5.17 38890 3 13 
Serine/threonine-protein phosphatase PP1-alpha catalytic 
subunit 
4506003 76 5.94 38242 1 5 
Poly(rC)-binding protein 1 
 
6754994 
 
193 6.66 37987 
 
4 12 
TALDO1 protein 
 
48257056 
 
122 6.35 37556 4 12 
Annexin A5  4502107 153 4.94 35972 3 12 
Prohibitin-2 6005854 
 
91 9.83 33276 2 20 
226 
 
Hyaluronan-binding protein 1/Mitochondrial matrix protein 
p32 
4502491 
 
209 4.74 31749 4 26 
Myristoylated alanine-rich C-kinase substrate 
 
153070260 94 4.74 31710 
 
2 9 
Prohibitin  4505773 197 5.57 29844 
 
5 29 
Proteasome activator complex subunit 3 
 
47117724 90 5.69 29604 
 
2 9 
Replication protein A 32 kDa subunit 
 
4506585 102 5.75 29344 2 14 
Tropomyosin alpha-3 chain isoform 2 (TPMsk3) 
 
19072649 95 4.72 28906 2 9 
Acidic leucine-rich nuclear phosphoprotein 32  
 
5453880 71 3.99 28684 
 
2 10 
Triosephosphate isomerase 
 
4507645 258 6.45 26943 
 
5 28 
B-cell receptor associated protein 1673514 96 9.57 23621 
 
3 28 
Transgelin-2 4507357  124 8.41 22551 3 21 
Ubiquitin-conjugating enzyme E2 K 
 
4885417 64 5.33 22509 
 
1 14 
Peroxiredoxin-1 4505591 86 8.27 22328 3 16 
Peroxiredoxin-2 32189392  141 5.66 22052 3 29 
Ras-related protein Rap-1A 4506413  81 6.38 21322 1 6 
Peptidyl-prolyl cis-trans isomerase A 10863927 113 5.06 20018  2 19 
Macrophage myristoylated alanine-rich C kinase 13491174 47 4.68 19575 
 
1 6 
Nucleoside diphosphate kinase B 4505409  
 
51 8.52 17403 
 
3 23 
227 
 
 
Table 3.3    TRIF interactors following 40 min poly(I:C) stimulation 
HEK293-TLR3 were transfected with HA-TRIF, after 20 h cells were stimulated with 20 μg/ml poly(I:C) for 40 min. Then IP of HA-TRIF was 
performed and IP-complex was analysed by LC-MS. The MS spectra of the peptide ions were identified using the Mascot software programme. 
Protein name NCBI 
accession no 
Mascot score PI MW Peptide 
Match 
Sequence 
Coverage % 
Trio  45439359  
 
48 5.96 349815 
 
3 1 
zinc finger protein 462 
 
114431236 62 7.53 289552 
 
3 1 
Ras GTPase-activating-like protein IQGAP1  4506787 
 
55 6.08 189772 
 
3 1 
Nucleolar transcription factor 1 
 
136652 46 5.63 89698 
 
1 2 
Serine/threonine-protein phosphatase 4 regulatory subunit 3B 39930397 
 
50 4.70 87960 
 
2 3 
Nuclear autoantigenic sperm protein 23503077 46 4.26 85476 1 1 
Glycyl-tRNA synthetase 
 
116805340  
 
51 6.61 83867 
 
3 5 
T-box transcription factor TBX3 28381401 54 8.30 79745 3 4 
SEC14-like protein 5 
 
150010661 56 6.08 79704 
 
2 3 
Mitogen-activated protein kinase 8 interacting protein 1 46249764 49 4.89  2 2 
R3H domain containing 2 
 
119617414  50 9.33 76607 
 
2 5 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3 variant 
 
62087546 
 
88 7.72 74939 
 
1 1 
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vitamin D3 receptor interacting protein  4838129 
 
50 6.71 73527 
 
2 5 
poly(ADP-ribose) polymerase  178152 
 
113 8.34 64291 
 
2 4 
pyruvate kinase 
 
33286418 
 
188 7.69 58480 
 
3 11 
polypyrimidine tract-binding protein 1 14165466  
 
60 9.21 57360 
 
2 6 
Lysosomal acid phosphatase 
 
115502439 
 
47 6.28 48719 
 
1 2 
alpha-enolase 
 
119339 
 
531 7.01 47487 
 
8 26 
HIV-1 Nef interacting protein  1800303 
 
56 6.92 45611 
 
1 5 
phosphoglycerate kinase 1 
 
4505763 
 
72 8.03 44992 
 
3 11 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4  119627246 53 9.44 44798 
 
2 5 
Fructose-bisphosphate aldolase A 
 
4557305 
 
109 8.30 39859 
 
4 20 
Inactive caspase-12 
 
300360580 58 5.63 39130 
 
2 11 
Glyceraldehyde-3-phosphate dehydrogenase 
 
7669492 
 
68 8.57 36204 
 
3 12 
heterogeneous nuclear ribo-nucleoprotein C-like 1 61966711  
 
54 3.94 32181 
 
1 4 
 
Table 3.4   TRIF interactors following 60 min poly(I:C) stimulation 
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HEK293-TLR3 were transfected with HA-TRIF, after 20 h cells were stimulated with 20 μg/ml poly(I:C) for 60 min. Then IP of HA-TRIF was 
performed and IP-complex was analysed by LC-MS. The MS spectra of the peptide ions were identified using the Mascot software. programme 
Protein name 
 
NCBI 
accession no 
Mascot score PI MW Peptide 
Match 
Sequence 
Coverage % 
Nucleoprotein TPR 114155142  
 
87 4.97 267537 
 
3 1 
 
Ral GTPase-activating protein subunit alpha-2 118600961  
 
49 5.74 213130 
 
3 2 
Ras GTPase-activating-like protein IQGAP1 4506787 
 
50 6.08 189772 
 
3 1 
Kinesin-like protein KIF21B 59799772 
 
53 7.94 184346 
 
1 7 
CAP-Gly domain-containing linker protein 1 261260059  58 5.29 162901 4 3 
Microtubule-associated tumor suppressor candidate 2 259016371 48 6.23 150915 3 3 
DEAH (Asp-Glu-Ala-His) box polypeptide 8 127797813 35 8.32 140070 3 2 
AF4/FMR2 family member 4 7656879  
 
52 9.33 127788 
 
3 3 
POTE ankyrin domain family member E  134133226  
 
54 5.83 122910 
 
2 2 
Inositol 1,4,5-triphosphate receptor, type 1, isoform CRA 119584312 
 
52 6.18 118754 
 
2 2 
proteasome activator 200 kDa iii 62467428 
 
57 7.57 114882 
 
2 2 
Coatomer subunit beta 7705369 50 5.72 108234 2 2 
Scaffold attachment factor B2 7661936  
 
51 5.84 107930 
 
3 3 
GluR4  
 
790538 
 
58 8.43 101487 
 
2 3 
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ADAM15 metargidin precursor 
 
1235674 55 6.03 90367 
 
2 2 
Phosphatidylinositol 3-kinase regulatory subunit beta 
 
317373311  
 
55 6.03 81843 
 
2 3 
E3 ubiquitin-protein ligase RNF6  
 
5174653 
 
53 9.16 78451 
 
2 5 
Nucleophosmin-anaplastic lymphoma kinase fusion protein  
 
609342 
 
36 6.43 76136 
 
1 3 
Coagulation factor XII 
 
145275213 
 
50 8.04 70068 
 
2 2 
Menin 
 
317373574 
 
61 6.14 68387 
 
2 3 
CREB-regulated transcription coactivator 1 
 
68565585 
 
43 5.65 67374 
 
1 2 
Zinc finger with UFM1-specific peptidase domain protein 
 
292494919 50 6.05 67192 
 
2 2 
Probable ATP-dependent RNA helicase DDX28 
 
296434476 
 
38 10.43 59777 
 
2 3 
 
Lysosomal acid phosphatase  
 
4557010 
 
49 6.28 48719 
 
1 2 
Heterogeneous nuclear ribo-nucleoprotein A1 288558857 
 
84 9.17 38839 
 
2 11 
 
 
Table 3.5    LPS-independent TRIF interacting proteins 
HEK293-TLR4 were transfected with HA-TRIF, after 20 h cells were collected and IP of HA-TRIF was performed, followed by LC-MS 
analysed of the IP-complex. The MS spectra of the peptide ions were identified using the Mascot software programme. 
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Protein name NCBI 
acession no 
Mascot 
score 
PI MW Peptide Match Sequence 
Coverage % 
Human immunodeficiency virus type I enhancer binding 
protein 1 
55662194 
 
53 7.92 299186 
 
3 1 
Mitogen-activated protein kinase kinase kinase 1 218512139 
 
49 7.93 166455 
 
3 1 
Collagen alpha-6(IV) chain  158264217 
 
51 9.31 164922 
 
2 1 
Rho GTPase-activating protein SYDE2 149274655 58 8.83 143770 
 
3 3 
Transcriptional regulating factor 1 
 
119624498 
 
51 6.51 107114 
 
2 2 
protocadherin gamma subfamily A 62087936 51 4.94 103200 1 1 
G protein-regulated inducer of neurite outgrowth 1 31418165 
 
55 8.33 103148 
 
3 3 
26S proteasome non-ATPase regulatory subunit 2  6174930 44 5.08 100890 2 3 
Disintegrin and metalloproteinase domain-containing protein 
15 
55960135 56 6.03 95683 
 
2 2 
intraflagellar transport 88 homolog 119628677 
 
59 5.79 91852 
 
4 7 
Inactive carboxypeptidase-like protein X2 
 
37182252 
 
47 6.03 86454 
 
3 1 
Nexilin 148839339 
 
42 5.31 80841 
 
2 3 
Protein DBF4 homolog A 5729734 43 8.03 77564 1 1 
Zinc finger protein 37 homolog 
 
 
4507963 52 9.26 73136 
 
2 4 
TANK-binding kinase 1-binding protein 1  
 
171769798 
 
39 5.62 68588 
 
1 2 
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Menin 
 
1945390 
 
51 6.14 68387 
 
1 2 
Exoribonuclease 1 
 
23271401 
 
52 6.29 40502 
 
2 5 
 
Table 3.6   TRIF interactors following 20 min LPS stimulation. HEK293-TLR4 were transfected with HA-TRIF, after 20 h cells were 
stimulated with 1 μg/ml LPS for 20 min. Then IP of HA-TRIF was performed and IP-complex was analysed by LC-MS. The MS spectra of the 
peptide ions were identified using the Mascot software programme. 
Protein name NCBI 
accession no 
Mascot 
score 
PI MW Peptide 
Match 
Sequence 
Coverage % 
Serine/threonine-protein kinase ATR 157266317 
 
48 7.17 304826 
 
4 1 
Nuclear mitotic apparatus protein 1 145559510 56 5.63 239217 2 1 
Clathrin heavy chain 1  4758012 
 
89 5.48 193291 
 
2 2 
Collagen alpha-6(IV) 148536823 51 9.31 164922 
 
2 2 
Leucine-rich PPR motif-containing protein 
 
31621305 
 
158 5.81 159023 
 
5 6 
Exportin-5 
 
22748937  
 
62 5.56 138368 
 
1 1 
 
Full-Length Vinculin 83753119 135 5.77 116498 4 5 
Poly [ADP-ribose] polymerase 1 190167  
 
137 8.99 113824 
 
3 4 
Next to BRCA1 gene 1 protein 296439290 
 
55 5.03 108486 
 
2 3 
Tetrahydrofolate synthase, cytoplasmic  115206   85 6.89 102191 2 3 
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Polypeptide BM28 
 
468704 
 
53 7.72 100102 
 
3 5 
Importin subunit beta-1 19923142 176 4.68 98442 3 5 
Protein zer-1 homolog 33589814 
 
50 5.43 89505 
 
3 1 
Protein transport protein Sec23A  38202214 
 
50 6.64 87033 
 
2 3 
Inactive carboxypeptidase-like protein X2 223005864 
 
48 6.40 86484 
 
2 1 
Transmembrane protein 8A 157676334  
 
63 7.67 86388 
 
2 2 
TNF receptor-associated protein 1 23272132 79 8.30 80350 2 2 
Segment polarity protein dishevelled homolog DVL-3 2612833 
 
64 6.18 78384 
 
4 7 
GRB2-associated-binding protein 3  18079323 
 
57 6.79 66244 3 5 
 
T-complex protein 1 subunit zeta  4502643  
 
238 6.23 58452 
 
4 15 
Heterogeneous nuclear ribonucleoprotein  14110420  
 
54 7.62 38584 
 
2 9 
Glyceraldehyde-3-phosphate dehydrogenase 7669492 
 
231 8.57 36204 
 
4 20 
Myristoylated alanine-rich C-kinase substrate  153070260 119 4.47 31710 
 
2 10 
Prohibitin 4505773 
 
124 5.57 29844 
 
2 11 
Proliferating cell nuclear antigen 4505641 82 4.57 29098 
 
3 18 
Phosphoglycerate mutase 1 4505753  220 6.67 28902 5 27 
234 
 
  
14-3-3 protein zeta/delta 4507953 
 
293 4.73 27902 
 
7 27 
Triosephosphate isomerase 4507645 
 
133 6.45 26943 
 
3 15 
Transgelin-2 
 
586000 
 
149 8.41 22551 
 
2 18 
Peroxiredoxin-2 32189392   
 
161 5.66 22052 
 
3 25 
Ras-related protein Rap-1A 51338607 87 8.36 21316 
 
1 8 
Peptidyl-prolyl cis-trans isomerase  10863927 
 
87 7.68 18233 
 
3 19 
Recognition particle 14 kDa protein  149999611 
 
75 10.0
5 
14677 
 
1 10 
Macrophage migration inhibitory factor 4505185  
 
57 7.57 12647 
 
1 7 
 
 
 
Table 3.7   TRIF interactors following 40 min LPS stimulation. HEK293-TLR4 were transfected with HA-TRIF, after 20 h cells were 
stimulated with 1 μg/ml LPS for 40 min. Then IP of HA-TRIF was performed and IP-complex was analysed by LC-MS. The MS spectra of the 
peptide ions were identified using the Mascot software programme. 
Protein name NCBI 
accession no 
Mascot 
score 
PI MW PeptideMatch Sequence 
Coverage % 
Low-density lipoprotein receptor-related protein 2 126012573 55 4.89 540699 4 1 
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Nucleoprotein TPR 114155142 65 4.97 267537 
 
2 1 
Scribble 18032008 
 
53 5.02 175809 
 
3 1 
MYB-binding protein 1A 157694492 58 9.34 149744 
 
2 2 
Cohesin subunit SA-1  62243696 47 5.40 145322 
 
3 3 
Insulin receptor substrate 4 4504733 67 8.72 134729 
 
3 2 
 
Transcription termination factor 2 130784 
 
47 6.63 130784 
 
2 2 
Hypoxia up-regulated protein 1  5453832 118 5.16 111498 
 
4 7 
CAS cellular apoptosis susceptibility protein  62297557 
 
300 5.51 111056 
 
6 10 
AP-2 complex subunit beta  4557469 
 
59 5.22 105414 
 
1 2 
Adaptor-related protein complex 1 (AP1)  119580203 
 
64 4.98 105111 
 
1 2 
Amyloid-like protein 1  4885065  56 5.54 72827 3 5 
Apoptosis-inducing factor 1 13431764 76 9.04 67149 2 5 
Dihydropyrimidinase-related protein 1 4503051 
 
47 6.55 62493 3 5 
T-complex protein 1 subunit zeta  
 
4502643  
 
81 6.23 58452 
 
2 6 
Tat binding protein 7 
 
263099 
 
63 5.52 51635 
 
3 4 
Forkhead box protein 166988458 57 5.25 50795 3 8 
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26S protease regulatory subunit 7 4506209 50 5.71 49009 
 
1 3 
Putative zinc finger CCHC domain-containing protein 18 300681209 
 
52 7.02 45538 3 7 
Glyceraldehyde-3-phosphate dehydrogenase 7669492 
 
380 8.57 36204 
 
10 40 
Myristoylated alanine-rich C-kinase substrate 
 
153070260 
 
128 4.74 31710 
 
3 9 
 
Annexin A5 
 
4502107  
 
62 4.49 35972 
 
1 4 
Prohibitin2 
 
6005854 
 
53 9.83 33276 
 
1 4 
Prohibitin 4505773 
 
81 5.57 29844 
 
1 7 
S-phase kinase-associated protein 1  52783797 
 
43 4.40 18820 
 
1 9 
 
 
Table 3.8   TRIF interactors following 60 min LPS stimulation. HEK293-TLR4 were transfected with HA-TRIF, after 20 h cells were 
stimulated with 1 μg/ml LPS for 60 min. Then IP of HA-TRIF was performed and IP-complex was analysed by LC-MS. The MS spectra of the 
peptide ions were identified using the Mascot software programme. 
Protein name NCBI 
accession no 
Mascot 
score 
PI MW PeptideMatch Sequence 
Coverage % 
Apolipoprotein B-100  178730 56 6.58 516675 
 
3 1 
PI-3-kinase-related kinase SMG-1 14132744 52 6 343765 3 1 
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Histone-lysine N-methyltransferase ASH1L 7739725 
 
52 9.46 
 
336214 
 
3 1 
Cadherin EGF LAG seven-pass G-type receptor 1 7656967 
 
56 5.59 334440 
 
2 1 
Probable E3 ubiquitin-protein ligase TRIP12 10863903 55 8.76 
 
222268 
 
3 2 
Leucine-rich repeat-containing protein 53 212286191 38 11.8 142104 
 
2 3 
Nuclear protein SA-2  2204215 
 
53 5.19 135176 
 
4 6 
SWI/SNF related, matrix associated 119604571 
 
54 9.26 120442 
 
3 3 
POTE ankyrin domain family member F 215273934 
 
47 5.83 123049 
 
2 4 
Discoidin domain-containing receptor 2 215273969 
 
38 5.10 97602 
 
1 1 
Metabotropic glutamate receptor 6 protein  2231438 
 
53  96652 
 
4 5 
Rho guanine nucleotide exchange factor 19 40255149 54 7.31 90012 3 3 
Nucleolar transcription factor 1  136652 41 5.63 89698 1 2 
U4/U6-associated RNA splicing factor 2853287 
 
51 9.53 77530 
 
3 7 
HERV-K_3q12.3 provirus ancestral Gag polyprotein 50400656 
 
33 9.26 74412 
 
1 2 
Mediator of RNA polymerase II transcription subunit 17 296437366 42 7.05 73367 
 
2 5 
Otolin-1 122937273 
 
37 8.60 49971 
 
1 2 
Developmentally-regulated GTP-binding protein 1 6685390 35 9 45849 1 5 
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cul-3 3360457 
 
53 9.56 39482 
 
1 5 
Absent in melanoma 2 (AIM2) 5902751 
 
43 9.79 39045 
 
1 3 
alpha enolase  
 
2661039 
 
262 6.53 36634 
 
4 18 
Glyceraldehyde-3-phosphate dehydrogenase  31645 
 
107 8.26 36205 
 
4 14 
Triosephosphate isomerase  4507645 69 6.45 26943 
 
2 11 
Dermcidin 
 
148271059 
 
36 6.08 11393 
 
1 10 
 
 
 
 
 
 
 
  
 
 
 
Appendix 2 
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2.1    General Materials 
 
2.1.1    Chemicals 
Acetic acid glacial, 100 %. Cat.  # 27221. Sigma-Aldrich.  
Acetonitrile. Cat. # A/0620/PB17. Fisher Scientific. 
Agar. Cat. # 05039. Fluka. 
Ammonium bicarbonate. Cat. # 09830-500G. Sigma-Aldrich 
Ammonium persulfate. Cat. # A3678-100G. Sigma-Aldrich. 
Ammonium sulphate. Cat. # A/6440/65. Fisher Scientific. 
Ampicillin salt. Cat. #  A0166-5G. Sigma-Aldrich. 
Bacto yeast extract. Cat. # 212750. B.D. Medical supplies. 
Bacto Peptone. Cat. # 21677. B.D. Medical supplies. 
β-Mercaptoethanol. Cat. # M7522-100 ml. Sigma-Aldrich. 
Bromphenol blue. Cat. # 11439-1. Sigma-Aldrich. 
Albumin, from Bovine Serum (BSA) Cat.  # A7906-100G. Sigma-Aldrich. 
Dimethylsulfoxide (DMSO). Cat. # D2650. Sigma-Aldrich. 
DL-Dithiothreitol, BioUltra, 99.5 % (DTT). Cat. # D9163-25G. Sigma-Aldrich. 
Ethanol. Cat. # 02860-2.5L. Fluka. 
Ethylene-diamin-tetraacetic acid-disodium salt (EDTA). Cat. # EG758-500G. Sigma-
Aldrich. 
Ethylene glycol tetraacetic acid (EGTA). Cat. #  E3889-10G. Sigma-Aldrich. 
Formalin. Cat. # F 8775-500 ml. Sigma-Aldrich. 
Formic acid. Cat. #  1002640100. Merck. 
Geneticin sulphate (G418). Cat. # BPE673-1.  Fisher Scientific. 
Glycerol. Cat. # BPE229-1. Fisher scientific. 
Glycine. Cat. # G/0800/60. Fisher Scientific. 
HEPES. Cat. # 54457-50G-F. Sigma-Aldrich. 
Hydrochloric acid. Cat. # 30720-2.5L. Sigma-Aldrich. 
Iodoacetamide. Cat # I1149-25G. Sigma-Aldrich. 
Isopropanol. Cat. # 278475-1L. Sigma-Aldrich. 
Methanol. Cat. # M/3900/17. Fisher Scientific. 
NP-40. Cat. # I3021-100 ml. Sigma-Aldrich.  
OPD (o-Phenylenediamine dihydrochloride) tablets. Cat. #  P9187-50SET. Sigma-
Aldrich. 
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Paraformaldehyde. Cat. # 158127-500G. Sigma-Aldrich. 
PBS Tablets. Cat. # P4417-100TAB. Sigma-Aldrich. 
Potassium ferricyanide. Cat. # 702587-250G. Sigma-Aldrich. 
Precision Plus Dual Colour Standards. Cat. # 161-0374. Bio-Rad. 
Complete protease inhibitor tablets. Cat. # 11836153001. Roche. 
Protogel (30 % (w/v) Acrylamide: 0.8% (w/v) bis Acrylamide). Cat. # EC-890. National 
Diagnostic.  
Silver Nitrate. Cat . # S/1280/46. Fisher Scientific. 
Sodium chlorid. Cat. # S/3160/63. Fisher Scientific. 
Sodium-dodecylsulfate (SDS). Cat. # L4390-1KG. Sigma-Aldrich. 
Sodium deoxycholate. Cat. # D6750-25G. Sigma-Aldrich. 
Sodium hydroxide pellet. Cat. # S/4920/60. Fisher Scientific. 
Sodiumorthovanadate. Cat. #  450243-10G. Sigma-Aldrich. 
Sodium potassium carbonate. Cat. # 86352-500G. Sigma-Aldrich. 
Sodium thiosulfate. Cat. # 72049-250G. Sigma-Aldrich. 
SYBR Safe DNA gel stain. Cat. # MP 33100. Invitrogen. 
Tetramethylethylenediamine (TEMED). Cat. # T9281-25 ml. Sigma-Aldrich. 
Tris Base. Cat. #  BPE 152-1. Fisher Scientific. 
Triton X-100. Cat. # T8787-100 ml. Sigma-Aldrich. 
TRIZOL. Cat. # 15596026. Invitrogen. 
Trypsin. Cat. # V5111. Promega. 
West Dura Extended Duration Substrate. Cat. # 34075. Fisher Scientific. 
Tween-20. Cat. # 8221841000. Merck. 
Water (DNAse, RNase, Protease free). Cat. # 4502. Sigma-Aldrich. 
 
2.1.2    Kits 
Plasmid purification: 
High speed Midi purification kit. Cat. # 12643. QIAGEN. 
Transfection: 
Lipofectamine 2000. Cat. # 11668019. Invitrogen. 
DreamFect
™
 Gold Cat. # DG81000. OZ Bioscience. 
Luciferase reporter gene assay: 
Dual-Luciferase Reporter Assay System. Cat.  # E194A. Promega.  
Coelenterazine Native. Cat. # 10110-1. Biotim. 
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D-Luciferin. Cat. # L8200. Biosynth. 
ELISA: 
Human IL-6, ELISA Kit. Cat. # DY206. R&D systems. 
Human TNFα, ELISA Kit. Cat. # 900-K25. Peprotech. 
Human Rantes ELISA Kit. Cat. # 900-K33. Peprotech. 
Human Pro-Inflammatory (7-plex) ELISA kit. Cat. #  K11008B-1. Meso 
ScaleDiscovery. 
Human MMP (3-plex) ELISA kit. Cat. # K11034C-1. Meso ScaleDiscovery. 
Human Rantes (single-plex) ELISA kit. Cat. # K111BFB-1. Meso ScaleDiscovery. 
Human IFNβ (single-plex) ELISA kit. Cat. # K111ADB-1. Meso ScaleDiscovery. 
 
2.1.3    Antibodies 
Primary antibodies: 
Anti-HA tag Mouse monoclonal antibody. Cat. # MMS-101P. Covance. 
Anti-V5 tag mouse monoclonal. Cat. # R960-25.  Invitrogen. 
Anti Myc tag mouse monoclonal antibody. Cat. # 2276. Cell signalling Technology.  
Anti-DVL3 rabbit polyclonal antibody. Cat. #3218. Cell signalling Technology.  
Anti-IκBα mouse monoclonal antibody.Cat. # 4814s. Cell signalling Technology. 
Anti-phosph-IRF3 rabbit monoclonal antibody. Cat. # 4947s. Cell signalling 
Technology. 
Anti-phosph-p65 rabbit monoclonal antibody. Cat. # 3033. Cell signalling Technology. 
Anti-Phosph-P38 rabbit monoclonal antibody. Cat. # 9211s. Cell signalling Technology. 
Anti-human ADAM15 goat monoclonal antibody. Cat. # AF935. R&D Systems. 
Anti-β-Actin mouse monoclonal antibody. Cat. #A1978. Sigma-Aldrich. 
Anti-human TICAM-1 rabbit polyclonal antibody. Cat. # X1827P. Exalpha. 
Anti-human TICAM-1 rabbit polyclonal antibody. Cat. # AL227. Alexis. 
Anti-human TICAM-1 rabbit polyclonal antibody. Cat. # PAB0317. Abnova. 
Anti-human Optineurin mouse monoclonal antibody. Cat. # SC-271549. Santa Cruz. 
IgG from rabbit serum. Cat. #I5006. Sigma-Aldrich. 
 
Secondary antibodies: 
Anti-rabbit IgG HRP. Cat. # W401B. Promega. 
Anti-mouse IgG HRP. Cat. # W402B. Promega. 
Anti-goat IgG HRP. Cat. # V805A. Promega. 
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Goat anti-mouse IgG Alex fluor 488. Cat. # A-11001. Invitrogen. 
Goat anti-mouse Alex fluor 568. Cat. # A-11011. Invitrogen. 
 
2.1.4    cDNA synthesis 
dNTPS. Cat. # N0447S. Biolabs. 
M-MLV Reverse Transcriptase. Cat. # BPE3208-1. Fisher Scientific. 
Random Hexamer Primers. Cat. # C118A. Promega. 
Rnase Inhibitor. Cat. # FQ-EO0381. Fisher Scientific. 
 
2.1.5    Real-time RT-PCR 
Primers sequence  
All primers were designed online using the Integrated DNA Technology software. 
Access at: http://eu.idtdna.com/Scitools/Applications/Primerquest/.  
Primers were purchased from, Euro fins MWG. 
Human IFN-β, forward 5’-AACTGCAACCTTTCGAAGCC-3’.  
Human IFN-β, reverse 5’-TGTCGCCTACTACCTGTTGTGC-3’. 
Human TNF-α, forward 5’-CACCACTTCGAAACCTGGGA-3’. 
Human TNF-α, reverse 5’-CACTTCACTGTGCAGGCCAC-3’. 
Human CCL5, forward, 5’-TGCCTGTTTCTGCTTGCTCTTGTC-3’. 
Human CCL5, reverse, 5’-TGTGGTAGAATCTGGGCCCTTCAA-3’. 
Human TRIF, forward, 5’-ACGCCATAGACCACTCAGCTTTCA-3’. 
Human TRIF, reverse, 5’-AGGTTGCTCATCATGGCTTGGTTC-3’. 
Human ADAM15, forward, 5’-TTCGCGAATCCAAGATCTCCACCT-3’. 
Human ADAM15 reverse, 5’-TCACCAACTCCACAGTCTTGGTCT-3’. 
Human MMP9, forward, 5’-TACCACCTCGAACTTTGACAGCGA-3’. 
Human MMP9, reverse,   5’-GCCATTCACGTCGTCCTTATGCAA-3’. 
Human MMP10, forward, 5’-AATGGATTGTGGCTCATTGGTGGG-3’.   
Human MMP10, reverse, 5’-TGGAAGTGGTTTAGGAGGAGGCAA-3’. 
Human GAPDH, forward, 5’-TTCGACAGTCAGCCGCATCTTCTT-3’. 
Human GAPDH, reverse, 5’-GCCCAATACGACCAAATCCGTTGA-3’. 
Murine DVL1, forward, 5’-ACAAAGGCCTATGCAGTAGTGGGT-3’. 
Murine DVL1, reverse, 5’-GCAGCGCTGAAGACATTGGTTGAT-3’. 
Murine DVL2, forward, 5’-ATGTGGCTCAAGATCACCATCCCA-3’. 
Murine DVL2, reverse, 5’-TAATCTTGTTGACGGTGTGCCGGA-3’. 
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Murine DVL3, forward, 5’-ACCATTCCCAATGCTTTCATCGGC-3’ 
Murine DVL3, reverse, 5’-TGATCTTGTTGACGGTATGGCGGA-3’ 
Murine IFN-β, forward, 5’-CTGGATGGTGGTCCGAGCAG-3’.  
Murine IFN-β, reverse, 5’-CACTACCAGTCCCAGAGTCC-3’.   
Murine IFN-α, forward 5’-ACAGGATCACTGTGTACCTGAGA-3’. 
Murine IFN-α, reverse 5’-GGGCTCTCCAGACTTCTGCTCTG-3’.   
Murine TNF-α, forward, 5’-CATCTTCTCAAAATTCGAGTGACAA-3’.                  
  
Murine TNF-α, reverse, 5’-TGGGAGTAGACAAGGTACAACCC-3’.  
Murine Rantes, forward, 5’-GGAGATGAGCTAGGATAGAGGG-3’.   
Murine Rantes, reverse, 5’-TGCCCATTTTCCCAGGACCG-3’. 
Murine IL-6, forward, 5’-GACAACTTTGGCATTGTGG-3’. 
Murine IL-6, reverse, 5’-ATGCAGGGATGATGTTCTG-3’. 
Murine GAPDH, forward, 5’-GCACAGTCAAGGCCGAGAAT-3’. 
Murine GAPDH, reverse, 5’-GCCTTCTCCATGGTGGTGAA-3’. 
Syber green Mater Mix. Cat. # QT650-05. Bioline. 
Real time RT-PCR was performed using DNA Engine Opticon system; MJ Research. 
 
2.1.6    Cell culture  
2.1.6.1    Cell lines 
Human embryonic kidney (HEK)293, HEK293-TLR3 and HEK293-TLR4 were a 
generous gift from Professor Kate Fitzgerald (University of Massachusetts Medical 
School USA). Human Astrocytoma cells U373-CD14 cells were a generous gift from 
Professor Paul Moynagh (Institute of Immunology, NUIM, Ireland). Immortalized 
cervical carcinoma cells (Hela) were a gift from Dr Martina Schröder, (Institute of 
Immunology, NUIM, Ireland). Wild-type immortalized murine bone-derived 
macrophages were a gift from Professor Douglas Golenbock, (University of 
Massachusetts Medical School USA).  
 
2.1.6.2    Cell culture media and supplements 
HyClone DMEM. Cat. # HyC001113Q. Fisher Scientific. 
RPMI Medium. Cat. # 61870-044. Invitrogen. 
Sodium Pyruvate. Cat. # S8636. Sigma-Aldrich. 
Penicillin/Streptomycin. Cat. # P0781-100 ml. Sigma-Aldrich. 
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Fungizone. Cat. # 15290-026. Invitrogen. 
Blasticidin. Cat. # A11139-03. Invitrogen. 
HygroGold. Cat. # ant-hg. Invivogen. 
FBS (Heat Inactivated). Cat. # 50867051810/500. BioSera. 
Dulbecco's Phosphate-Buffered Saline (PBS). Cat. # 14190-169. Invitrogen. 
Trypsin EDTA. Cat. # T4174. Sigma-Aldrich. 
5 ml pipette. Cat. # tkv-670-051R. Fisher Scientific. 
10 ml pipette. Cat. # tkv-670-071L. Fisher Scientific. 
25 ml pipette. Cat. # tkv-670-091F. Fisher Scientific. 
T175 flasks. Cat. # 83.1812.302. SARSTED. 
T75 flasks. Cat. # 83.1813.302. SARSTED. 
6 well plates. Cat. # tkt-520-030t. Fisher Scientific. 
96 well tissue culture plates. Cat. # 831835. SARSTED. 
Collagen coated  Coverslip. Cat. # 354089. BD Biosciences. 
Cell Scrapers. Cat. # 83.1830. SARSTED. 
Cryotube Vials  Nunc. Cat. # CRY-960-090S. Fisher Scientific. 
Cryo Canes. Cat. # CC-302. Tocris Bioscience. 
 
2.1.7    Plasmids and bacteria 
The following plasmids were kindly provided by the following individuals. 
pCDNA3-HA-TRIF by Prof. Shizuo Akira, (Osaka University,  Japan ). 
pCDNA4-V5-ADAM15 by Prof. Edwards Dylan (University of East Angelia, United 
Kingdom). 
pCDNA3-Myc-MyD88 by Prof.  Luke O’Neill, (Trinity College Dublin, Ireland). 
pCDNA3-Myc-Optineurin by Prof. Swarup, (Centre for Cellular and Molecular 
Biology, India). 
pCDNA3- Myc DVL1, pCDNA3-Myc-DVL2, and pCDNA3-Myc-DVL3 by Prof. 
Hsien-Yu Wang, (Stony Brook University, NY, USA). 
pFOS-Flag-Aim2 by Dr. Kate Fitzgerald (University of Massachusetts, Medical School, 
USA). 
NFκB-Luc, p125-Luc, PRII-luc and PRDIII-luc by Prof. Luke O’Neill (Trinity College 
Dublin, Ireland). 
Rantes promoter-luc by Prof. Paul Moynagh (Institute of Immunology, NUIM, Ireland). 
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PCMV1-HA-Beta-catenin, and Lef-Luc by Prof. Li (Chinese Academy of Sciences, 
China). 
DH5α subcloning efficiency competent cells. Cat . #  18265-017. Invitrogen. 
LB broth (10 g tryptone, 10 g NaCl, 5 g yeast extract (with 20 g Agar for plates; 1L) 
was used for bacterial transformation of plasmid 
 
2.1.8    Equipment  
Analytical balance SI234. Denver Instrument.  
Centrifuge 5804. Eppendorf. 
CO2 Incubater. Fisher Scientific. 
Gryo Rocker SSL3. STUART. 
Heat-stir SB162. STUART. 
IKA Vortex. Genius. 
Luminoscan. Fisher Scientific. 
Magnetic stirrer. SM1 STUART. 
Mastercycler. Eppendorf. 
pH meter ultra-basic. Denver instrument. 
Plate shaker PMS-1000 Grant-Bio. 
Roller mixer SRT9. STUART. 
ROTANTA 460R centrifuge. Lennox. 
See saw rocker SSL4. STUART. 
Spectrafuge 16M. Labnet. 
Specrtometer ELX800. Bio-Tek. 
 
2.1.9    TLR ligands 
Lipopolysaccharides  (LPS) TLR grade. Cat. # 581-010-L002. Alexis. 
Polyinosinic:polycytidylic acid (poly(I:C). Cat. # tlrl-pic. Invivogen. 
R848. Cat. # tlrl-r848-5. Invivogen. 
 
2.1.10     esiRNAs,  DVLs inhibitor and EGF  
esiRNA human ADAM15. Cat. #. EHU076821. Sigma-Aldrich. 
esiRNA  human Optineurin. Cat. #. EHU077201. Sigma-Aldrich. 
esiRNA control. Cat. #. AM16106. Ambion. 
DVL-PDZ Domain Inhibitor. Cat. #. 322338. Calbiochem 
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Recombinant human epidermal growth factor. Cat. #. 236 EG. R&D  (generous gift 
from Dr Shirley O'Dea, Institute of Immunology, NUIM, Ireland). 
 
 
Table 2.2.1 10 % resolving gel 
Protogel (30 % (w/v) Acrylamide: 0.8 % (w/v) bis 
Acrylamide). 
5 ml 
1.5 M Tris-CL, pH 8.8 3.8 ml 
H2O 5.9 ml 
10 % SDS 150 µl 
10 % SDS 150 µl 
TEMED 6 µl 
 
 
Table 2.2.2 5 % staking gel 
Protogel (30 % (w/v) Acrylamide: 0.8 % (w/v) bis 
Acrylamide). 
1ml 
0.5 M Tris-CL, pH 6.8 1.5 ml 
H2O 3.35 ml 
10 % SDS 60 µl 
10 % SDS 60 µl 
TEMED 6 µl 
 
Table 2.2.3  10 x running buffer  
25 mM Tris Base  30.3 g 
192 mM glycine 144 g 
0.1 % SDS  10 g 
H2O Fill to 1L 
 
Table 2.2.4 1 x running buffer 
10 x running buffer 100 ml 
H2O 900 ml 
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Table 2.2.5 5 x loading buffer (50ml)  
Glycerol  15 ml 
10 % SDS 10 ml  
0.5 M Tris-CL, pH 6.8 12.5 ml 
Bromophenol blue  10 mg 
H2O 12.5 ml 
 
Table 2.2.6     10 x transfer buffer pH 8.5  
25 mM Tris Base  30.3 g 
192 mM glycine  144 g 
H2O Fill to 1L 
 
Table 2.2.7 1 x transfer buffer 
10 x Transfer buffer 100 ml 
Methanol 200 ml 
H2O 700 ml 
 
Table 2.2.8 10 x TBS, pH 8 
Tris Base 12.11g 
Sodium chloride  87.6 g   
H2O Fill to 1L 
 
Table 2.2.9 1 x TBST pH 8  
10 x TBST 100 ml 
H2O 900 ml  
Tween-20 1 ml 
 
 
 
 
